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Abstract 
Angiogenesis, the formation of new blood vessels from those that already exist, plays an 
essential role in development, homeostasis and tumour growth. As such, targeting 
angiogenesis is seen as crucial in treatment of cardiovascular diseases or cancer. Therapies 
directed against vascular endothelial growth factor and its major receptor, VEGFR2 
(vascular endothelial growth factor receptor 2), whilst effective in a number of cancers, are 
not without side-effects due to the role this signalling pathway plays in vascular 
homeostasis. Because of their restricted expression, fibronectin binding endothelial 
integrins, especially αvβ3- and α5β1-integrins, have emerged as alternative anti-angiogenic 
targets to neovasculature, particularly in the case of β3. However, neither global nor 
conditional knockouts of these integrins block tumour angiogenesis beyond acute 
deletions, and clinical trials of blocking antibodies and peptides directed against these 
extracellular matrix receptors have been disappointing. To gain novel insight into how 
αvβ3-integrin regulates outside-in signal transmission, in this thesis we have optimised an 
enrichment and mass spectrometry workflow to undertake an unbiased analysis of the 
molecular composition of the mature endothelial adhesome, and profiled changes that 
occur when β3-integrin function or expression are manipulated. In so doing, we have 
uncovered β3-integrin dependent changes in microtubule behaviour that affect cell 
migration and offered some potential explanations as to why current inhibitors have failed 
clinical trials. β3 negatively regulates microtubule stability/targeting to focal adhesions and 
these changes are driven by Rcc2 (Regulator of Chromatin Condensation 2) and Anxa2 
(Annexin A2) regulation of Rac1 (Ras-related C3 botulinum toxin substrate 1). As a result, 
cell migration, angiogenesis and tumour growth in the absence of β3 are susceptible to low 
doses of clinically relevant microtubule inhibitors.  
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Chapter one – Introduction 
Angiogenesis 
The definition of angiogenesis is the formation of new vasculature from existing vessels. 
Animals with a blood supply need to develop a functioning vascular system during 
embryogenesis and maintain this throughout their lives. Animals continue to grow, develop 
and respond to their environment long after birth and as a result, angiogenesis must also 
be able to continue beyond embryogenesis to facilitate this. 
Oxygen does not diffuse through tissue quick enough to satisfy the respiratory needs of 
most cell types, hence cells typically cannot survive beyond 50 to 100 µm from an oxygen 
source1. Complex organisms therefore will need a vascular system to move oxygenated 
blood around the body and re-oxygenate blood in specialised organs such as lungs for air 
breathing animals or gills for water breathing animals. The vascular system is then also 
used to deliver nutrients necessary for tissues to function and remove waste products. In 
mammals the vascular system consists of arteries, veins and capillaries all with the same 
basic structure of a lumen which allows for blood flow, a layer of endothelial cells 
connected by tight, adherens and gap junctions2, a shared basement membrane around the 
endothelial cells3 and then a number of supporting cells called pericytes or smooth muscle 
cells with additional layers such as an adventitia in larger vessels to provide elastic 
support4. Endothelial cells are the key cell type in vasculature, forming the endothelium 
which faces the blood on one side and the rest of the body on the other where they control 
the movement of substrates and cells between them5. 
Before angiogenesis can occur, vasculogenesis must first occur to develop the initial 
vasculature of an animal de novo. Vasculogenesis and angiogenesis share many aspects, 
such as regulation by similar growth factors that target endothelial cells and that 
vasculogenesis will create the vessels from which angiogenesis occurs later to develop 
smaller vessels such as capillaries6. In embryonic vasculogenesis, hemangioblasts develop in 
the extra-embryonic mesoderm in the yolk sac at 7.5 days post gestation in mice7. 
Hemangioblasts are multipotent stem cells that form and reside in “blood islands”, 
resembling the bone marrow stem cell niche in adults, where they give rise to both the 
hematopoetic and endothelial lineages8. Hemangioblasts begin to form VEGFR2 positive 
angioblasts which form vessels directly in the adjacent mesoderm by further differentiating 
into VEGFR2 and VE-cadherin (Vascular endothelial cadherin) positive endothelial cells, 
both key markers of endothelial identity; angioblasts also circulate through the primitive 
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vasculature to form embryonic blood vessels throughout the rest of the embryo and in the 
initial vascularisation of organs which develop later such as kidneys or lungs9,10. Continued 
vasculogenesis in the embryo lays down the foundation for the development of the heart 
and the primitive vascular plexus which is further developed and remodelled by 
angiogenesis to give rise to the complete vascular system11. 
Angiogenesis itself can occur by two main mechanisms – intussusceptive and sprouting. 
Intussusceptive angiogenesis involves an existing vessel becoming bifurcated by the 
protrusion of opposing vessel walls and contact of the endothelial cells, a formation of a 
transluminal pillar and invasion of fibroblasts and pericytes which results in the separation 
of the lumen into two spaces12. Sprouting angiogenesis will be the main focus of this thesis 
and referred to from now on as just “angiogenesis”. 
Hypoxia 
 
Hypoxia is one of the most potent drivers of angiogenesis and it is a clear signal that the 
metabolic demands for oxygen are not being met within tissues. Hypoxia could be triggered 
by a sudden increase in cellular activity, such as during embryonic development, or after 
disruption of existing blood vessels during traumatic injuries13. A family of “hypoxia 
inducible factors” such as Hif1a (Hypoxia inducible factor 1 alpha subunit) are the primary 
mechanism behind hypoxia triggered signalling. Activity of proly-hydroxylase enzymes such 
as PHD2 (Prolyl hydroxylase domain containing protein 2) are dependent on molecular 
oxygen, which provides the means behind oxygen sensing intracellularly14. PHD2 and 
related enzymes use molecular oxygen to hydroxylate prolyl or asparaginyl residues with 
one oxygen atom and use the other atom to convert 2-oxoglutarate to carbon dioxide. 2-
oxoglutarate is a key intermediate in the citric acid cycles, the generation of which is 
dependent on sufficient glucose for acetyl-CoA generation and sufficient oxygen in the 
electron transport chain, proving another pathway for Egnl1 to react to oxygen levels as 
well as glucose availability15. In normoxia, Egnl1 is able to hydroxylate a proline residue in 
two very highly conserved oxygen dependent degradation domains of Hif1a16 which 
initiates binding to an E3 ubiquitin ligase complex via Vhl (Von Hippel-Lindau tumour 
suppressor )17. Once bound to Vhl, Hif1a is ubiquitinated and targeted for degradation by 
the proteasome18. Therefore under normoxia cellular levels of Hif1a are low and 
angiogenesis is not triggered. During hypoxia however, Egln1 is not able to function 
without sufficient oxygen and Hif1a is not sent for degradation. Hif1a is continually 
expressed in order to allow response to changing oxygen levels, so without degradation 
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levels begin to rise at which point Hif1a is translocated to the nucleus where it binds 
Hif1b19. Once in the nucleus other cofactors such as Ep300 (E1a binding protein p300) and 
Crebbp (Creb binding protein) bind to form a functioning transcription complex that target 
hypoxia response elements20. Many genes contain these hypoxia response elements in 
their promoters such as VEGF (Vascular endothelial growth factor) and Epo 
(Erythropoietin), with a significant proportion being involved in angiogenesis; for a full list 
see review by Wenger et al21 and an overview of the process can be seen in figure 1-1. 
Hif1a’s ability to activate genes such as Nos2 (Nitric oxide synthase 2) and Slc2a1 (Solute 
carrier family 2, facilitated glucose transporter member 1) which produces nitric oxide to 
increase blood flow and increase glucose availability for glycolysis/anaerobic oxidation 
respectively22,23. These outcomes serve to both increase oxygen supply and decrease 
oxygen demand in an attempt to temporarily achieve normoxia; Hif1a’s primary target, 
VEGF, is the means by which a longer term solution to hypoxia is achieved. 
VEGF Pathway 
 
The VEGF family of proteins includes VEGF-A, VEGF-B, VEGF-C, VEGF-D and Pgf (Placental 
growth factor)24 and the family can be expanded further by considering the slice variants of 
VEGF-A, VEGF-B and Pgf as well as the further post translational processing of VEGF-A, 
VEGF-C and VEGF-D25. VEGF-A, as the most studied VEGF protein, has many splice variants 
including VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A206 
with VEGF-A165 been considered the prototype, and potentially most relevant to our 
studies, isoform26. Examples of how the different splice variants are formed from the VEGF-
A transcript are shown in figure 1-2. Even the splice variants of a single VEGF can have 
widely different roles in angiogenesis such as the VEGF-A isoforms which can be divided 
into pro-angiogenic VEGF-Axxx and anti-angiogenic VEGF-Axxxb groups27. As well as the exact 
form being expressed, the gradient of VEGF in a tissue is also important for regulating the 
direction and strength of an angiogenic response through guidance of the chemotactic 
response of endothelial cells28. This gives another mechanism for which angiogenic 
responses can be regulated, using the ability of some isoforms of VEGF, such as VEGF-A165 
to bind glycosaminoglycans within heparin side chains found in perlecan in tissues or 
syndecan on cell surfaces29. This sequestration of VEGF limits the diffusion distance, 
keeping the angiogenic response local, and also creates a kind of VEGF store that can be 
released by MMPs (Matrix metalloproteases)30 such as when MMP9 is secreted by 
neutrophils during inflammation or in cancer angiogenesis31.  
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Given the complexity of the roles of VEGF isoforms and considering our studies are 
primarily focused on the endothelial cells which receive these signals it is more useful to 
focus on the VEGF receptors. Three main VEGF receptors are known – VEGFR1, VEGFR2 and 
VEGFR3, all of which are receptor tyrosine kinases, meaning they undergo dimerization 
upon ligand binding, activation of intrinsic tyrosine kinase activity and autophosphorylation 
of tyrosine in the intracellular domains which creates binding sites for downstream 
signalling molecules32.VEGFR1 is able to find VEGF-A, VEGF-B and Pgf, and has a particularly 
high affinity for VEGF-A than the other receptors, but has very low intrinsic tyrosine kinase 
activity33. Additionally a soluble form of VEGFR1 is also produced, meaning that both the 
membrane and soluble forms compete with the other VEGF receptors for VEGF and as a 
result is considered anti-angiogenic due to its ability to prevent VEGF from reaching pro-
angiogenic receptors34. VEGFR3 is important in lymphatic endothelium and is primarily a 
receptor for VEGF-C in order to activate Akt1 (AKT serine/threonine kinase 1) although has 
been known to form a heterodimer with VEGFR2 to activate Erk1 (Extracellular regulated 
kinase 1) in response to certain isoforms of VEGF-A and C35,36. 
VEGFR2 is the main pro-angiogenic receptor in angiogenesis. Canonical activation of 
VEGFR2 starts with the binding of appropriate ligands including VEGF-A splice variants and 
some processed VEGF-C and D forms which induces formation of a VEGFR2 heterodimer37, 
whereas non-canonical activation involves mechanical stimuli to activate tyrosine 
phosphorylation often through VE-cadherin involvement38. It is worth noting that VEGFR2 
heterodimers such as VEGFR1-2, which is thought to supress VEGFR-2 tyrosine 
phosphorylation by the VEGFR1’s higher affinity for VEGF39 and direct inhibition by a PI3K-
alpha (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform) 
pathway40. The formation of signalling of the VEGFR2 homodimer can be augmented by co-
receptors. The main VEGF co-receptor, Nrp1 (Neuropilin-1), can bind also bind VEGF-A 
allowing it to form a complex with the VEGFR2 homodimer enhancing its downstream 
signalling effects41, this role of Nrp1 can be somewhat antagonised by binding with Sem3a 
(Semaphorin 3a) preventing VEGFR2 association42. Classifying Nrp1’s role in VEGF-A driven 
angiogenesis as simply a co-receptor underrates its importance in generating sufficient 
downstream VEGFR2 signalling, as highlighted by the fact that global and endothelial 
specific knockouts of Nrp1 result in early embryonic lethality43,44. Efnb2, another key co-
receptor, can also form complexes with VEGFR2 to spatially control VEGFR2 patterning on 
cell surfaces which helps to control directionality of angiogenic responses by binding with 
ephrin receptors and also assist in VEGFR2 internalisation which is essential for 
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downstream signalling in response to VEGF-A binding45,46. VEGFR2 can also form complexes 
with integrins. Complexes with β1 occur when VEGF-A is bound to ECM (Extracellular 
matrix) that the integrin also binds to, localising the whole complex to focal adhesions and 
results in prolonged activation of VEGF signalling. This combined β1/VEGFR2 binding and 
localisation to the area of VEGF-A loaded ECM is not able to happen with soluble VEGF47. β3 
is known to interact with VEGFR2 in the presence of vitronectin, the primary ligand for 
αvβ3 but not its alternative ligands such as fibronectin48. The β3/VEGFR2 complex involves 
several other partners such as Src and Sdc1 (Syndecan-1) (both components of focal 
adhesions) and when activated, it promotes substantial cross activation of both the integrin 
and the VEGF receptor pathways, enhancing angiogenesis49,50. VEGFR2 can also form 
complexes with VE-cadherin where it participates in the flow sensing signalling of VE-
cadherin through VEGFR2’s PI3K-alpha and Erk1 signalling pathways51. Different complexes 
of VEGFR2 form a network of interactions where different co-receptors and VEGF ligands 
control the rate and specificity of downstream signalling from VEGFR2. For example β3 can 
negatively regulate angiogenesis by sequestering Nrp1, preventing its pro-angiogenic 
association with VEGFR252. 
Once activated, VEGFR2 induces several well-known pathways involved in endothelial cell 
activation, proliferation and migration, which are all key for angiogenesis, such as the 
Phospholipase c gamma 1-Erk1/2, PI3K-alpha-Akt1-Mtor (Mechanistic Target Of 
Rapamycin) and Src pathways53. Activated VEGFR2 binds Phospholipase c gamma 1 which 
catalysis the breakdown of PIP2 (Phosphatidylinositol 4,5-bisphosphate) to IP3 (Inositol 
triphosphate) and DAG (Diacylglycerol)25. IP3 in turn triggers the release of intracellular 
calcium stores from the endoplasmic reticulum via the calcium channel/IP3 receptor Itpr354. 
Calcium and DAG together activate Pkcb (Protein kinase C beta) which in turn drives the 
Raf1 (Raf-1 proto-oncogene, serine/threonine kinase )/Mapk pathway55. Targets of Erk1/2 
include cyclins, cyclin-dependent kinases and Myc which increases endothelial cell 
proliferation as well as post-translational regulation of Fak1 (Focal adhesion kinase 1) and 
Pxn, promoting endothelial cell migration55,56. Calcium released from the Phospholipase c 
gamma 1-Erk1/2 pathway also binds Calm1, allowing it to bind and activate Ppp3cc57 which 
dephosphorylates the transcription factor Nfatc1 (Nuclear factor of activated T-cells 1), 
allowing it to enter the nucleus and increase the expression of many angiogenesis related 
genes58 as well as decrease the expression of VEGFR1 which prevents VEGF from being 
sequestered and increasing its availability for VEGFR2 signaling59. 
16 
 
The PI3K-alpha-Akt1-Mtor pathway starts with activation of PI3K-alpha by Src or VE-
cadherin recruited to VEGFR260. PI3K-alpha then converts PIP2 to PIP3 (Phosphatidylinositol 
3,4,5-trisphosphate) which binds to and activates Akt1. Akt1 and PI3K-alpha have many 
downstream targets that are involved in endothelial cell survival, proliferation and 
apoptosis61 as well as vascular permeability and maturation in established vessels62. An 
important downstream target of this PI3K-alpha pathway is Mtor, which has its main 
inhibitor Tsc2 (Tuberous sclerosis 2) deactivated by Akt1 phosphorylation and is also 
phosphorylated directly by Akt163. Mtor, once activated, drives angiogenesis by promoting 
endothelial cell Fak1 and actin cytoskeleton remodeling which assists in adhesion to ECM64. 
Src recruitment via the Tsad adaptor also gives VEGFR2 another pathway it can signal by to 
regulate endothelial cell junctions and vascular permeability65. Major Src substrates also 
include key focal adhesion proteins Fak1 and Pxn, and cytoskeletal components aiding with 
endothelial cell migration by promoting focal adhesion turnover and cell shape changes66,67. 
Whilst hypoxia driven VEGF expression is the main driver behind most angiogenesis is it not 
the only one that should be considered. Other growth factors and cytokines play important 
roles such as transforming growth factors, fibroblast growth factors, epidermal growth 
factors, angiopoietins and more68. Many of these play tissue and situation specific roles in 
angiogenesis, helping local vasculature deciding in judging the balance of pro and anti-
angiogenic signals, especially given the fact that hypoxia is subjective in tissues and is 
relative to the local physiological norm i.e. normoxia for the prostate would be severely 
hypoxic for the heart69,70. 
Many of the VEGF effects described so far prepare and start angiogenic processes in 
endothelial cells. For example, VEGF signalling will begin to activate the quiescent 
endothelial cells in existing vasculature, by causing them to loosen their cell-cell junctions 
and start to degrade the shared basement membrane using proteases71. The majority of 
the pathways utilised by VEGFR2 also increase endothelial cell proliferation, generating 
enough endothelial cells to form the new vessels at the site of hypoxia72. VEGFR2 signalling 
also guides directional migration in endothelial cells towards the source of the VEGF, 
through the influences on focal adhesion proteins Fak1 and Pxn as well as driving Cdc42 
(Cell division cycle 42) directed migration through Phospholipase c beta 373. This process 
needs to be carefully controlled to ensure that endothelial cells migrate towards the 
hypoxic area but still maintain a connection to the existing vasculature to connect to the 
circulatory system. Endothelial cells organise themselves into a leading tip cell that moves 
towards the source of VEGF and a trailing line of connected stalk cells74. Endothelial cells 
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express several Notch receptors which are transmembrane receptors for a number of cell 
surface Notch ligands including Dll4 (Delta like canonical notch ligand 4) also expressed on 
endothelial cells75. VEGFR2 signalling induces filopodia extension, centralising VEGF sensing 
and guiding endothelial cells towards the source of VEGF; the leading endothelial cell with 
filopodia is known as the tip cell74,76. Only one tip cell is needed to guide the connected 
stalk of other endothelial cells towards the source of VEGF, hence the tip cell phenotype is 
supressed in other endothelial cells leading them to become stalk cells. VEGFR2 signalling 
does this by increasing expression of Dll4, which then binds to Notch receptors on adjacent 
cells77. The notch receptor is then cleaved by membrane bound ADAM10 (A disintegrin and 
metalloproteinase domain) and , ADAM17 or other proteases, releasing the Notch 
intracellular cytoplasmic domain78. This domain acts as a transcription factor to target 
many Notch responsive genes, as well as supressing the expression of VEGFR279. As a 
result, the endothelial cell closest to the source of VEGF will express the most Dll4 
becoming the tip cell and signalling the others to become stalk cells, ensuring the orderly 
extension of the stalk to the source of VEGF80. Stalk cells are not totally unresponsive to 
VEGF however, those closest to the source will proliferate the most compared to those at 
the base of the sprout but this is not thought to be nearly as important for the progression 
of the sprout as the pulling force generated by the migration of the tip cell76,81. 
Other Pathways in Angiogenesis 
 
Before, throughout and after the directional migration of the endothelial cells towards a 
VEGF source, constant ECM turnover is required82 which requires adaptation in the 
repertoire of ECM receptors in endothelial cells. Quiescent endothelial cells normally 
express integrins such as α1β1, α2β1, α3β1, α5β1, α6β1, α6β4 and αvβ5, the majority of 
which bind laminins or collagens found within the basement membrane of the vessel. 
During angiogenesis, fibronectin and vitronectin are laid down by the endothelial cells 
themselves or fibroblasts. As these ECM components are not found commonly in basement 
membranes82–84, there is the sudden switch in endothelial cells to express appropriate ECM 
receptors such αvβ3 and more α5β1 . ECM degradation is also a key step in angiogenesis, 
for example, tip cells are known to produce and cluster MMP14 at the leading edge in 
order to degrade ECM and create a path through the 3D matrix for which the developing 
sprout will migrate, which leaves behind a space for the eventual mature tube of the 
capillary85,86. Endothelial cells produce a variety of ECM components including collagens, 
fibronectin and laminins, with the exact mixture of ECMs deposited depending on the 
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maturity or progress of angiogenesis. This allows endothelial cells to produce a provisional 
ECM whilst migrating and forming new vessels but a more basal-like ECM once vessels 
begin to mature87,88. 
Lumen formation is an important step in angiogenesis, forming the hollow space for blood 
flow within vessels, and this begins early in angiogenesis once stalk cells have formed89. 
Two distinct mechanisms are thought to be responsible for lumen formation in stalk cells: 
one involving a process called intracellular or cell hollowing and another called extracellular 
or cord hollowing. Cdc42, Rac1 and MMP14 are all important to both of these 
mechanisms89,90. MMP14 is particularly important in lumen formation and the creation of 
the vascular guidance tunnel by proteolysis of the interstitial ECM started by the migrating 
tip cell91. Adhesion to the surrounding ECM is also important in lumen formation, with 
integrins relevant to the local ECM composition being important such as α2β1 for collagen 
matrices92 or α5β1 and αvβ3 for three dimensional fibrin matrices93. Integrins and Cdc42 
are critical in establishing apical-basal polarity in endothelial cells, which is required to 
ensure all cells in the new sprout are orientated correctly to the luminal and abluminal 
surfaces94. Once polarised, endothelial cells respond to continuing VEGF signalling by 
activating several Rho-dependent kinases such as Rock1 (Rho associated coiled-coil 
containing protein kinase 1) through VEGFR2. Rock1 then inhibits actin depolymerisation 
and phosphorylates Mlc, driving the assembly of an actomyosin complex that opens up the 
space between opposing endothelial cells to produce the lumen95. Finally, in order for the 
lumen to become useful and a blood flow achievable, a loop including the nearest currently 
perfused vessel must form in a process known as vessel anastomosis96. Multiple sprouts 
will be recruited to a hypoxic area, eventually leading to two tip cells from different sprouts 
coming into contact where a concentration of tissue macrophages facilitates cell-cell 
contacts between them using VE-cadherin and leads to eventual fusing to produce a closed 
loop97,98. Once a loop has formed there is a now a complete path for blood to flow from the 
existing vessel towards the hypoxic area and then back towards the original vessel. The 
initiation of blood flow acts as a potent trigger for vessel maturation and stabilisation, as a 
lack of flow is an indicator of unsuccessful angiogenesis and leads to regression of the 
sprouts – a process that happens naturally during the formation of mature vascular beds99. 
Blood flow can be sensed by endothelial cells using a variety of mechanosensory complexes 
and triggers the strengthening of cell-cell contacts primarily via VE-cadherin, deposition of 
basement membranes and recruitment of pericytes to strengthen the vessel, additionally 
giving it the smooth muscle tools to control blood flow in the future100,101. 
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Angiogenesis in Cancer 
 
Angiogenesis is a tightly controlled event important during many physiological processes 
such as embryonic development, growth, wound healing and more but due to its 
complexity, can go wrong or be co-opted in many pathologies96. In cancer for example, 
tumours grow to just a few mm across without a vascular supply and subsequently, the 
induction of angiogenesis is considered a key milestone in progression of the disease 
termed the “angiogenic switch”102. For example the RIP-Tag mouse model of spontaneous 
pancreatic cancer shows a dramatic induction of angiogenesis in a subset of hyperplastic 
islets at 7 to 12 weeks, transforming the subset from benign carcinomas in situ to 
malignant tumours – a process dependent on VEGF as the main driver of 
angiogenesis103,104. In these situations non transformed endothelial cells have been hijacked 
by transformed tumour cells to connect them to the circulatory system. This model is 
driven by the expression of the SV40T oncogene with a rat insulin promoter105. Whilst the 
RIP-Tag model has provided many insights into the biology of angiogenesis in tumours, it 
has failed to produce meaningful clinical progress for most patients with pancreatic cancer. 
This is likely due to the type of pancreatic cancer observed in the model, a neuroendocrine 
origin tumour, which is much rarer than the types that occur in patients such as pancreatic 
ductular adenocarcinomas which are very poorly vascularised, demonstrating that 
angiogenesis may not always be essential for tumour growth106,107. Poor vascularisation is 
common in cancers, and even within vascularised tumours there will be significant pockets 
of hypoxia owing to tumour heterogeneity – these areas often contain the most 
malignantly transformed cells due to the changes make to their metabolism to cope with 
the lack of oxygen13,108,109. Even if angiogenesis is dispensable for tumour growth, tumours 
that recruit a blood supply can use it to seed distant metastatic sites through the 
bloodstream110. 
Cancers often have lower oxygen requirements than surrounding tissues due to the 
Warburg effect where they favour glycolysis to produce intermediate metabolites for DNA 
synthesis and cell growth111. This still creates a huge demand for glucose, amino acids and 
other nutrients hence the need for angiogenesis is still present. Hypoxia is a mixed blessing 
for cancer cells as it can mean a lack of oxygen, however the stabilisation of Hif1a will 
upregulate metabolism, migration and survival genes benefiting cancer progression as well 
as the production of VEGF109. Tumours produce high levels of VEGF, due to hypoxia, 
benefits of other Hif1a targets and the common mutation of targets such as Ras genes that 
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increase VEGF production112. Even with rampant angiogenesis, there is never enough blood 
supply to satisfy the continual growth of the tumour or penetrate the hypoxic core 
resulting in chronic VEGF release113. Experiments carried out comparing spikes of VEGF 
production using adenovirus vectors to chronic VEGF production showed that acute VEGF 
results in mature and regularly spaced vessels, just like physiological angiogenesis, however 
chronic VEGF results in chaotic, large and leaky vessels with poor blood flow like in 
tumours114. Leaky and inefficient vasculature is common in tumours due to the constant 
stimulation with VEGF; normal angiogenesis requires VEGF levels to fall eventually as VEGF 
stimulation increases vascular permeability by loosening endothelial cell-cell contacts115. 
Tumours also promote angiogenesis by a number of other means. For example they recruit 
and convert resident fibroblasts to cancer activated fibroblasts (CAFs) which are known to 
promote angiogenesis by production of VEGF, Il6 (Inteleukin 6) and other cytokines which 
results in the kind of aberrant vessels seen in tumours116,117. Conversion of fibroblasts is 
thought to be an irreversible process leading to a continual increase in these pro-
angiogenic signals over time, again creating leaky vasculature118. This means the factors 
produced by CAFs are important to consider in designing anti-angiogenic or anti-cancer 
therapies, as well as the factors produced by the tumour. Just like myofibroblasts in wound 
healing, CAFs produce large amounts of ECM including fibronectin, which promotes 
endothelial cell activation and migration via fibronectin binding integrins115,119. Deposition 
of large amounts of ECM, combined with the large number of cancer cells, results in a busy 
cancer stroma that is stiffer and highly crosslinked and both of these features promote 
angiogenesis by increased integrin signalling120,121. These ECMs horde large amounts of 
VEGF and other growth factors/cytokines that are liberated upon breakdown by the MMPs 
also produced by CAFs122. Tumours also recruit and transform immune cells giving rise to a 
large resident population of tumour associated macrophages123. Several potential 
explanations exist for the pro-angiogenesis phenotypes of high levels of immune cells in 
tumours, including the production of MMP9 by immune cells to degrade ECM to release 
VEGF and other factors, which further antagonises the leakiness of vessels, drawing in 
more immune cells 124. Constant recruitment of fibroblasts and immune cells in tumours, 
driving sustained and aberrant angiogenesis gave rise to the idea that cancers are “wounds 
that never heal”125. 
Preventing angiogenesis from occurring is therefore an attractive anti-cancer therapy. 
Firstly, cancer cells themselves originate due to mutations in their genomes and retain the 
ability to mutate further genes during their development. As a result cancers can quickly 
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develop resistance to chemotherapy by mutating targeted genes, degrading drugs, 
supressing apoptosis pathways or increasing drug efflux126. Endothelial cells, even those co-
opted into providing tumour vascular, have a stable genome meaning that their options for 
developing resistance are fewer and hence the goal of preventing or regressing tumour 
vasculature is a good strategy127. Secondly, as tumour vasculature is chaotic and poorly 
organised, the overall perfusion of tumours is often quite low compared to normal tissue. 
This means that even with a highly effective chemotherapeutic agent, it will be difficult to 
deliver a sufficient dose to the tumour. Some anti-angiogenic therapies have been designed 
to prune the weaker vessels of the tumour to leave a more mature and stable network, a 
process known as vessel normalisation, with the goal of increasing perfusion and delivery 
of a second chemotherapeutic drug to the tumour128. 
VEGF was the one of the landmark discoveries in angiogenesis research and ultimately lead 
to the development of bevacizumab, a monoclonal antibody against VEGF, for use initially 
in colorectal cancer where it has increased progression free survival in combination with 
chemotherapeutic drugs such as 5-fluorouracil129. Bevacizumab was treatment was found 
to normalise tumour vasculature within 12 hours, with a reduction in blood flow but 
crucially no change in uptake of radionucleotide labelled glucose; within a combination 
therapy setting this means it would reduce vascularisation of the tumour but improve the 
delivery of the chemotherapeutic130. Reducing VEGF levels would halt the chronic VEGF 
phenotype of tumours mentioned above, allowing unnecessary vessels to regress and 
others to mature/stabilise131. Bevacizumab is also being applied to other conditions with 
pathological angiogenesis such as wet macular degeneration where is causes leaky vessels 
to regress132. Anti-angiogenic therapies based on interfering with VEGF signalling are prone 
to treatment escape as alternative growth factors can also be powerful angiogenic stimuli. 
Tumours can switch to producing other growth factors or produce ever increasing amounts 
of VEGF, taking advantage of the poor delivery of the anti-VEGF agent in tumours, by 
selection of subclones with these properties within the tumour133. Other mechanisms of 
treatment escape include vessel mimicry by tumour cells, induction of 
intussusceptive angiogenesis or pro-angiogenic signalling from CAFs or immune cells134. The 
next stage in many areas of angiogenesis research is to understand precisely why previous 
anti-angiogenesis drugs have failed in certain cases: by looking closer at the mechanism of 
the drug and understanding better how endothelial cells respond to them. 
  
22 
 
Figure 1-1 Hif1a Pathway Under Hypoxia and Normoxia 
 
 
Hypoxia response pathway diagram showing the differential pathways of Hif1a under 
normoxic and hypoxic conditions. This includes the proteasomal degradation of Hif1a after 
ubiquitination and the induction of hypoxia response element containing genes. Taken 
from Thirlwell et al135 
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Figure 1-2 VEGF-A Splice Variants 
 
Differential splicing of the mRNA transcript with 8 possible exons and binding/cleavage 
sites shown (top). Resulting VEGF-A isoforms 206, 189, 165, 145 and 121 are formed from 
different combinations of these exons. Figure taken from Holmes et al136 
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Integrins 
Cell adhesion and migration is dependent on interactions with the ECMs surrounding cells. 
Many types of ECM receptors exist in cells but the most important type for considering 
endothelial cell adhesion and migration are integrins137. Integrins are a family of 24 
heterodimeric cell surface receptors composed of 18 possible alpha and 8 possible beta 
subunits, where different combinations of alpha and beta subunits form receptors with 
unique ligand specificity such as towards collagens, laminins or RGD (Arginine, glycine, 
asparagine tri-peptide) containing proteins138. The fibronectin receptors α5β1 and αvβ3 are 
of particular interest in endothelial cell adhesion and migration due to their prominent 
associations with angiogenesis139. As well as simply mediating adhesion to the ECM, 
integrins are also key signalling molecules. Successful ligation to an ECM is useful 
information to a cell that needs to be passed inwards in a process known as outside-in 
signalling whereas the activation of the integrin in the first place, to be able to bind ECM, is 
known as inside-out signalling140. 
Integrins consist of a large extracellular domain, a transmembrane domain and a short 
cytoplasmic tail. The shape of the extracellular domain is regulated to control the ability of 
the integrin to bind ligands i.e. its activation, such as in leukocytes where their ICAM1 
(Intracellular adhesion molecule 1) and VCAM1 (Vascular cell adhesion protein 1) binding 
integrins are only activated at sites of infection, to ensure they arrest in blood vessels at 
the correct location141. Interactions between the transmembrane domains of integrin 
heterodimers confer a bent structure to the extracellular domain keeping it inactive142, 
which can be seen in figure 1-3 where the proximity of the transmembrane domains causes 
the subunits to fold down together. Mutations that affect interactions of the 
transmembrane domains such as G708N of β3 leave the integrin heterodimer constitutively 
active with much higher affinity for ligand binding143. Two important and conserved 
interaction sites in the transmembrane domain are both thought to need disruption in 
order to result in complete integrin activation termed the inner and outer membrane 
clasps; the angle of the transmembrane domains relative to the membrane and each other 
is crucial in ensuring both these clasps can interact with each other and is controlled by 
binding of factors to the cytoplasmic tails144. 
Inside-out Signalling 
 
Tln1 (Talin 1) is a critical regulator of integrin activation, as can be seen in figure 1-3 where 
separation of the transmembrane domains permits the integrin to assume its active 
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confirmation. Its head domain binds to integrin beta cytoplasmic tails to contribute to 
activation and its rod domain binds directly to actin and to Vinculin, which also links to the 
actin, helping establish a strong connection between integrins and the actin 
cytoskeleton145,146. The Tln1 rod domain contains another integrin beta cytoplasmic tail 
binding site allowing the linking of multiple integrins147. Tln1 is often the final step in 
integrin activation so can be used as a marker of focal adhesions, where integrins cluster 
together at sites of adhesion148. Members of the kindlin family, such as Kindlin-1, Kindlin-2 
and Kindlin-3, are important co-activators of integrins along with Tln1 and share a similar 
FERM domain that allows localisation and binding to integrin beta tails149. Some studies 
have suggested that Kindlin-2 in endothelial cells activates αvβ3 whilst Kindlin-3 activates 
α5β1 with some overlapping functions (endothelial cells do not express Kindlin-1),  but this 
does not seem consistent across different sources of endothelial cells144,150. For example 
other studies show that Kindlin-3 deletion in mice phenocopies Glanzmann 
thrombasthenia, a condition which is caused low levels of β3 in platelets resulting in 
chronic bleeding from a lack of platelet aggregation and binding to fibrinogen151,152.  
Unlike Tln1, kindlins are not thought to activate integrins directly but instead do so through 
the many proteins they recruit to the cytoplasmic tail the integrins153. One of these 
proteins, Ilk (Integrin linked kinase), binds directly to Kindlin-2 and acts as a scaffold to 
recruit further activation proteins such as Pxn and Parvin alpha154. Another important 
interactor known as Migfilin also binds directly to Kindlin-2 and is recruited during integrin 
activation, knockouts of which have been shown to impair integrin activation, cell 
spreading and focal adhesion formation155. The binding of Migfilin is thought to act as a 
switch in integrin activation because of its proposed mechanism of action where it 
displaces Filamin-a from the integrin cytoplasmic tail156. Filamin-a is an actin crosslinking 
protein involved in regulating the actin cytoskeleton but it is also thought to have roles in 
recruiting integrins to membrane regions where actin protrusions are forming157,158. 
Filamin-a however is an integrin inhibitor, possibly preventing premature activation of 
integrins once recruited to the actin cytoskeleton until Migfilin displaces it159. 
Outside-in Signalling 
 
Once integrins have been sufficiently activated, with their extracellular domains in an open 
confirmation, they can bind their respective ligands. Successful ligation of ECM is an 
important signal controlling many cellular processes for example survival, with a lack of 
ECM ligation often triggering a form of cell death called anoikis160. Integrin cytoplasmic tails 
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are themselves though have no inherent enzymatic activity, therefore they need to recruit 
signalling proteins directly or via adaptors161. Ligand binding to integrins induces a 
conformational change throughout the protein, resulting in the recruitment of the outside-
in signalling machinery to the cytoplasmic tail162. Fak1, like Tln1 and kindlins, contains a 
FERM domain, which normally is bound to the kinase domain of Fak1. Integrin ligand 
engagement recruits Fak1 to the integrin beta cytoplasmic tail via the FERM domain, 
freeing up the kinase domain to autophosphorylate Y397 and partially activate Fak1163. This 
initial phosphorylation recruits Src, which itself is activated by conformational changes 
induced by interaction with Fak1, resulting in further phosphorylation and activation of 
Fak1164. The Fak1/Src signalling complex is one of the most important outside-in signalling 
complexes created by integrin ligation163. Fak1/Src phosphorylates Bcar1 (Breast Cancer 
Anti-Estrogen Resistance Protein 1) creating SH2 (Src homology domain 2) domain binding 
sites for proteins such as Crk (CRK proto-oncogene, adaptor protein)165 then Bcar1 and Crk 
in turn regulate the actin cytoskeleton and promotes migration through Dock1 (Dedicator 
of cytokinesis 1) and Rac1166. Further complexes recruited to activated Fak1/Src include 
Grb7 (Growth factor receptor bound protein 7) and PI3K-alpha 167,168 which worth together 
to regulate cell migration via Rac1 in their respective signalling pathways169,170. Other 
important downstream targets of Fak1/Src are several RhoA (Ras homologue family 
member A) family kinases which regulate actomyosin to control cell migration171. 
Pxn is a well-known scaffold protein recruited to integrins to regulate outside-in signalling 
and is often used as a focal adhesion marker172. Pxn is phosphorylated and recruited by 
Fak/Src, which also creates SH2 sites for proteins like Crk to bind as mentioned above173. 
Pxn also contains domains that bind Vinculin which functions as a link to the actin 
cytoskeleton174. 
Some of the proteins that played a role in the activation of integrin are still bound to the 
integrin beta cytoplasmic tails and play a role in outside-in signalling. Recently, Tln1 has 
been found to be a mediator of the mechanosensory abilities of integrins175. Due to its 
position between the integrins and the actin cytoskeleton145, tln1 is in a unique position to 
measure the force being applied on the actin cytoskeleton by the integrin by using its rod 
domains R1 to R13 where bundles of these rod domains are pulled apart by the tension 
generated upon cell adhesion either by unzipping domains or shearing between them176. 
RIAM (Rap1-Interacting GTP Adapter Molecule) is a protein that binds to R3 of Tln1 to 
recruit it to the plasma membrane in order to support activation of integrins but upon 
unzipping of this domain its binding site is lost and is replaced by Vinculin, a process which 
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supports the maturation of a focal adhesion as tension forces increase177. Increasing 
tension across Tln1 rod domains gradually unwinds the whole molecule, revealing binding 
sites for more molecules such as Kank1 (KN Motif and Ankyrin Repeat Domains 1) which 
recruits microtubules to mature focal adhesions178. 
Focal Adhesions 
 
Often a concentration of integrins will be found on the same area of the plasma 
membrane, such as where a large collagen fibre or fibronectin fibril contacts the cell. These 
matrices can have binding sites for more than one integrin heterodimer at a time; 
additionally ECMs such as collagen and fibronectin can interact and crosslink each other, 
resulting in a clustering of integrin binding sites179–181. Therefore the integrins on the cell 
surface will also cluster forming large protein complexes known as focal adhesions182. 
Integrins, direct and indirect interaction partners make up focal adhesions which in total 
can contain several hundred different proteins183. When focal adhesions first begin to form, 
with clusters of activated integrins binding their ligands, they are known as nascent 
adhesions. These nascent adhesions can be triggered to mature depending on the 
migratory needs of the cell such as by the Tln1 domain tension mechanism mentioned 
earlier184,185. When considering fibronectin adhesion, focal adhesions can be considered 
nascent if they rely on β1 for adhesion but mature if they rely on β3186. Whereas other 
classification systems divide them into fibrillar adhesions containing β1 only, which give the 
cell high mobility, and focal adhesions containing both β1 and β3, which generate strong 
tension forces187. Focal adhesions are able to support cell mobility by being the main 
structures upon which cells migrate. In order to do this they must be dynamic structures 
that can assemble where needed at the leading edge of the cell but disassemble at the 
retracting edge, whilst still providing enough anchorage for actomyosin driven cell 
migration in-between assembly and disassembly188. Fibrillar adhesions are particularly good 
at aiding cell migration because they extend in the direction of migration from the edge of 
a mature focal adhesion, then disassemble from the rear edge at the same time which 
creates a tread milling adhesion that provides anchorage precisely where needed for the 
migrating cell to pull against189. Tln1, as an activator of integrins and key tension sensor, is 
an excellent promoter of focal adhesion maturation under the appropriate conditions as 
well as other proteins such as RhoA and Rock1 which assist in linking focal adhesions to 
actin stress fibres formed during cell migration188,190 Focal adhesion disassembly, which is 
as important for cell migration as focal adhesion disassembly, and is regulated by several 
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factors including microtubules, Kif5b (Kinesin family member 5B), Dnm2 (Dynamin-2), Fak1 
dephosphorylation, and Capn2 (Calpain 2)191–193. 
Integrin Trafficking 
 
As outlined above, focal adhesions must be able to assemble and disassemble in order to 
allow successful migration of the cell. The key components of the adhesions, such as 
integrins, will need to be trafficked to and from the adhesive fronts of the cell. Many 
different pathways control internalisation, recycling and degradation of integrins from the 
cell surface, for a full review see Bridgewater et al194. The way integrins are trafficked 
depends on the situation and cell type. For example proteins important in angiogenesis 
such as Nrp1 have been shown to promote the internalisation of active α5β1 during 
adhesion to fibronectin in Rab6 containing endosomes195. Recycling of integrins back to the 
surface in endothelial cells is also important for migration and tube formation in vitro 
which is controlled by Arf6 (ADAP-ribosylation factor 6) particularly in HGF mediated 
angiogenesis196. Many of the components of integrin trafficking pathways, like Arf6, are 
shared by other trafficking pathways such as the VEGF pathway where it acts downstream 
of VEGFR2 to control Rac1 activation197. Therefore when assessing the roles of integrins in 
angiogenesis it will be important to also consider the knock on effects any manipulation 
will have on other pathways. 
Microtubules have an important role on the trafficking of many cargos (see later). They can 
participate in the trafficking of integrins by providing a polarised pathway from the centre 
of the cell to the adhesive front at the edge when they target focal adhesions196. 
Microtubules that target focal adhesions can induce rapid disassembly such as when 
Mapk4k (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4) is targeted to 
microtubule tips via EB2 and then recruits GEFs (Guanine exchange factors) to activate Arf6 
triggering integrin internalisation198 
 
Cross Talk 
 
Integrin are known for their ability to cross talk to other pathways, particularly growth 
factor receptor pathways such as VEGFR2 or Egfr (Epidermal growth factor receptor), 
therefore the impact of integrins on cell behaviour can be dramatic199. Sometimes this 
cross talk is vital for the action of the integrin itself such as where Egfr signalling via Pkcb is 
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required for αvβ5 directed migration on vitronectin200. Other examples include α6 integrins 
which can associate with Erbb2 (Erb-B2 receptor tyrosine kinase 2 or HER2) to promote cell 
invasion and proliferation much in the same way that the activated growth factor 
heterodimer of Errb2/Egfr would201. Many of the molecules mentioned earlier in integrin 
signalling themselves are involved in receptor tyrosine kinase responses, particularly Src 
downstream of growth factor receptors such as Egfr, Met and various Gpcrs (G protein 
coupled receptors)202. Src, acting downstream from these receptors, can influence many of 
the same pathways activated by integrins including PI3K-alpha and create phosphorylated 
binding sites for SH2 domain containing adaptors such as Grb7203,204 
Integrin β3 
 
Fibronectin binding integrins play a particularly important role in angiogenesis. αvβ3 is a 
vitronectin/fibronectin/von Willebrand factor receptor that is upregulated in angiogenic 
vasculature205. Often β3 is the target of manipulation in studies on endothelial cells as the 
only compatible alpha subunit is αv, whereas αv can form heterodimers with β3 or β5; 
manipulations of αv could therefore result in unwanted disruption of β5206. Early studies 
indicated that β3 could be a pro-angiogenic molecule due to the timing of its upregulation 
and because blockade of the integrin induced apoptosis in endothelial cells207, which was 
thought to be because of the loss of anti-apoptotic signalling form Fak1/Src208. β3 is known 
to exhibit extensive cross talk with VEGFR2, particularly when bound together after 
engagement with vitronectin, resulting in Src dependent cross-phosphorylation and 
activation of both molecules48,209. Cross-activation between β3 and VEGFR2 has also been 
observed via PI3K-alpha210. These findings led to the development of αvβ3 inhibitors 
designed to halt tumour angiogenesis such as Cilengitide®, a cyclic RGD mimetic resembling 
the αvβ3 binding site of fibronectin, which entered clinical trials. Despite promising in vitro 
and in vivo studies, where Cilengitide® caused apoptosis of endothelial cells, slowed 
migration and reduced the growth of tumours210,211, it ultimately failed in phase III212. 
Cilengitide® was well tolerated in patients due to the restriction of αvβ3 to only actively 
proliferating vasculature, and it exhibited good pharmacokinetics such as by being able to 
cross the blood brain barrier leading to the suggestion that failure was due to the choice of 
target213. Detailed investigations into the effects of Cilengitide® on endothelial cells and 
angiogenesis revealed that whilst high doses of the RGD-mimetic did inhibit angiogenesis, 
low doses actually promoted it, providing clues that β3 may not have been the purely pro-
angiogenic molecule it was thought to be214. 
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Further investigations have confirmed β3 can have anti-angiogenic roles. β3-null mice 
exhibit enhanced pathological angiogenesis215. VEGFR2 has been shown to be a key protein 
responsible for β3-null phenotypes as it is upregulated to increase pro-angiogenic signalling 
as well as cause an increase in VEGF dependent permeability without β3216,217. Previously it 
was thought that β3 and VEGFR2 were cross-activating by promoting increased signalling in 
each other’s downstream pathways, so it was initially strange that β3 appeared to be 
supressing VEGFR2 effects. An explanation for this came when it was discovered that β3 
bound to the VEGF co-receptor Nrp1, and prevented its association with VEGFR252. Co-
depletion of Nrp1 and β3 leads to a significant reduction in tumour angiogenesis, backing 
up the suggestion that β3 limits Nrp1/VEGFR2 associations and pro-angiogenic signalling218. 
Pharmacological inhibition of Nrp1 however is not likely to be as straight forward as with 
β3, or tolerated as well in patients, due to the fact that constitutive deletions of Nrp1 are 
lethal in mice embryonically43. However a small deletion of the cytoplasmic tail of Nrp1 
does still synergise with β3 inhibition in preventing angiogenesis without the embryonic 
lethality218,219. β3 also has other known anti-angiogenic roles such as being the receptor for 
tumstatin, a fragment of basement membrane collagen IV released during MMP9 
degradation common in angiogenesis and tumour growth, acting as a kind of negative 
feedback220. 
Defining an integrin like β3 as simply pro or anti-angiogenic is likely an over simplification 
that has complicated the field of angiogenesis research. Evidence has arisen that the 
precise contribution of β3 to angiogenesis is context dependent for example pro-
tumorigenic in the brain but anti-tumorigenic in ovarian cancer221,222. An interesting 
interpretation of β3 is that it is indeed pro-angiogenic, but depletion of this integrin leads 
to compensation in endothelial cells to account for its loss and that this compensation 
results in a net gain of angiogenic potential. This was highlighted by recent studies that 
showed a short term depletion of β3 reduced angiogenesis and tumour growth but long 
term depletion increased both223. Regardless of β3’s actual role in angiogenesis, it is still of 
use as a targeting aid in delivering payloads to angiogenic vasculature224. 
Whilst this compensation method is not currently known, it is worth considering the other 
major fibronectin binding integrin in endothelial cells α5β1. Much of the integrin signalling 
cascade of β3 is common to β1 and it is also expressed at higher levels on angiogenic 
vasculature225. Like β3, β1 is also known to have pro and anti-angiogenic functions such as 
the binding of endostatin in a similar way to β3 binding tumstatin226. β1 also has its own 
relationship with Nrp1195. The precise nature of β3 compensation in endothelial cells, and 
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whether this involves β1 or another mechanism, is something that was investigated in this 
thesis. 
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Figure 1-3 Model of the Inactive and Active Confirmations of Integrins 
 
A realistic model of the inactive confirmation of integrin αIIbβ3 (left) and a hypothetical 
model of the active integrin (right). Alpha chains (blue), beta chains (green), Talin-1 (purple) 
and a fragment of fibronectin (red). Image created by the RCSB Protein Data Bank based on 
crystal structures 142,227–229.  
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The Adhesome 
The adhesome is a vast network of proteins involved in regulating cell-matrix adhesions 
including adhesion, signalling and structural proteins230. The adhesome of any given cell is 
matrix dependent, but on integrin ligating ECMs it will include at its core the focal adhesion 
but also an expanded network of other types of adhesion sites and supporting 
cytoskeletons etc231. An overview of families of proteins known to be present in focal 
adhesions can be seen in figure 1-4. 
Methodology 
 
Adhesion research papers using traditional biochemistry approaches had identified about 
160 adhesome members230. A step change in methodology to a non-candidate adhesome 
member identification process came in the form of protein mass spectrometry, made 
possible by advances such as commercial iron trap mass spectrometers232, which soon 
increased the number of known adhesome proteins to over 2000186. Quantitative mass 
spectrometry is critical to understanding how the stoichiometry of adhesome members 
would change upon a gene deletion or drug challenge233, this would be a useful feature to 
understand how compensation for the loss of β3 for example is achieved as some 
adhesome proteins are essential for endothelial cell migration and need to be recruited by 
other means. Several strategies can be employed to achieve quantitative mass 
spectrometry, most of which make use of heavy isotopes of carbon, nitrogen or hydrogen 
to change the mass of peptides in a predictable way to assist in 
identification/quantification. These include: metabolic labelling, where organisms or 
cultures are fed labelled nutrients which are incorporated into their proteins naturally; 
chemical labelling, where a reaction is carried out to couple isotope containing moieties to 
proteins; spike-in controls, where pre-labelled peptide libraries are added in with samples 
of interest during mass spectrometry to generate quantifications by comparison; and label-
free, where no labelling or spiking is carried out234. Label-free quantitative mass 
spectrometry has been made possible by advances in quantification algorithms and 
improved accuracy of mass spectrometers, which simplifies experimental designs by 
omitting labelling steps also reducing the costs from the expensive isotopes235. Whole cell 
proteomics, i.e. mass spectrometry of whole cell lysates, whilst useful in some studies is 
not appropriate for identifying adhesome members. Peptide coverage of higher organism 
proteomes is still very low despite steady gains, meaning that abundant proteins in whole 
cell lysates would likely be identified instead of more interesting transiently interacting 
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members of the adhesome236. Instead some kind of purification is needed to enrich for 
adhesome proteins before mass spectrometry to decrease background but also increase 
the likelihood of protein identification/quantification. Crosslinking compounds have been 
used to covalently link adhesome proteins to substrates of interest such as fibronectin to 
assist in enrichment186,237. Chemically reversible crosslinkers are often used which have 
predictable target sites in peptides, which allow them to be used successfully in mass 
spectrometry where their modifications that affect peptide masses can be accounted for to 
still give accurate quantification238,239. 
Contents of the Adhesome 
 
Previous adhesome studies have shown that an entire class of adhesome components, LIM 
domain proteins, are recruited to nascent focal adhesions during their development to 
mature focal adhesions and that this recruitment is dependent on the ability of the cell to 
sense matrix stiffness through integrin engagement and Myh2 (Myosin heavy chain 2) 
activity233. Pxn is an example of an important LIM domain protein recruited during focal 
adhesion maturation154. Others include Zyx (Zyxin), recruited during stress sensing to 
reinforce the link between focal adhesions and the actin cytoskeleton or Migfilin, carrying 
out the same role as Zyx but also linking to Filamin-a155,240. Further adhesome studies found 
this Myh2 sensing was dependent on α5 containing integrins which lead to the maturation 
of focal adhesions and use of αv integrins, which were not further dependent on Myh2 but 
instead regulated the response to the matrix stiffness indicated by α5, therefore 
cooperation between both α5β1 and αvβ3 was needed to achieve the correct sensing and 
response to matrix stiffness186. Work by Schiller et al186,233 highlighted the usefulness of 
Gene Ontology services, where datasets are provided that can be used to annotate 
quantitative mass spectrometry results to allow the identification of an entire class of 
proteins with similar domains, structures or functions that are co-regulated rather than 
only being able to identify single proteins241,242 and an example of this analysis can be seen 
in figure 1-4. Other studies of the adhesome have used mass spectrometry to identify 
proteins that were not previously known to have adhesion roles. For example Rcc2 was 
originally identified as a microtubule regulator, often found in the nucleus particularly 
during cell division, but was identified as having a negative role in cell spreading by 
interacting with other adhesome members Rac1 and Arf6243,244. Finally the fields of 
adhesome research are being advanced further with the use of more advanced tools such 
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as activation state dependent antibodies which have been used to discover that active 
α5β1 recruits microtubules to focal adhesions but the inactive integrin does not237. 
Whilst there have been several thousand proteins identified in published adhesome 
studies, comparison between them has identified a core consensus adhesome of only 60 
proteins245. These 60 represent the proteins absolutely essential for forming adhesions, and 
the thousands of other proteins are the matrix and cell-dependent proteins that can 
participate in cell adhesion. The majority of adhesome studies mentioned so far have been 
carried out in fibroblasts and none have been published studying endothelial cells. 
Additionally no study has been carried out to identify the role of β3 in regulating the 
adhesome in cells. It is very likely that the inclusion of certain proteins in the non-
consensus adhesome depends greatly on the integrins available, matrix and cell type. 
Endothelial specific proteins such as Nrp1 interact with integrins, focal adhesion proteins 
and regulate focal adhesion turnover, potentially making the endothelial adhesome unique 
compared to other cell types52,246,247. Other endothelial specific proteins such as VE-
cadherin also influence focal adhesions through crosstalk with integrins via RhoA and other 
connections248,249. Crosstalk between integrins and growth factor receptors discussed 
earlier is common in many cell types, and endothelial cells have a unique complement of 
receptors including the VEGF receptors which are known to influence cell adhesion by 
phosphorylation of Fak1 through Src and Hsp90 (Heat shock protein 90 )250.
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Figure 1-4 Protein Domains Found in the Adhesome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An overview of the types of protein domain families often found in the adhesome by mass spectrometry experiments and their relative abundances by 
shown by area. Adapted from Schiller and Fässler251.  
37 
 
Microtubules 
Microtubules are a major type of cytoskeleton in mammalian cells, with the others being 
the actin cytoskeleton and the intermediate filament network. They are made up of 
primarily alpha and beta tubulin monomers, with 4 other tubulin families that play 
supporting roles in the microtubule filament252. Alpha and beta tubulin monomers come 
together to form dimers, these dimers then polymerise, alpha contacting beta, with other 
dimers to form a protofilament and 13 protofilaments are complexed together to form the 
hollow tube of the microtubule structure (shown in figure 1-5A); the alpha then beta 
structure gives microtubules a polarity with the first beta monomer exposed as the minus 
end and the last alpha moment exposed as the plus end253. Dimers can only be added or 
removed from the microtubule at the plus end meaning that the balance of polymerised 
and free tubulin controls the fate of the microtubule254. Tubulins are GTPases meaning they 
bind GTP (Guanine tri-phosphate) and hydrolyse it to GDP (Guanine di-phosphate), when 
bound to GTP, tubulin dimers are able to polymerise into microtubules, but shortly 
afterwards hydrolysis occurs and GDP tubulin is prone to disassembly255. However often 
more GTP bound tubulin is incorporated onto the plus end of the microtubule, blocking the 
earlier bound GDP tubulin from disassembly. The delay between tubulin addition at the 
plus end and the hydrolysis of GTP creates a “GTP cap” that protects the microtubule from 
disassembly254, also shown in figure 1-5A. Microtubules can exhibit dynamic instability, 
meaning they can switch rapidly from growing and shrinking behaviours. If addition of GTP 
bound tubulin monomers slows, then the hydrolysis of GDP will catch up and reach the end 
of the microtubule, where exposed GDP bound tubulin will fall off followed by a chain 
reaction of depolymerisation along the microtubule known as catastrophe. At any point, 
bound GTP tubulin can bind to the shrinking plus end to “rescue” the microtubule and re-
establish the GTP cap allowing stable growth256. Control of the dynamic instability of 
microtubules is carried out by a vast array of proteins that bind to the plus end and 
regulate polymerisation, depolymerisation, GTP hydrolysis and direction of the growth 
known as +TIPS (Microtubule plus end tracking proteins)257. Other proteins that regulate 
microtubule behaviour that bind to tubulin dimers are known as MAPs (Microtubule 
associated proteins) such as Map6 which stabilities microtubules to halt cold induced 
disassembly258. Low temperatures cause spontaneous microtubule disassembly of 
unprotected microtubules and so cold stability can be a useful assay in determining if 
microtubules are being actively protected by MAPs or +TIPs259,260. 
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Function 
 
Microtubules have both structural and transportation roles in cells, meaning that targeting 
of their growth direction is key for ensuring the correct function. Microtubules for example 
interact with two major types of motor proteins: dyneins which move cargo to the minus 
end of the microtubule and kinesins which move cargo to the plus end261. Entire vesicles 
can be coupled to these motor proteins, for example vesicles containing proteins from the 
golgi apparatus for exocytosis are carried along microtubules leading to the cell 
membrane262.Microtubule networks are needed to give structural support to the retracting 
edge of migrating cells, but must also be able to shrink so they do not hinder the full 
retraction, hence the need for dynamic and controlled growth/shrinkage263. Microtubules 
can also affect cell migration by direct association with focal adhesions, delivering Dyn2 to 
disassemble focal adhesions via Fak1 interactions191. 
Regulation 
 
As described above, microtubules have a complicated existence with multiple opportunities 
for regulatory proteins to influence their behaviour by binding tubulin mononers, dimers 
and the microtubule polymer. Many of these interaction sites are binding sites for 
microtubule targeting drugs. Most drugs fall into two categories: those that destabilise the 
microtubule and those that stabilise them. Both categories commonly interfere with cell 
division and migration, due to those processes relying on the dynamic instability of 
microtubules and hence too stable or unstable networks will hinder them, making 
microtubule targeting drugs attractive anti-cancer agents264. Three sites have been 
characterised in microtubules where drugs are known to bind. The taxane site is found in 
the GDP bound active site of beta tubulins, and drugs which bind here force a 
conformational change in the tubulin to resemble that of the GTP bound tubulins, 
inhibiting disassembly like the GTP cap265. Taxanes such as paclitaxel and epothilones such 
as epothilone B are examples of clinically used drugs which stabilise microtubules this 
way266,267. The “vinca site”, named for where vinca alkaloid drugs bind, is again found near 
the active site of beta tubulins but of the GTP confirmation, preventing GTP hydrolysis but 
importantly binds to the alpha and beta tubulin dimer inducing premature assembly in 
solution and preventing existing microtubules from being extended268. Vinca site binding 
drugs, such as vinblastine, also bind to plus ends of microtubules and produce a slight curve 
in the protofilaments, preventing them from assembling properly. This process is also 
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known as an end-poisoning mechanism269,270. The other site, known as the colchicine site, is 
found on the interface of the alpha and beta tubulin dimerisation site. Drugs such as 
colchicine are microtubule destabilisers that prevent microtubule assembly and induce 
their disassembly when colchicine bound dimers are incorporated into the microtubule271. 
The vast array of drugs available make manipulating microtubules in vitro and in vivo 
possible. 
Interactions with Focal Adhesions 
 
Microtubules have been observed targeting nascent focal adhesions as well as inducing the 
disassembly of mature focal adhesion, suggesting they have multiple roles to play in focal 
adhesion dynamics191,272. Microtubules can influence the formation of focal adhesions via 
Rac1 by activating Rac1 GEFs at membrane protrusions to promote adhesion after 
protrusion during cell migration273. Rac1 activity is important in regulating microtubule 
behaviour in addition to the actin cytoskeleton and focal adhesions, therefore these 
processes will compete for the attention of activated Rac1 and as a result will be 
linked274,275. As well as inducing focal adhesion assembly after membrane protrusion, 
microtubules also deliver the integrins to this area via transport proteins276. After focal 
adhesions formation, microtubules continue to deliver components to focal adhesions, 
transforming them into mature focal adhesions277. This attraction to focal adhesions is 
often termed microtubule capture, as various +TIPS such as Clip1 (CAP-Gly domain 
containing linker protein 1) can become linked to focal adhesions278. Microtubules 
themselves participate in the protrusion of the cell membrane at the leading edge, but also, 
their stimulation of focal adhesion formation subsequently leads to their capture at 
adhesions favouring the maturation of focal adhesions only where integrin ligation occurs 
will lead to further delivery of cargo by microtubules in a kind of feedback loop279. 
Microtubules have been observed targeting mature focal adhesion at the rear of a 
migrating cell to stimulate their disassembly and cause detachment, allowing the cell to 
contract the rear edge to move forward280. Microtubules target these mature focal 
adhesions by growing parallel to actin fibres towards the terminus where the adhesion is 
found, in a process dependent on crosslinkers of microtubules and actin such as 
spectraplakins like Macf1 (Microtubule actin crosslinking factor 1)281; in contrast the 
targeting of nascent adhesions at the front of the cell seems dependent on microtubule 
capture by the focal adhesion as mentioned above, possibly because the actin cytoskeletal 
links to these adhesions haven’t yet matured. Without Macf1, microtubules at the rear 
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edge of migrating cells are disorganised and focal adhesion turnover is reduced confirming 
this alternative mechanism of microtubule targeting to focal adhesions282. Microtubule 
induced disassembly of focal adhesions is not one way, as upon focal adhesion disassembly 
the microtubule also undergoes catastrophe in a Pxn dependent process283. Figure 1-5B 
shows a brief overview of different ways microtubules can target focal adhesions. 
Microtubules in Angiogenesis 
 
Cell adhesion and migration are critical processes in angiogenesis, therefore microtubule 
dynamics have strong influences on endothelial cell behaviour, with microtubules known to 
regulate endothelial cell migration284,285. Aside from regulating focal adhesions, 
microtubules are also known to influence angiogenesis by controlling VEGFR2 
internalisation, as shown when microtubule disruption lead to an accumulation of VEGFR2 
on the surface of endothelial cells286. As a result, microtubule inhibitors are increasingly 
used in tumours due to both their anti-cancer and anti-angiogenic effects, as both 
outcomes will serve to shrink tumours and often the endothelial cells respond to better to 
lower, sub-toxic, doses of the inhibitors than cancer cells which often develop 
resistance126,264,287. Several microtubule inhibiting drugs are being evaluated for anti-
angiogenic treatment such as paclitaxel288 and some are being used in combination with 
other types of chemotherapeutics such as fosbretabulin, which has very strong anti-
angiogenic effects such as vessel loss and endothelial cell death289,290. 
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Figure 1-5 Overview of Microtube Assembly and Behaviour in Cell Migration 
  
A The 13 protofilament cylinder structure and key processes highlighting the dynamic 
instability of microtubules. GTP-tubulin dimers adding to the plus end (top) allow growth of 
the microtubule whereas subsequent hydrolysis to GDP-tubulin allows the filament to 
shrink. The area between the plus end and the point of hydrolysis is known as the GTP-cap. 
Figure adapted from Bowne-Anderson et al256. B A schematic showing how microtubules 
can interact with focal adhesions across their lifecycle during cell migration. Microtubules 
can sometimes be targeted to nascent adhesions (A) or track along actin fibres to existing 
focal adhesions (B). Recruitment to mature focal adhesions can occur via adaptors via 
A
B
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proteins such as Clasps or Clips (C). Focal adhesions have been observed increase 
disassembly at the rear of the cell when they are targeted by microtubules. Adapted from 
Stehbens et al291 
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Aims 
 
Given that β3 presents such an interesting target for anti-angiogenic therapy, this project 
was designed to add to existing knowledge of the role of β3 in the endothelial adhesome in 
an attempt to explain why compensation for the loss of the integrin occurs. This 
compensation for the loss of the integrin215 has resulted in disappointing outcomes when 
targeting it in vivo. Candidate based approaches have identified proteins such as Nrp1 
which can enhance angiogenesis upon loss of β3218 leading us to believe there could be 
other undiscovered mechanisms. A non-candidate approach would be needed to help 
uncover the full role of β3 in the adhesome, which could be used to manipulate 
angiogenesis in combination with β3 targeting. 
To fulfil the above objectives, more detailed aims include: 
1. Develop a non-candidate approach that can be used to uncover the role of β3 in 
the adhesome 
2. Define the endothelial adhesome for the first time to provide a robust dataset to 
refer back to upon β3 depletion and to confirm our non-candidate approach was 
valid by confirming the presence of expected angiogenic proteins based on 
literature 
3. Use our validated method to define the adhesome of β3+/+, β3+/- and β3-/- 
endothelial cells as well as those under treatment with c(RGDfV) (Cyclo(-Arg-Gly-
Asp-D-Phe-Val) trifluoroacetate). This data can then be used to identify the roles of 
Integrin β3 in the adhesome and compensation pathways for its loss 
4. Target the identified compensation pathways as a potential anti-angiogenic 
treatment in vitro and in vivo 
5. Once pathways are validated and confirmed useful, then elucidate the molecular 
mechanism behind them by further mining adhesome data and other available 
datasets 
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Chapter two – Materials and Methods 
Reagents 
All reagents were purchased from Sigma-Aldrich (Poole, UK) unless stated otherwise and all 
antibodies used are listed in table 2.1. VEGF-A164, hereafter referred to as VEGF was made 
according to Krilleke et al292. EMD66203, referred to as c(RGDfV),was purchased from  
Mice and Genotyping 
All mice used were from a mixed C57BL6/129 background. β3-/- mice were obtained from 
β3+/- x β3+/- crosses, where each mouse had a single β3 knockout allele, also generating 
β3+/+ littermates. Original β3 knockout mice were obtained from Hodivala-Dilke et al151. 
Pdgfb (Platelet derived growth factor subunit b) tamoxifen inducible cre (referred to as 
Pdgfb cre) mice were obtained from Marcus Fruttiger293 (UCL, London, UK) and Tie1 
(Tyrosine-protein kinase receptor 1) constitutively driven cre (referred to as Tie1 cre) mice 
were obtained from Reinhard Fässler294 (Max Planck, Martinsried, Germany). Both cre lines 
were crossed to β3 floxed mice295 obtained from Jochen Schneider (University of 
Luxembourg, Luxembourg) to generate double β3 floxed cre positive or negative 
littermates. All animal experiments were performed in accordance with UK Home Office 
regulations and the European Legal Framework for the Protection of Animals used for 
Scientific Purposes (European Directive 86/609/EEC). 
Endothelial Cell Isolation and Immortalisation 
Mouse ECs were isolated from the lungs of mixed C57BL6/129 background mice. The lungs 
were finely chopped with scalpels and then digested with collagenase type I solution. 0.2% 
(w/v) collagenase type I solution was prepared in PBS (Phosphate buffered saline) with 
1mM MgCl2 and CaCl2, allowed to auto-digest for 1 hour at 37˚C, diluted in half with more 
PBS with 1mM MgCl2 and CaCl2 and supplemented with DNase at 1 to 1000 dilution. After 1 
hour of digestion at 37˚C, lungs were passed 3 times through a 19 gauge needle and then 
once through a 21 gauge needle. Lung digests were then centrifuged at 400 g for 5 minutes 
and resuspended in mouse lung endothelial cell medium prepared as per Reynolds and 
Hodivala-Dilke296, consisting of DMEM/F12 20% FBS with penicillin/streptomycin, glutamine 
and 50 mg L-1 endothelial mitogen (Biogenesis). The cells were then plated on 0.1% gelatin, 
10 µl ml-1 collagen and 10 µl ml-1 fibronectin coated T75 flasks. After 24 hours flasks were 
washed once with PBS to remove non adhered cells. Once flasks were confluent, they were 
positively sorted for ICAM2 (BD Biosciences Clone 3C4). 3 ml of PBS with 1 to 1000 dilution 
of ICAM2 was incubated directly on the lung culture flask at 4˚C for 30 minutes on a rocker. 
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Antibody solution was removed and the flask washed with ice cold PBS before adding a 
sheep anti-rat IgG dynabeads (ThermoFisher) solution at 1 to 1000 in 3 ml media then 
incubated for 30 minutes at 4˚C on a rocker. Beads solution was removed and cells washed 
twice with ice cold PBS before trypsinisation. The cell solution was then placed in a 
magnetised tube rack and non-bead coated cells removed with a media wash. Finally, the 
cells were removed from the rack, resuspended in media then plated on a coated T25 flask 
as above. A second round of sorting was carried out a week later. 
Immortalisation was carried out as per Robinson et al52. Briefly, primary endothelial cells 
were treated with polyoma-middle-T-antigen containing retrovirus media (supernatant of 
GgP+E cell line from ATCC) supplemented with 8 µg ml-1 polybrene for 6 hours at 37˚C. 
Afterwards retrovirus media was removed and replaced with mouse lung endothelial cell 
medium. Retrovirus exposure was repeated the next day. Immortalisation was confirmed 
by culture for 4 weeks and were subsequently used in experiments up till passage 20. 
Endothelial identity was routinely checked by flow cytometry as per Ellison et al218. 
Focal Adhesion Enrichment 
Focal adhesion enrichment for mass spectrometry was developed by Schiller et al233 and 
adapted for endothelial cells. IMMLECs (Immortalised mouse lung endothelial cells) were 
starved in serum-free OptiMEM® (ThemoFisher) for 3 hours and seeded at 6 x 10-6 cells per 
plate in 10 cm plates that were previously coated with 10 µg ml-1 fibronectin or 0.01% poly-
l-lysine (Mw 150,000 to 300,000) in PBS overnight at 4°C and blocked in 1% BSA (Bovine 
serum albumin) in PBS for 1 hours at room temperature. Cells were adhered for 90 minutes 
to allow for mature focal adhesions to form and either stimulated with 30 ng ml-1 VEGF at 
37°C in the last 10 minutes or not at all. Cells were washed in PBS with 1 mM CaCl2 and 1 
mM MgCl2 before being incubated with 0.05 mM DPDPB (1,4-Bis[3-(2-
pyridyldithio)propionamido]butane) and 0.5 mM DSP (Dithiobis(succinimidyl propionate) 
for 5 minutes to crosslink focal adhesions to the plate. This reaction was quenched with 1 
M Tris-HCl pH 7.5 before cells were lysed in RIPA (Radioimmunopreciptation assay buffer) 
for 30 minutes on ice with occasional agitation. RIPA was collected without scraping, and 
the plates were blasted with a high-shear flow jet of RO (Reverse osmosis) water to remove 
cell debris. The flow of RO water was approximately 7 litres per minute through a 20mm 
diameter tube compressed to 1 mm to form a nozzle. Crosslinked proteins were eluted 
with 2 ml DTT (Dithiothreitol) buffer (25 mM Tris-HCl pH 7.5, 10 mM NaCl, 0.1% SDS, 100 
mM DTT) for 1 hour at 60°C in a sealed and humidified chamber. 8 ml of acetone was 
added to this solution and left overnight at -20°C to allow the proteins to precipitate with 
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10 µl GlycoBlue™ Coprecipitant (ThemoFisher). Samples were centrifuged at 13,000 g for 
30 minutes and the acetone layer removed. The pellet was then resuspended in 30 µl EB 
buffer (3% SDS, 60 mM sucrose, 65 mM Tris-Hcl pH 6.8) before being used in western 
blotting, silver staining or mass spectrometry (see below) as the “crosslinked material” 
Western Blotting 
Protein samples were homogenised using acid-washed glass beads in a Tissue Lyser 
(Qiagen) at 50 Hz for 2 minutes before being centrifuged at 12,000 g for 10 minutes at 
room temperature and then quantified using DC™ Protein Assays (Bio-Rad) where 
appropriate. Samples were loaded onto 10% SDS-PAGE (Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis) gels then transferred to a nitrocellulose membrane and 
incubated for 1 hour in 5% milk powder in PBS with 0.1% Tween 20 followed by overnight 
incubation in primary antibody diluted 1:1000 in BSA in PBS with 0.1% Tween 20 at 4°C. The 
membranes were then washed 3 times using PBS with 0.1% Tween 20 before being 
incubated with the appropriate horseradish peroxidase conjugated secondary antibody 
(Dako) diluted 1:2000 in 5% BSA in PBS with 0.1% Tween 20 for 1 hour at room 
temperature. The blot was visualised using Pierce® ECL Western Blotting Substrate kit 
(ThermoFisher) and chemiluminescence detected in a LAS-3000 darkroom (Fujifilm UK Ltd). 
Silver Staining 
Silver staining was carried out on 2 µl of the crosslinked material samples from focal 
adhesion enrichments carried out as above along with 2 µl of total cell lysates as controls. 
These samples were run on 10% SDS-PAGE gels before being silver stained using the 
Pierce™ Silver Stain Kit (ThermoFisher). 
Mass Spectrometry 
Three good quality crosslinked material samples, as determined by silver staining, were 
pooled together and analysed three times by label-free mass spectrometry at the 
Fingerprints Proteomics Facility, Dundee University, Dundee, UK as per Schiller et al233. 
Peptides were identified and quantified using MaxQuant software with the Andromeda 
peptide database. 
Adhesion Assay 
96 well plates were coated in 10 µg ml-1 fibronectin in PBS overnight at 4°C then blocked 
with 1% BSA in PBS for 1 hour at room temperature. 20,000 cells were seeded into each 
well and allowed to adhere for 90 minutes. Cells were then washed with PBS with 1 mM 
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MgCl2 and 1 mM CaCl2 3 times to remove non adhered cells and fixed with 4% PFA 
(Paraformaldehyde) for 10 minutes at room temperature. After a further PBS wash, cells 
were stained with 1% methylene blue in 10 mM borate buffer pH 8.5/50% methanol for 30 
minutes at room temperature. Excess stain was removed with RO water before a 50% 0.1 
M HCl/50% ethanol destain solution was used for 10 minutes at room temperature. The 
destain solution was then moved to a new plate and read absorbance was measured at 630 
nm. Adhesion assay was adapted from Ellison et al218. 
Immunocytochemistry 
20,000 IMMLECs were seeded onto FN (Fibronectin) coated/BSA blocked coverslips (acid 
washed and baked before coating) and adhered for 90 minutes before being washed with 
PBS and immersed in -20°C methanol for 20 minutes. Coverslips were then washed with 
PBS, blocked for 10 minutes at room temperature with 0.5% BSA, 1% goat serum (or 1% 
donkey serum where anti-Nrp1 antibody was used) in PBS with Triton X-100 and incubated 
with primary antibody diluted 1:250 for 1 hour at room temperature. After subsequent PBS 
washes, the coverslips were incubated with the appropriate goat (or donkey for anti-Nrp1 
staining) raised Alexa-Fluor® (ThermoFisher) conjugate secondary antibodies diluted 1:500. 
Coverslips were washed again in PBS before being mounted onto slides using Prolong® 
Gold with DAPI (ThermoFisher). 
Simultaneous tubulin and actin staining was carried out using PHEMO fixation297. 20,000 
cells were seeded onto FN coated/BSA blocked coverslips (acid washed and baked before 
coating) and adhered for 90 minutes. Coverslips were then washed with PBS at 37°C and 
fixed with PHEMO buffer (68 mM PIPES, 25 mM HEPES, 15 mM EGTA and 3 mM MgCl2) 
with 3.7% PFA and 0.05% glutaraldehyde for 10 minutes at 37°C. 2 further washes in 
PHEMO buffer were carried out for 10 minutes each at 37°C before a final wash in PBS at 
room temperature. Blocking and staining was then carried out as above but with phalloidin 
diluted 1:100 in PBS to stain actin filaments (ThermoFisher A12380). 
Nucleofection 
All plasmid constructs and siRNAs were transfected into IMMLECs using nucleofection, a 
highly effective method of transfecting endothelial cells without using viruses298. After 
trypsinisation and counting, 1 x 106 cells were resuspended into 100 µl of transfection 
buffer (200 mM HEPES, 137 mM NaCl, 5 mM KCl, 6 mM D-glucose, 7 mM Na2HPO4) and 
mixed with 3 µg of ON-TARGET plus SMARTpool siRNA (Dharmacon), ON-TARGET plus Non-
targeting Control Pool siRNA or GFP-Pxn plasmid (Maddy Parsons, King’s College London, 
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London, UK). Nucleofection was carried out using an Amaxa™ Nucleofector II (Lonza) on the 
T-005 setting.  
Live Cell Imaging 
IMMLECs were transfected with a GFP-tagged Pxn cDNA expression (provided by Maddy 
Parsons299) construct by nucleofection and allowed to recover overnight before a fraction 
were seeded on FN coated/BSA blocked coverslips (acid washed and baked before coating) 
and adhered for 3 hours. Cells were then treated with 100 nM SiR-Tubulin and 1 µM 
verapamil (Cytoskeleton Inc CY-SC002) overnight. Coverslips were then imaged individually 
on an Axiovert (Zeiss) inverted microscope where one image of a GFP-positive cell was 
taken every minute for 30 minutes at 37°C and 5% CO2 in green and far-red channels. 
During imaging media was replaced with phenol-free OptiMEM® with 2% FBS containing 
100 nM SiR-Tubulin and 1 µM verapamil. The total area of adhesive fronts was assessed by 
measuring the growth of GFP-Pxn positive areas between the 1st and 30th image and then 
the number of microtubules that entered the adhesive front over 30 minutes were 
counted. 
Cell Viability 
96 well plates were coated in 10 µg ml-1 fibronectin in PBS overnight at 4°C then blocked 
with 1% BSA in PBS for 1 hour at room temperature. 10,000 IMMLECs were seeded into 
each well and were allowed to adhere for 3 hours. Cells were then treated with a wide 
range of microtubule inhibiting agents overnight before being washed with PBS and fixed 
with 4% PFA for 10 minutes at room temperature. Methylene blue staining and analysis 
was carried as above for adhesion assays. Experiments were repeated using a narrower 
range of microtubule inhibiting drugs to find the exact dose at which 90% of cells survived 
compared to untreated control. 
Random Migration 
24 well plates were coated with 10 µg ml-1 fibronectin in PBS overnight at 4°C and then 
blocked with 1% BSA for 1 hour at room temperature. 10,000 ECs were seeded per well and 
allowed to recover overnight.  Media was then replaced with media containing one of the 
following microtubule targeting agents: 5 nM Paclitaxel (Abcam 120143), 1 nM Epothilone 
B (Abcam 141271), 10 µM  Colchine (Abcam 120663), 0.4 µM Mebendazole (Abcam 
141246), 0.5 µM Fosbretablin (Sigma-Aldrich SML1131) or 1 µM Eribulin provided by 
Katherine Weilbaecher (Washington University, St Louis, USA) (DMSO (Dimethyl sulfoxide) 
was used as a control). Alternatively, 0.08 µM Tanespimycin (Abcam 171433) as an Hsp90 
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inhibitor was used. A phase contrast image was taken of each well every 20 minutes using 
an inverted Axiovert (Zeiss) microscope for 15 hours at 37°C and 5% CO2. The ImageJ plugin 
MTrackJ300 was then used to manually track individual cells and the speed of random 
migration was calculated. 
In Vivo Tumour Assay 
The syngenic mouse lung carcinoma cell line (derived from C57BL6 mice) CMT19T was used 
in all tumour experiments, as per Steri et al223. Under anaesthetic, mice were injected 
subcutaneously in the flank with 1 x 106 cells. Tumours then grew for 7 days, at which point 
they were palpable through the skin, before the mice were treated with 0.15mg kg-1 
Eribulin intravenously once a week for 2 weeks or 8 mg Doxorubicin kg-1 at day 11 and 14 
via intraperitoneal injection. After 21 days mice were culled and tumours were excised, 
photographed and measured for volume using a digital caliper. Tumours were bisected 
along the midline, fixed overnight in 4% paraformaldehyde, preserved for several days in 
cryoprotectant (20% sucrose, 2% poly(vinylpyrrolidone) in PBS), embedded in gelatin (8% 
gelatin, 20% sucrose, 2% poly(vinylpyrrolidone) in PBS) before being snap frozen and stored 
at -80°C. 
Immunohistochemistry 
5 µm cryosections were prepared from frozen tumours and stained as described 
previously223. Images were acquired on an Axioplan (Zeiss) epifluorescent microscope. 
Additionally, scans of complete sections were achieved using the AxioVision MosaiX plugin. 
Tissue area and vessel counts were obtained using ImageJ, as described in Ellison et al218. 
Microtubule Cold Stability Assay 
Microtubule cold stability assays were carried out as described in Ochoa et al259. Briefly: 
750,000 ECs were seeded per well of a 6 well plate (FN coated/BSA blocked as described 
earlier) and allowed to adhere for 75 minutes at 37°C before being moved to ice for 15 
minutes. Cells were then washed with PBS and then 100 µl of PEM buffer (80 µM PIPES pH 
6.8, 1 mM EGTA, 1 mM MgCl2, 0.5% Triton X-100 and 25% (w/v) glycerol for 3 minutes. A 
second brief wash was performed with 50 µl PEM buffer. All PEM buffer was collected and 
pooled together with 150 µl EB buffer (3% SDS, 60mM Sucrose, 65mM Tris-HCL pH 6.8) at 
2X concentration. Remaining material on the plate was then extracted using 300µl of EB 
buffer. Samples were then used in Western blotting analysis. 
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Additionally, the same procedure was used on ECs adhered to FN coated/BSA blocked 
coverslips (acid washed and bake-sterilised before coating). They were seeded as per the 
immunocytochemistry method then underwent the cold stability assay as above except 
that, immediately after PEM washing, the slides were immersed in -20°C 100% methanol 
for 20 minutes. Coverslips were stained as in the rest of the immunocytochemistry method. 
In some cases the Rac1 inhibitor NSC23766 (Abcam 142161) was used during the cold 
stability assay. Cells were adhered for 60 minutes at 37°C before being treated with 50 µM 
NSC23766 or DMSO control for 15 minutes at 37°C. Cells were then moved to ice for a final 
15 minutes before finishing the procedure as above. 
Active Rac1 Assay 
6 x 106 ECs were seeded onto FN coated/BSA blocked 10 cm plates and allowed to adhere 
for 90 minutes. Rac1 Activation Magnetic Beads Pulldown Assay kit (Millipore 17-10393) 
was then used per manufacturer’s instructions by lysine cells in MLB (Magnesium lysis 
buffer) before using Pak1-PBD (P21 (Rac1) activated kinase 1 – P21 biding domain) beads to 
pull-down active Rac1. Pull-down material was then loaded directly onto a gel for western 
blotting. 
Statistical Analysis 
All graphs presented show the mean as the bar height ± standard error of the mean. 
Statistical significances between means were calculated using Student’s t-test where ns, *, 
**, *** and **** represent p > 0.05, p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 
respectively. 
Significance analysis of microarrays301 was carried out within the Perseus statistics 
package302 using  250 randomisations in a permutation based false discovery rate of 0.01 
for truncation with an S0 cut-off of 1 to identify statistically significant proteins between 
two samples. 
51 
 
Antibodies 
Target Supplier Catalogue Conjugate Application 
Acta2 Abcam 124964   Immunohistochemistry 
Anxa2 Abcam 41803   Western Blotting 
Emcn (Endomucin) Santa Cruz Biotechnology 65495   Immunohistochemistry 
Filamin-a Abcam 76289   Western Blotting 
Gapdh 
(Glyceraldehyde-3-
phosphate 
dehydrogenase) Abcam 9484   Western Blotting 
Goat ThermoFisher A-11055 Alexa® 488 Immunocytochemistry 
Hspa1a (Heat shock 
protein family A 
(Hsc70) member 1A) Santa Cruz Biotechnology 7298   Western Blotting 
β3 Cell Signalling 4702   Western Blotting 
Erk1/Erk2 Cell Signalling 4695   Western Blotting 
Mouse Dako P0447 Horse radish peroxidase Western Blotting 
Mouse ThermoFisher A-11004 Alexa® 568 Immunocytochemistry 
Nrp1 Cell Signalling 3725   Western Blotting 
Nrp1 R and D Systems AF566   Immunocytochemistry 
Ptk1 Cell Signalling 3285   Western Blotting 
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Pxn Abcam 32084   Western Blotting / Immunocytochemistry 
Rabbit Dako P0448 Horse radish peroxidase Western Blotting 
Rabbit ThermoFisher A-11008 Alexa® 488 Immunocytochemistry / Immunohistochemistry 
Rac1 Merck 05-389   Western Blotting 
Rat ThermoFisher A-11077 Alexa® 568 Immunohistochemistry 
Rcc2 Abcam 70788   Western Blotting 
Tln1 Sigma T3287   Western Blotting / Immunocytochemistry 
Tuba (pan) Abcam 7291   Western Blotting 
Tuba (pan) Abcam 52866   Immunocytochemistry 
Vim (Vimentin) Cell Signalling 5741   Western Blotting 
 
List of all primary and secondary antibodies used.
53 
 
Chapter three – Isolation and Mass Spectrometry of the 
Endothelial Cell Adhesome 
The aim of this chapter is to optimise and adapt the adhesome enrichment technique 
developed by Schiller et al233 to work with endothelial cells. Quality control methods are 
also needed to ensure efficient use of mass spectrometry time. Additionally, the 
configuration of MaxQuant required testing in order to successfully identify proteins 
modified during the adhesome enrichment. 
Development of Adhesome Enrichment Method 
Focal adhesions and the wider adhesome are known to consist of over 2400 proteins, 
although across multiple experiments and cell types the absolute core consensus is only 
about 60 proteins245. Cell matrix, integrin availability, cell type and culture conditions can 
all make a big difference to the adhesome, therefore it was important that we devised a 
method to specifically identify the endothelial cell adhesome before we could study the 
role β3 plays in its composition. 
All adhesome proteins could, in theory, be identified from a whole cell lysate by western 
blotting or mass spectrometry techniques. However many components of the adhesome 
are transient in nature: associating with one another upon events such as matrix 
engagement, engaging downstream effectors or de-associating with each other upon focal 
adhesion maturation. Even the core of the adhesome, the integrins, can exchange freely 
with the cytoplasmic pool by internalisation or recycling as well as move diffusely across 
the cell membrane in the right conditions303. Trafficking of integrins, for example, can 
include endocytosis from the membrane and degradation or recycling via, for example, 
Rab4 (Ras-related protein 4) or Rab11/Arf6 pathways194. Whole cell analysis could capture 
integrins at any of these points, complicating analysis, so we decided it was necessary to 
enrich for proteins present in adhesion complexes under defined conditions. An effective 
enrichment would give us a snapshot of the adhesome which could then be compared to 
previous studies in other cells and provide us with a means to study how β3 affects the 
composition of the adhesome. 
Historically, identification of focal adhesion components was carried out by co-
immunoprecipitations for the desired integrin, such as when Nrp1 was identified as a 
component with β3 containing focal adhesions52. In order to reduce non-specific 
interactions with the antibody, stringent lysis buffers are used which can prevent transient 
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or weak interactions. Unless an activation-state specific antibody is used to 
immunoprecipitate, which exist for β1304 but not mouse β3, then integrins in other cell 
compartments (as mentioned earlier) would also be precipitated. Additionally this would 
not have allowed us to study the adhesome in β3 deficient cells. 
At least two suitable techniques have been developed to enrich for adhesome complexes 
and have so far been applied to fibroblasts. One method developed by Humphries et al244 
employs (ECM)  ligand coated beads to pull down adhesion complexes from cell lysates and 
chemical crosslinking to preserve transient interactors before purification. Another method 
by Schiller et al233 allows cells to adhere on matrix coated dishes, followed by chemical 
crosslinking of dish/matrix/adhesion complexes and high shear flow washing to remove 
non adhesome material. The Humphries et al method has greater flexibility of ligand choice 
(any whole or part of an ECM molecule could be used) as the cells can be grown on any 
substrate before lysis and pulldown using beads coated with ligand of interest. Whereas 
the Schiller et al method requires the ECM to be something that the cells will adhere to 
natively without other required matrices because it is these attachments to the ECM that 
will become the adhesome sample. In this case, assisting cells that may not adhere to a 
single component ECM with additional matrices could complicate analysis. Using beads to 
pull down complexes in cell lysates could also run the risk of isolating β3 from any cell 
compartment that has the potential to be activated and bind matrix as it is possible during 
cell lysis and homogenisation that aberrant activation could occur. We therefore decided to 
adapt the Schiller et al method for use in endothelial cells as we thought this would provide 
a better snapshot of proteins actively involved in cell adhesion in a more physiologically 
relevant setting. The downside was that cells can also stick to substrates using non-integrin 
adhesions (which would also be crosslinked) but this was overcome by using a PLL (Poly-l-
lysine) negative control to identify these adhesion components as cells will still adhere to 
PLL treated surfaces305. 
As adhesome enrichment had not been carried out on endothelial cells before we 
therefore used conditions outlined by Schiller et al for fibroblasts as a starting point where 
cells are allowed to adhere onto fibronectin for 90 minutes before being crosslinked for 5 
minutes, lysed with RIPA for 30 minutes and then shear washed. Crosslinking with the cell 
permeant reversible crosslinkers DSP and DPDPB for only 5 minutes was designed to allow 
the highest ratio of adhesome to non adhesome protein crosslinking. DSP (also known as 
Lomant’s reagent) can crosslink primary amines such as the N-terminus of peptides and the 
side chain of lysine that are approximately 1.2 nm across proteins in a complex306. DPDPB 
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crosslinks thiol groups (such as those found on the amino acid cysteine) approximately 1.99 
nm apart238. Both DSP and DPDBP can be reversed by thiol-based reducing agents such as 
DTT allowing any crosslinked proteins to be eluted and analysed. A five minute incubation 
with both crosslinkers before carrying out the remainder of the adhesome enrichment 
protocol and then western blotting showed that the DSP/DPDBP combination could diffuse 
into cells, crosslink proteins and prevent adhesome components from being washed away 
(figure 3-1A). Nrp1 and β3, previously reported members of the adhesome307, were 
detected in the crosslinked material and not the untreated indicating the crosslinkers were 
functional under the conditions used. Additionally Hspa1a and Fak1, as intracellular 
members of the adhesome186, were also detected with crosslinker treatment meaning DSP 
and DPDBP were able to successfully diffuse through the cell membrane. The absence of 
Nrp1, β3, Hspa1a and Fak1 in the non-crosslinked (DMSO control) elution shows these 
proteins do not bind sufficiently to the matrix to avoid being blasted away during washing. 
Control lysates taken from the RIPA used to break apart the cells showed that crosslinking 
did not disrupt important epitopes required for immunoblotting. 
The next step in optimising the protocol was to check that the cells adhered to the PLL 
negative control (also see figure 3-3) and that it was functioning correctly as such. As seen 
in figure 3-1B there was less β3, Hspa1a and Gapdh detected in the crosslinked material 
from cells adhered to PLL than fibronectin. Proteins expected to be involved in adhering to 
fibronectin such as β3 were only enriched when cells adhered to fibronectin and not PLL 
suggest the crosslinking was specific to adhesion complexes. In the RIPA derived samples 
there were equal amounts of all immunoblotted proteins in the PLL and fibronectin 
conditions indicating that IMMLECs are able to adhere to PLL in 90 minutes. It was also 
important to test that cells deficient in β3 (genetically heterozygous cells) are still able to 
adhere to both fibronectin and PLL to allow subsequent investigations into the role of β3 in 
the adhesome. In the crosslinked material, fibronectin adhered samples, roughly equal 
amounts of Hspa1a and Gapdh were detected in β3+/+ and β3+/- cells meaning the β3+/- 
cells had no trouble adhering. There was less β3 however but this was expected due to the 
genetic differences in the cells – also reflected in the RIPA samples. 
Whilst the crosslinking, general enrichment, acetone precipitation and PLL as a negative 
control were working successfully in endothelial cells; a problem, identified in figure 3-1B, 
was that Gapdh was also been detected in the crosslinked material samples. Gapdh, a key 
housekeeping gene involved in glycolysis, is commonly used as a loading control308 hence 
its use on figure 3-1B. However unlike Hspa1a, another commonly used loading control309, 
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Gapdh is not found in reported adhesomes186,233,237,310. The combination of two loading 
controls, Gapdh and Hspa1a, has shown that the enrichment process was still not specific 
enough and allowed too many non-adhesome proteins to be detected in the final western 
blots. Alternatively the crosslinkers may be penetrating too deep into the cell and 
crosslinking cytoplasmic material, which could have been explored further if other 
optimisation steps failed. A range of optimisation attempts were carried out and the 
solution was to change from a benchtop RO water system (Milli-Q® EMD Millipore) to an 
industrial scale RO plant which provided much higher water pressure for the high shear 
flow washing stage. 
Figure 3-2A shows the result of the water pressure optimisation. Of the crosslinked 
material samples, a single lane is marked with an * to show that this sample was shear 
washed with the Milli-Q® system whereas the remaining were washed with the higher 
pressure RO plant. The low pressure * sample showed a higher intensity signal for all 
antibodies tested. Importantly, the Gapdh signal had now been removed in the higher 
pressure washed samples hence the adhesome enrichment had been successful and did 
not include non-adhesome proteins. To ascertain the depth of crosslinking achieved (i.e. 
how far the crosslinkers diffused past the cell membrane) we also looked at the signalling 
molecules Erk1 and Erk2. These proteins, also known as Erk1/2, have many roles in 
signalling cascades within cells but are also known to translocate to focal adhesions to 
facilitate outside-in signalling upon cell adhesion311. Our ability to detect small and 
potentially transient members of the adhesome using crosslinkers would give a greater 
meaning to the studies performed later. Additionally, as an alternative focal adhesion 
marker to Fak1 (seen in figure 3-1A), Tln1 has been detected in the crosslinked material 
samples even with the higher pressure washing. Tln1 recruitment to integrins requires that 
Fak1 binds first and begins signalling for the generation of a focal adhesion312. Therefore we 
were confident that IMMLECs were forming mature and functional focal adhesions during 
the 90 minute adhesion to fibronectin in the conditions used for adhesome enrichment. 
High pressure washing had also not affected our ability to enrich for Nrp1, β3 and Hspa1a. 
A reversible Ponceau-S stain on the nitrocellulose membrane used for immunoblotting in 
figure 3-2A is shown in figure 3-2B. The * lane again showed many more bands than the 
higher pressure washed lanes and resembled the adjacent RIPA lysates. Higher pressure 
shear washing was therefore useful to further remove non-adhesome cell contents and 
leave behind only crosslinked proteins. 
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In the same experiment we also tested if VEGF, the main growth factor implicated in 
angiogenesis313, could affect the ability of cells to adhere to fibronectin and prevent a 
successful adhesome enrichment although it was also likely that because VEGF can 
promote migration of endothelial cells directly or through interaction with Nrp1, it could 
actually enhance adhesion314. This could result in an increased detection of proteins in PLL 
negative controls with VEGF stimulation but, as seen in figure 3-2A, this was not the case. 
Being able to use VEGF without affecting the adhesome enrichment procedure would 
prove useful later to help us define the endothelial cell adhesome. 
Despite increasing the water pressure during optimisation, another problem became 
evident. Figures 3-2A, B and C have biological repeats from different preparations included 
on the same western blots; there was a noticeable inconsistency with the intensity of the 
detected signals. This is particularly evident in figure 3-2C where the Filamin-a signal varied 
widely between the duplicate +VEGF crosslinked material samples. As a focal adhesion 
protein that links the actin cytoskeleton to integrins and regulates their 
activation/downstream signalling315, it should have shown a consistent signal, especially 
since all the samples generated in figure 3-2C came from β3+/+ cells. The same sample with 
a high FlnA also showed an abnormally high Vim signal whereas one of the - VEGF samples 
was completely missing a Vim signal. As an intermediate filament, Vim is found to associate 
with β3 positive adhesions in endothelial cells316 and so it should have been present in 
adhesome enriched samples and at consistent levels in β3+/+ cells. Pxn, another focal 
adhesion marker like Tln1 and FAK317 also showed the inconsistency between biological 
repeats. Taken together these observations suggest that the water pressure used may still 
not be high enough to achieve consistent adhesome enrichments. This was problematic 
considering we did not have access to an even higher pressure RO water source. We 
speculated however that we were on the cusp of having sufficient water pressure and that 
western blotting consisting of Gapdh and multiple focal adhesion markers would be 
sufficient to identify the successful adhesome enrichments from the unsuccessful ones. 
However it was not practical to use this method in further identification of the endothelial 
cell adhesome because it required western blotting of the whole sample, leaving none 
remaining for non-candidate analysis. 
Another reason why we could not have used western blotting in further analysis of the 
endothelial adhesome was highlighted by Nrp1 immunoblots (figures 3-1B and 3-2A). The 
intensity of Nrp1 signals were sometimes below the limit of detectability in western 
blotting. Using protein arrays to immunoblot for several hundred proteins at once to profile 
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the endothelial adhesome would also not have been practical for the same reason. It was 
likely that many of the adhesome proteins were represented in the adhesome at even 
lower amounts than Nrp1. Scaling up our adhesome enrichment protocol beyond 6 million 
IMMLECs per sample would have been impossible practically and economically, leaving the 
only other solution to defining the adhesome being mass spectrometry. 
Finally, as seen in figure 3-3, we confirmed the conditions chosen for adhering cells for use 
in adhesome enrichments produce focal adhesions matching the observations made in 
figures 3-1 and 3-2. Tln1 was not found in adhesome samples when adhered to PLL and no 
focal adhesions structures are observed in cell staining of β3+/+ IMMELCs unlike when 
fibronectin coating is used. Nrp1 staining followed the same pattern but also overlapped 
with Tln1 staining when cells adhered to fibronectin, again confirming that Nrp1 was a 
member of the adhesome as observed in figures 3-1 and 3-2. The fact that cells were still 
present to be stained after two washes when adhered to PLL (indicated by the DAPI signals 
showing a cell nucleus present) double confirmed that IMMLEC cells are able to adhere to 
PLL successfully. In the development of the adhesome enrichment technique. Schiller et 
al233 carried out staining experiments to validate their procedure where Pxn was used as a 
marker of focal adhesions and Transferrin (CD71)  as a negative control after high shear 
flow washing. In our experiments it was difficult to stain after the washing stages so instead 
figure 3-3 shows staining on un-washed cells using PLL as a negative control for focal 
adhesion formation. Both methods, in our interpretation, show the concept of focal 
adhesion enrichment and the PLL negative control functioned as expected. 
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Figure 3-1 Adhesome Proteins Can be Crosslinked in Endothelial cells and Poly-l-
Lysine Functions as a Negative Control 
 
A Adhesome enrichment was carried out on β3+/+ IMMLECs adhered to fibronectin for 90 
minutes before being treated with DMSO or crosslinkers (DSP/DPDPB), lysed with RIPA 
buffer then shear flow washed. Crosslinked material was eluted using DTT then acetone 
precipitated and western blotted along with the collected RIPA buffer as Whole Cell Lysate 
for Nrp1, β3, Fak1 and Hspa1a. B Adhesome enrichment carried out as above but adhering 
β3+/+ or β3+/- IMMLECs to fibronectin or PLL. Samples were then western blotted for 
Nrp1, β3, Hspa1a and Gapdh. 
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Figure 3-2 Higher Pressure Washing Reduced Sample Complexity 
 
A Adhesome enrichment was carried out on β3+/+ and β3+/- IMMLECs adhered to 
fibronectin or PLL for 75 minutes then stimulated with VEGF(+) or DMSO(-) for 15 minutes 
before being treated with crosslinkers (DSP/DPDPB), lysed with RIPA buffer then shear flow 
washed. Crosslinked material was eluted using DTT then acetone precipitated and western 
blotted along with the collected RIPA buffer as Whole Cell Lysate for Tln1, Nrp1, β3, 
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Hspa1a, Erk1, Erk2 and Gapdh. All adhesome enrichments were carried out with high 
pressure RO water shear washing except * sample which used a Mill-Q® benchtop system. 
B A ponceau stain of the membrane used in panel A before antibody incubation. C 
Adhesome samples were generated as above except only β3+/+ IMMLECs used and all 
adhered to fibronectin. Samples were western blotted for Filamin-a, β3, Vim and Pxn. 
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Figure 3-3 Endothelial Cells Adhere to Fibronectin and Poly-l-Lysine 
 
β3+/+ ECs were adhered to fibronectin (top row) or poly-l-lysine (bottom row) coated/BSA 
blocked coverslips for 90 minutes before fixing and immunostaining for neuropilin-1 (Nrp1-
green) and talin-1 (Tln1-red) along with a nuclear stain (DAPI-blue). Scale bar = 10 µm.  
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Quality Control and Experimental Design Development of Adhesome 
Enrichment 
Ponceau-S staining, as seen previously in figure 3-2B, hinted at a possible way of screening 
for successful adhesome enrichments to use in downstream analysis. The * sample had 
clearly received insufficient shear washing. However to generate a Ponceau-S stain visible 
to the naked eye required use of the whole sample meaning it could not be used for 
anything other than screening ahead of a single western blot. Far more sensitive protein 
staining methods exist such as Coomassie or silver staining directly on the gel after 
SDS/PAGE. We wanted to investigate whether using 1/6 of the crosslinked material would 
be sufficient to screen for successful enrichments, which would leave 5/6 for western 
blotting or mass spectrometry. Although some Coomassie stains are compatible with mass 
spectrometry (and only a few silver stains), silver staining was chosen as the preferred 
method due to its greater sensitivity318. Compatibility with mass spectrometry was not 
considered an issue as we were taking a fraction of the sample for testing and leaving the 
rest unstained for future analysis. 
Figure 3-4A showed the comparison between high and low pressure shear washing using 
silver staining. Like earlier, the * sample had received insufficient washing compared to the 
other crosslinked material samples. Interestingly, the * sample closely resembled the RIPA 
lysate control samples indicating that a large amount of non-adhesome proteins must have 
remained after blasting and would not have represented a clean adhesome enrichment 
sample. Silver staining 1/6 of the crosslinked material directly on SDS/PAGE gels was 
therefore selected as the best screening method: if no bands were detected, then the 
sample was excluded (most likely due to crosslinking failure or sample loss during acetone 
precipitation); or if the crosslinked material resembled the RIPA lysate control, then the 
sample was also excluded. 
In order to generate a complete picture of the adhesome we needed to generate three 
datasets for every cell genotype/drug/condition to be tested – fibronectin, fibronectin with 
VEGF and PLL adhesomes. Fibronectin as a positive control and PLL as a negative control 
would be essential for defining the endothelial adhesome whereas fibronectin with VEGF 
would help identify proteins enriched in the adhesome during angiogenic responses. Not 
including a PLL with VEGF sample saved time and costs, a strategy employed by Schiller et 
al233 where fibronectin, fibronectin with blebbistatin and PLL adhesome enrichments were 
carried out to define the fibroblast adhesome and the role of mysosin II which is inhibited 
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by blebbistatin319. Like blebbistatin, VEGF was not expected to make a big impact on the 
PLL adhesome and fibronectin vs fibronectin with VEGF two sample comparisons would be 
able to identify proteins regulated by VEGF.  
Silver staining, as well being used as a quality control, was also able to show protein 
differences between adhesome enrichments. For example, the differences between the FN 
crosslinked material samples were obvious compared to PLL which had fewer proteins can 
be seen in figure 3-4B. It was reassuring to observe proteins in the PLL sample as none 
were seen in the Ponceau-S staining (figure 3-2B); this meant that IMMLECs can both 
adhere to PLL and still generate a crosslinkable, enrichable adhesome – essential for 
identifying non-integrin dependent adhesion proteins. Figure 3-4B also revealed subtle 
differences with VEGF treatment in the crosslinked material therefore it was considered 
worth the investment to use VEGF treated samples in further analysis. Additionally there 
were fewer proteins stained in all three crosslinked material samples than the RIPA lysate 
control indicating successful enrichment. We used the silver stains shown in figure 3-4B as 
the standard to compare later adhesome enrichments to when carrying out quality control 
of samples. 
Given the successful optimisation of all three kinds of adhesome enrichments we used the 
schematic outlined in figure 3-5 to generate data for further analysis. Many biological 
replicates of each type of adhesome enrichment were generated for β3+/+, β3+/-, β3-/- 
and c(RGDfV) (a specific integrin αvβ3 inhibitor) treated IMMLECs. The crosslinked material 
from these enrichments were subjected to silver staining as quality control, with three 
replicated matching the banding patterns seen in figure 3-4B pooled together. Pooled 
samples were then sent for Nano LC-MS/MS analysis using an LTQ Orbitrap mass 
spectrometer as per Schiller at el233. Each pooled sample was analysed three times via 
technical repeats through the mass spectrometer yielding three raw files each. The 
advantages for analysing pooled samples three times rather than analysing three individual 
samples once will be discussed below. 
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Figure 3-4 Silver Staining as an Indication for Successful Adhesome Enrichment 
 
A Adhesome enrichment was carried out on β3+/+ and β3+/- IMMLECs adhered to 
fibronectin or PLL for 90 minutes before being treated with crosslinkers (DSP/DPDPB), lysed 
with RIPA buffer then shear flow washed. Crosslinked material was eluted using DTT then 
acetone precipitated then run of a SDS-PAGE gel before being silver stained. All adhesome 
enrichments were carried out with high pressure RO water shear washing except * sample 
which used a Mill-Q® benchtop system. B Adhesome enrichment was carried out as above 
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with only β3+/+ IMMLECs adhere for 75 minutes before being stimulated with VEGF(+) or 
DMSO(-) for 15 minutes. Samples were then ran on an SDS-PAGE gel and silver stained. 
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Figure 3-5 Experimental Design for Defining the Endothelial Adhesome Incorporating 
Silver Staining Quality Control 
 
A schematic of the experimental design for defining the endothelial adhesome. Triplicate 
adhesome samples that pass silver stain quality control from IMMLECs adhered to 
fibronectin or poly-l-lysine and treated with VEGF or DMSO are pooled into a single sample 
before being analysed by mass spectrometry. Statistical analysis of three LC-MS/MS 
repeats reveals the fibronectin and VEGF dependent adhesomes of endothelial cells. 
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Optimisation of MaxQuant Label Free Quantification 
Thermo raw files, containing LC-MS/MS spectra, were obtained after sample analysis by 
LTQ Orbitrap. Briefly, three stages of computation analysis were carried out on the data: 
MS/MS spectra were identified as peptides using the Andromeda database320, peptides 
were matched to proteins predicted from the mouse genome and LFQ (Label free 
quantification) was carried out to work out the relative abundance of each protein in the 
samples. All of this was carried out using the quantitative proteomics software package 
MaxQuant321. 
Optimisation of MaxQuant parameters was carried out in order to generate the maximum 
useful amount of data from the limited three raw files per condition. MaxQuant, like any 
mass spectrometry software, has a greater chance of identifying and quantifying proteins 
with a greater number of technical repeats as shown in table 3-1 where increasing the 
number of samples included gave more protein identifications. Three repeats was the 
largest viable number of repeats attainable due to cost and time considerations. During 
optimisation, MaxQuant generated full data files outlining LFQ of proteins in samples 
however many of these were not useful for further consideration in the context of cell 
biology due to only a small number of files being analysed at any one time with sometimes 
incorrect methods. Hence only the metadata of these MaxQuant runs will be included in 
this thesis, not the full “test” files. 
Quality of the MaxQuant runs was assessed using the number of unique proteins identified 
and the specific identification of the following proteins: β3, αv, α5, β1, Nrp1, Rac1, Tln1 and 
VE-cadherin. Detection of the fibronectin binding integrins listed was considered critical in 
order to perform downstream analysis as well as the key focal adhesion marker Tln1. We 
had previously shown Nrp1 was detectable in the endothelial adhesome218 therefore it was 
important to make sure the “depth” of the dataset was still good enough to do so again. 
Rac1 detection was considered important as it is a known transient member of the focal 
adhesions322 and could have been present at low levels and therefore difficult to detect – 
much like Erk2/3 was studied previously (figure 3-2A). Finally VE-cadherin was included as 
an endothelial cell marker323 as its detection was evidence of endothelial identify in 
IMMLECs. 
Table 3-1 shows the metadata results of the first four test runs of MaxQuant using 
adhesome enrichment samples that had been screened by silver staining previously as per 
figure 3-4. Test 1, as a benchmark, used default settings for MaxQuant which automatically 
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detected conditions used in the LC-MS/MS runs using the metadata associated with the 
supplied raw files. It showed that from six runs, 802 proteins could be detected however 
only 4/8 of the “quality” proteins were detected. Given the successful detection previously 
by western blot of most of these quality proteins then the failure to detect all eight 
indicated MaxQuant was not calibrated properly to analyse our LC-MS/MS runs. It was 
tempting to speculate that some of the undetected quality proteins are ones that are 
difficult to detect by mass spectrometry. This could be because these proteins do not 
produce many uniquely identifiable peptides after trypsin cleavage and ion fragmentation, 
or that the unique peptides they produce are inherently unstable and break down into non 
unique peptides (shared by other proteins in the sample) before being detected in the 
spectrometer324. However all of the chosen quality proteins have been detected by 
previous groups using mass spectrometry so it should have been possible to detect them in 
our samples as long as their abundance was not too low233,237,245,325.  
Comparing test 1 and test 2 showed us that the match between runs feature of MaxQuant 
was able to increase the quality of proteins detected in the sample. The match between 
runs algorithm allowed MaxQuant to use information from one sample to assist in peptide 
identification in another sample because they were both generated at the same time with 
identical experimental conditions. Briefly, if within sample X a peptide could be identified 
from an MS/MS spectra but not in the technical or biological repeats samples Y and Z, then 
the retention times of unidentified MS/MS spectra in samples Y and Z could be matched 
(within a certain tolerance depending on the specifications of the mass spectrometer) to 
the retention time of the successfully identified MS/MS spectra in sample X. If a match is 
found, then the previously unidentified but retention time matched MS/MS spectra of 
samples Y and Z are assumed to be the sample peptide identified in sample X – providing of 
course that the low quality MS/MS spectra in samples X and Y do not show enough 
information to disprove that assumption. Crucially, the quantification for the identified 
peptide (and later whole protein) is calculated only from the information in the single 
samples to give three separate and independently calculated quantifications326. In test 2, 
this feature allowed information from multiple runs to detect enough extra peptides to 
identify two extra quality proteins compared to test 1. The re-quantify feature, used in test 
3 for the first time, did not significantly increase the number of proteins detected but also 
was not detrimental to the quality of the analysis so was used for all subsequent runs. Test 
4 showed that more samples supplied to MaxQuant for analysis increased the number of 
proteins detected and quality, therefore in the next chapter, we aimed to analyse as many 
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samples simultaneously as was possible for defining the endothelial adhesome. This also 
meant it was preferable to analyse a single pooled sample three times rather than three 
individual samples once, as it allowed MaxQuant to achieve a better depth of analysis. 
Although match between runs and re-quantify features had increased the quality of the 
runs, it was still not satisfactory and could have led to our subsequent analysis lacking a 
strong conclusion due to incomplete mass spectrometry readouts. We suspected that the 
crosslinkers used in the adhesome enrichment process, DSP and DPDPB, had permanently 
modified peptides despite the DTT reduction reversing the crosslinking process. These 
modified peptides would have different mass/charge ratios to unmodified peptides and 
therefore not match anything present in the Andromeda database so they would remain 
unidentified. 
The DPDPB and DSP crosslinking reactions for adjacent proteins can be seen in figure 3-6A 
and 3-6B respectively. DPDBP, as a thiol reactive compound, crosslinks cysteine residues 
with the reducible/reversible sulphur-sulphur bond in close proximity whereas DSP, as an 
anime reactive compound, crosslinks lysine residues (or the N-terminus of proteins) with its 
reducible/reversible bond distant from the crosslinked protein. This meant that, as seen in 
figure 3-6C, DPDBP crosslinker reversal with DTT left the original proteins unchanged but 
DSP (in figure 3-6D) left behind part of its spacer arm. Adhesome enriched samples were 
generated by using these crosslinkers to stabilise the adhesome against high pressure shear 
washing, therefore most of the proteins in our samples were crosslinked with either DSP 
and/or DPDPB at least once. DPDBP treatment and reversal was “invisible” to MaxQuant 
but DSP permanently altered peptide mass/charge ratios. If any of these alterations 
occurred on unique peptides for important proteins then MaxQuant failed to identify these 
proteins, explaining why the quality of our runs was lower than expected. 
Custom modifications can be added into Andromeda and one such modification was 
automatically included by MaxQuant to account for the acetamidation of thiols by IAA 
(Iodoacetamide). Disulphide bonds between adjacent cysteines in proteins are strong 
enough to resist fragmentation in mass spectrometry327. Therefore, it is common practise 
to permanently modify cysteines after reduction using IAA to prevent disulphide bonds 
reforming in downstream sample preparation, as carbamidomethylated cysteine residues 
cannot form these bonds. The reaction can be seen in figure 3-6E where IAA’s reaction with 
a thiol side chain is shown. IAA can potentially react with any thiol group so at this point is 
was unclear whether it would also react with the thiol group generated through the 
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reduction of DSP crosslinked proteins. If IAA was able to carbamidomethylate the products 
shown in figure 3-6D it was unknown if it would do so at the same rate as with normal 
cysteine residues as it could have been slower due to steric hindrance by the DSP spacer 
arm. Therefore we did not know if the IAA reaction would proceed to completion with 
reduced DSP crosslinked proteins (i.e. if every DSP modified protein would be 
carbamidomethylated). 
New custom modifications were added to Andromeda searches to account for the possible 
peptide modifications outlined above: DSP-N-terminus, DSP-lysine, carbamidomethylated 
DSP-N-terminus and carbamidomethylated DSP-lysine. All of these modifications were 
included in the MaxQuant test 5 in in table 3-2. Whilst this resulted in more proteins being 
identified than in test 3 (table 3-1) the quality was lower. This suggested that the IAA 
reaction with DSP treated proteins did proceed to completion and the unnecessary DSP-N-
terminus/DSP-lysine modifications were causing MS/MS spectra to be misidentified. We 
speculated that, because there were no real DSP-N-terminus/DSP-lysine modifications in 
our samples, this was leading MaxQuant to identify incorrect proteins from the mislabelled 
MS/MS spectra where it thought it could see modified peptides. This also reduced the pool 
of correctly identified MS/MS spectra that could be used to search for the quality proteins 
we were looking for explaining the lower quality of test 5. In test 6 we removed DSP-N-
terminus/DSP-lysine modifications but kept the carbamidomethylated versions. This gave a 
better quality result with less proteins identified so we believed we had removed the 
incorrect proteins seen in test 5. 
In mass spectrometry sample preparation, trypsin was used to digest proteins before LC-
MS/MS. Trypsin cleaves C terminally after arginine and lysine residues328 and the 
assumption that all proteins would be cleaved in this way before fragmentation into ions 
was used by MaxQuant to help in the identification of proteins. However trypsin cannot 
always access its cleavage site if the protein has been post-translationally modified, hence 
MaxQuant by default tries to account for up to two missed cleavages per protein during its 
identification algorithms239,321,329. Carbamidomethylated DSP-lysine in our samples also had 
the potential to block trypsin cleavage therefore we increased the maximum number of 
permitted missed cleavages to from two to three or four in tests 7 and 8 respectively. 
Comparing test 6 and 7 revealed that allowing for an extra missed cleavage allowed 
MaxQuant to identify more proteins but test 8, despite identifying more proteins, gave a 
much lower quality readout. Test 8’s failure was likely due to the same reason as test 5’s 
failure – i.e. “four missed cleavage” proteins did not actually exist in our sample hence the 
72 
 
misidentified MS/MS spectra generated incorrect identifications and subtracted from 
correct identification of the quality proteins. In summary, the conditions of test 7 in table 3-
2 were chosen for use in defining the endothelial adhesome. 
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Table 3-1 MaxQuant Test Runs – Parameter Optimisation 
 
Test ID Samples Included MaxQuant Settings Proteins Identified Quality 
1 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Default 802 4/8 
2 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Match between runs 797 6/8 
3 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Match between runs; Re-quantify 799 6/8 
4 FN-β3+/+(x3),FN-β3+/+ with 
VEGF(x3), 
FN-β3+/-(x3) and FN-β3+/- with 
VEGF(x3) 
Match between runs; Re-quantify 977 7/8 
Metadata from MaxQuant trial runs of adhesome enrichments from β3+/+ and β3+/- IMMLECs adhered to fibronectin with or without VEGF stimulation. 
The effects of using MaxQuant setting “match between runs” and “re-quantify” as well as increasing amount of available data (samples included) are shown 
on the number of proteins identified and the quality of the datasets. Quality was assessed by successful identification of the following 8 proteins: β3, αv, 
α5, β1, Nrp1, Rac1, Tln1 and VE-cadherin. 
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Figure 3-6 Reactions of DSP, DPBBP, DTT and IAA in Protein Mass Spectrometry 
 
A Reaction of DPDBP crosslinker with adjacent cysteine residues.  B Reaction of DSP 
crosslinker with adjacent lysine residues and/or protein n termini. C Reaction of the 
reducing agent DTT with DPDBP crosslinked proteins. D Reaction of the reducing agent DTT 
with DSP crosslinked proteins. E Reaction of IAA with thiol groups in proteins. Figure 
generated using freeware ACD/ChemSketch © Advanced Chemistry Development, Inc. 
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Table 3-2 MaxQuant Test Runs – Protein Modification 
Test ID Samples Included MaxQuant Settings Proteins 
Identified 
Quality 
5 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Match between runs; Re-quantify; DSP-lysine; DSP-N-terminus; 
Carbamidomethylated DSP-lysine; Carbamidomethylated DSP- N-terminus 
937 5/8 
6 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Match between runs; Re-quantify; Carbamidomethylated DSP-lysine; 
Carbamidomethylated DSP- N-terminus 
856 8/8 
7 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Match between runs; Re-quantify; Carbamidomethylated DSP-lysine; 
Carbamidomethylated DSP- N-terminus; 3 missed cleavages 
872 8/8 
8 FN-β3+/+(x3) and FN-β3+/+ with 
VEGF(x3) 
Match between runs; Re-quantify; Carbamidomethylated DSP-lysine; 
Carbamidomethylated DSP- N-terminus; 4 missed cleavages 
942 6/8 
 
Metadata from MaxQuant trial runs of adhesome enrichments from β3+/+ IMMLECs adhered to fibronectin with or without VEGF stimulation. Additional 
MaxQuant settings were tested compared to those in 3-1 to assess their effects on the number of proteins identified and the quality of the dataset. 
Different variable modifications were included in MaxQuant searches resulting from the residue left by the DSP crosslinker after DTT treatment and 
carbamidomethylation. Quality was assessed by successful identification of the following 8 proteins: β3, αv, α5, β1, Nrp1, Rac1, Tln1 and VE-cadherin. 
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Chapter four – Analysis of the Endothelial Cell and Integrin β3 
Dependent Adhesomes 
The aim of this chapter is to identify a method of robust statistical analysis to identify the 
endothelial cell and β3 adhesomes from the mass spectrometry data generated using 
adhesome enrichments. This would begin to identify pathways of interest for further in 
vitro and in vivo experimentation in later chapters. 
Statistical Analysis of the Endothelial Cell Adhesome 
In order to define the endothelial adhesome we needed to generate the following β3+/+ 
IMMLEC samples: three fibronectin adhered, three fibronectin adhered with VEGF 
stimulation and three poly-l-lysine adhered. Additionally we needed to define the β3 
dependent endothelial adhesome using β3+/- and β3-/- IMMLECs later. Given that all sets 
of samples would have been generated using the same techniques and subjected to the 
same kinds of statistical analysis it was tempting to generate all samples simultaneously in 
order to minimise variations between experiments. Long term stability of crosslinking 
reagents could have, for example, been an issue for generating consistent adhesome 
samples as they are susceptible to hydrolysis306 and hence degrade over time in normal 
laboratory conditions. Other experimental variations such as day to day changes in water 
pressure for high shear washing could have also created large discrepancies between 
samples not collected at the same time. Our own experience showed that generating 
adhesome samples on different days gave unacceptable variations between what should 
have been identical samples. Figure 4-1A showed that samples generated from the same 
IMMLECs with the same conditions (β3+/+ on fibronectin) but on different days had a lower 
correlation than samples generated on the same day with different conditions such as 
β3+/+ on fibronectin vs β3+/+ on fibronectin with VEGF stimulation, seen in figure 4-1B. In 
a sense, our no VEGF to plus VEGF variations were smaller than our day to day variations 
i.e. the signal to noise ratio was too low for any meaningful conclusions. This mirrored 
experiences by Schiller et al233 who advised us personally about the need for carrying out all 
sample generation at once. 
However, generating so many samples at once turned out to be impractical given the 
number of IMMLECs required (five repeats of 6 million IMMLECs per condition) and the 
processing time required for different stages of enrichment meant having too many 
samples to process severely impacted our ability to generate useful enrichments. As a 
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solution, we decided to generate our samples in stages depending on which comparisons 
we wanted to make. Therefore β3+/+ vs β3+/- samples were generated separately from 
β3+/+ vs β3-/- samples (etc. . .). This did create duplicate β3+/+ samples but we discovered 
these could be averaged using MaxQuant to give acceptable correlations between samples, 
as shown in figure 4-1C.  
Our endothelial adhesome data was therefore much more robust than originally planned: 
three β3+/+ day one samples were pooled together and analysed three times by LC-
MS/MS; three β3+/+ day two samples were pooled together and also analysed by LC-
MS/MS three times; this was carried out for all three matrices/conditions. The six LC-
MS/MS runs were analysed in three pairs using MaxQuant – β3+/+ day one repeat one with 
β3+/+ day two repeat one and so on. The initial MaxQuant dataset, shown in 
supplementary table 1, contained 1497 identified proteins with LFQ values. MaxQuant, by 
default, contains FASTA information for common contaminant proteins such as human 
keratins from skin/hair found in most laboratories, bovine serum proteins found in the BSA 
fractions used in blocking fibronectin or poly-l-lysine plates and pig trypsin which was used 
to digest proteins prior to LC-MS/MS analysis. Most of these were identified in our initial 
dataset along with other human contaminants, but as we were working with mouse 
derived cells these were easily identified amongst our genuine hits, and subsequently 
removed. Additionally, MaxQuant controlled for false discoveries by reversing all protein 
sequences predicted from the mouse genome and searched for their possible existence in 
our LC-MS/MS runs. Several were identified in our initial dataset which were used to 
estimate our false discovery rate (used later in statistical calculations). After removal of 
contaminant and reverse-identified proteins we also filtered our datasets by removing 
proteins that were not detected in all three LC-MS/MS repeats generated from one pooled 
sample. We hoped this would give us a reliable and stringent dataset to be used to define 
the endothelial adhesome. Finally the LFQ values were normalised by a log base 2 
transformation and missing values were imputed from the total dataset to fill 0 
(undetected) values with low LFQ values. This served to generate normal distributions and 
fill invalid numbers generated by the log transformation of 0, both of which were necessary 
for statistical tests carried out later. These data transformations were carried out using 
Perseus, a statistics programme developed specifically to carry out typically used analyses 
in mass spectrometry investigations302, as well as all further statistical analysis mentioned 
in this thesis. 
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As a first stage of analysis, unsupervised hierarchical clustering based on average Euclidian 
distance was carried out using the normalised LFQ values to identify clusters of co-
regulated proteins in the context of matrix type or VEGF stimulation. This allowed us to 
distinguish genuine fibronectin adhesome proteins from poly-l-lysine bound nonspecific 
adhesion proteins as well as any proteins over-represented upon VEGF stimulation i.e. 
those whose inclusion in the adhesome is VEGF dependent. In figure 4-2, we show that our 
LC-MS/MS repeats cluster together horizontally, confirming that they all give very similar 
results. We defined 12 vertical clusters using a distance threshold of 3.34. Based on similar 
expression patterns between some adjacent clusters we defined clusters A to C as VEGF-
enriched proteins, D to F as fibronectin enriched proteins or the non-VEGF adhesome and 
G-L as poly-l-lysine enriched proteins. As our clusters were based on Euclidian distance and 
not human intuition and could not therefore be defined manually without the risk of 
biasing our results, we decided on 12 clusters as this gave the clear separation of A-C, D-F 
and G-L without introducing too many unnecessary clusters. For example, by eye it appears 
cluster F should be easy to separate into smaller clusters but the unsupervised clustering 
algorithm would have only done this after defining many other clusters first. 
At this point we also added several annotations to our dataset from publically available GO 
(Gene ontology)241 and KEGG (Kyoto encyclopaedia of genes and genomes)330 databases, 
which link proteins together that are known to have similar roles (GOBP), functions 
(GOMF), sub-cellular localisation (GOCC) or biological pathway (KEGG pathway). 
Annotation and hierarchical clustering information were combined to generate 
supplementary table 2 where all 1064 proteins that were clustered after data filtering (see 
above) are shown along with their corresponding cluster. Additionally, proteins with 
angiogenesis associated annotations are shown highlighted at the top. Many of the 
highlighted proteins are specific to endothelial cells confirming the endothelial identity of 
the IMMLECs used in our investigations as well as other markers in the rest of the table 
such as VE-cadherin. Supplementary table 2 and figure 4-2 as shown represent our 
complete endothelial cell adhesome. 
Following up changes in 1064 proteins in our endothelial cell adhesome would have been 
inappropriate and time consuming, especially as we had not yet considered statistical 
significance, therefore we decided to identify what types of proteins were over-
represented in the VEGF, fibronectin or poly-l-lysine groups of clusters. Performing Fisher’s 
exact t tests331 allowed us to investigate “enrichment” using our clustering and annotation 
datasets. All annotations that passed the FDR (False discovery rate) threshold and were 
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hence significantly enriched or depleted in the VEGF, fibronectin or poly-l-lysine clusters 
are listed in table 4-1. Leukocyte trans-endothelial migration (KEGG, p=9.71 x 10-5) proteins 
were enriched in the fibronectin adhesome but not the VEGF adhesome suggesting our 
cells represent quiescent vasculature without VEGF-stimulation, as intended. This category 
also includes many endothelial specific CAMs (Cell adhesion molecules) that have not been 
detected in other cell adhesomes332. Critically the focal adhesion category (KEGG, p = 9.31 x 
10-7) was enriched in the fibronectin adhesome but also significantly depleted in the poly-l-
lysine adhesome (p= 9.49 x 10-5). This finding confirmed to us that the entire process of 
adhesome enrichment was working successfully, from sample generation to mass 
spectrometry to statistical analysis, in order for focal adhesion proteins to successfully 
cluster and be enriched only on fibronectin and not poly-l-lysine. Also reassuring was that 
many other cell adhesion/migration associate categories were significantly depleted in the 
poly-l-lysine adhesome: focal adhesion (GOCC, p=5.99 x 10-5), cell projection (GOCC, p=3.03 
x 10-5), cell adhesion (GOBP, p=1.61 x10-6) and lamellipodium (GOCC, p=1.38 x 10-4). These 
categories were not detected as significant enrichments in the fibronectin (D to F) clusters 
due to them being separated from the VEGF (A to C) clusters, which were also adhered to 
fibronectin, when running the Fisher’s exact t test. This was done to prevent unnecessary 
repetition of results. 
Separating fibronectin with VEGF and fibronectin without VEGF groups of clusters for 
enrichment analysis allowed us to detect enrichment of the cell projection category (GOCC, 
p=8.62 x 10-5) in the adhesome with VEGF stimulation. Given that VEGF induces migration 
in endothelial cells333, normally towards a hypoxic area in response to injury or a tumour, 
we speculated that the short VEGF stimulation time of 15 mins was sufficient to start this 
process – beginning with cell projection. Therefore we knew that our VEGF was having the 
correct effect on our cells under the adhesome enrichment conditions. VEGF stimulation 
also caused an enrichment of microtubule proteins (GOCC, p=1.6 x 10-4). Microtubules are 
important to many processes within cell migration, see review by Etienne-Manneville for 
more information279, and are also known to be involved in VEGFR2 downstream signalling 
and sorting in response to VEGF286. Given microtubules’ known roles in regulating 
migration, their enrichment in the adhesome suggested that their role in endothelial cell 
migration was related to focal adhesions. 
Another way to visualise the endothelial adhesome was to create an interaction map. 
Publically available protein-protein interaction databases are commonly used in mass 
spectrometry investigations to illustrate how networks can be formed between proteins 
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detected. This would help us detect interesting “nodes” or convergent points in our 
networks that could be manipulated to affect endothelial cell behaviour. Many different 
protein-protein interaction databases exist, each created from different types of 
experiments or computationally predicted instead. We chose to use the PINA (Protein 
interaction network analysis platform) database because it contains a compilation of six 
manually curated databases - MIPs MPact, HPRD, DIP, BioGRID, MINT and IntAct334. 
Another advantage of PINA was that the creators have already filtered out duplicate entries 
that would have been created from the merging of the six parent databases to create a 
non-redundant dataset335. We were able to probe the PINA database to obtain the 
interactions of our 1064 proteins in the endothelial adhesome. For example β3 interactors 
included: αv, Pxn and Filamin-a. Showing the protein-protein interactions of 1064 would be 
impractical to display, instead we chose to initially create a network for the fibronectin 
clusters (D-F) defined in figure 4-2 and only show proteins up to two connections from the 
fibronectin binding integrins detected. Cytoscape, a network interaction visualisation tool 
designed especially for biomolecular applications336, was used to visualise the fibronectin 
(clusters D-F) adhesome in figure 4-3. 
Many ribosomal protein were detected in the fibronectin adhesome and labelled black in 
figure 4-3 where they formed a strong interacting network, indicated by their close 
proximity derived from the preferred layout algorithm of Cytoscape. It was tempting to 
speculate that ribosomes/ribosomal proteins are present exclusively in the fibronectin 
adhesome and not in non-integrin or other adhesomes. However no significant enrichment 
of such proteins was detected in fisher exact t tests seen in table 4-1. Some ribosomal 
categories, such as translation pre-initiation and RNA transport, were actually enriched in 
the poly-l-lysine adhesome which led us to believe instead that these ribosomal proteins 
are not specific to the fibronectin adhesome. There is some evidence to suggest that 
proteins can be synthesised at the edges of distance cells and that ribosomes can be 
targeted to β3 adhesions337 therefore it would be interesting to follow these proteins when 
we studied the β3 adhesome later. It is worth noting that many of these ribosomal proteins 
are notoriously nonspecific interactors in mass spectrometry experiments and are well 
represented in the contaminant repository for affinity purification-mass spectrometry 
data338. 
Figure 4-3 also demonstrated that Ilk, Pxn, Fak1 and Vcp (Vasolin containing protein), with 
their unique coloured edges, are key nodes in the endothelial adhesome due to their high 
number of interactors. If we wanted to influence adhesion of endothelial cells to 
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fibronectin then manipulating these four proteins could be a good place to start. Pxn and 
Fak1 are critical members of focal adhesions, hence their use in optimisation of the 
adhesome enrichment technique in chapter 3. Ilk, as a kinase, is ubiquitously expressed and 
essential to the functioning of focal adhesions as it allows integrins who have no intrinsic 
enzymatic activity to signal downstream as part of outside-in signalling for example339.It 
was therefore not surprising that Pxn, Fak1 and Ilk were found as important components in 
the endothelial adhesome but due to their ubiquitous nature, they would probably not be 
useful in specifically targeting endothelial cells in anti-angiogenic therapies. Vcp is thought 
to function as a chaperone and endocytosis regulator340,341 but is not known to have any 
role in angiogenesis or cell migration. Therefore it was possible its position in the 
endothelial adhesome was due to its localisation near the cell membrane for endocytosis 
and showed a high number of edges in interaction analysis due to its chaperone abilities. 
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Figure 4-1 Correlations between Adhesome Samples 
 
Log LFQ values from MaxQuant analysis of β3+/+ IMMLECs adhesome samples: A 
fibronectin day one and fibronectin day two, B fibronectin day one and fibronectin with 
VEGF day C and C Fibronectin repeat one (average day one and two) and fibronectin repeat 
two (average day one and two). R2 correlation is shown for each graph. 
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Figure 4-2 Hierarchical Clustering of the Endothelial Adhesome 
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A Unsupervised hierarchical clustering based on Euclidian distance threshold of 3.34 of 
three fibronectin, three fibronectin with VEGF and three poly-l-lysine β3+/+ IMMLEC 
adhesome samples. Clusters were labelled A-L. Generated using Perseus analysis of 
MaxQuant output. Red indicated high expression and green indicated low expression. B 
Angiogenesis associated proteins were defined using the GOBP annotations: GO:0001525, 
GO:0002040, GO:0002042, GO:0016525, GO:0045765 and GO:0045766 and displayed in a 
heatmap (red high expression and green low expression) with their clusters as defined by 
panel A. The heatmap represents the average Z-score from 3 poly-l-lysine adhesomes (PLL), 
3 fibronectin + VEGF adhesomes (VEGF) and 3 fibronectin adhesomes (FN).
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Table 4-1 Enrichment Analysis of the Endothelial Adhesome 
Clusters 
Category 
column Category value 
Category 
size 
Intersection 
size 
Enrichment 
factor P value 
Benj. Hoch. 
FDR 
VEGF GOCC name mitochondrial inner membrane 19 11 4.6316 2.25E-06 3.93E-04 
VEGF GOCC name organelle inner membrane 24 12 4 5.75E-06 8.60E-04 
VEGF GOCC name mitochondrial membrane 25 12 3.84 9.77E-06 1.36E-03 
VEGF GOCC name microtubule 41 14 2.7317 1.60E-04 9.85E-03 
VEGF GOCC name myelin sheath 66 20 2.4242 4.26E-05 3.72E-03 
FN KEGG name Arrhythmogenic right ventricular cardiomyopathy (ARVC) 17 16 2.2708 6.52E-06 1.27E-03 
PLL GOCC name eukaryotic 43S preinitiation complex 12 12 2.1714 8.46E-05 6.11E-03 
PLL GOCC name eukaryotic 48S preinitiation complex 13 13 2.1714 3.84E-05 3.66E-03 
PLL GOCC name eukaryotic translation initiation factor 3 complex 12 12 2.1714 8.46E-05 5.90E-03 
PLL GOCC name proteasome accessory complex 12 12 2.1714 8.46E-05 5.71E-03 
PLL GOCC name small nuclear ribonucleoprotein complex 21 21 2.1714 6.70E-08 2.00E-05 
PLL GOCC name translation preinitiation complex 13 13 2.1714 3.84E-05 3.50E-03 
PLL KEGG name Proteasome 21 20 2.068 1.72E-06 5.02E-04 
FN KEGG name Leukocyte transendothelial migration 22 18 1.974 9.71E-05 8.12E-03 
PLL GOCC name proteasome complex 22 20 1.974 1.04E-05 1.36E-03 
FN KEGG name Focal adhesion 46 35 1.8357 9.31E-07 5.44E-04 
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VEGF GOCC name cell projection 145 33 1.8207 8.62E-05 5.64E-03 
PLL KEGG name RNA transport 43 32 1.6159 8.28E-05 9.69E-03 
PLL KEGG name Spliceosome 62 44 1.541 2.70E-05 3.95E-03 
PLL GOCC name catalytic step 2 spliceosome 53 37 1.5159 1.99E-04 9.91E-03 
PLL GOCC name nuclear speck 53 37 1.5159 1.99E-04 9.68E-03 
PLL GOCC name nucleoplasm part 119 80 1.4598 4.25E-07 9.88E-05 
FN GOCC name nucleolus 221 127 1.3865 2.97E-08 2.07E-05 
FN GOCC name intracellular non-membrane-bounded organelle 402 208 1.2484 4.09E-08 2.14E-05 
FN GOCC name non-membrane-bounded organelle 402 208 1.2484 4.09E-08 1.71E-05 
PLL GOCC name protein complex 380 210 1.2 2.15E-06 4.10E-04 
PLL GOCC name macromolecular complex 575 304 1.148 3.93E-07 1.03E-04 
FN GOCC name macromolecular complex 575 204 0.85598 5.15E-06 8.29E-04 
FN GOCC name protein complex 380 123 0.78095 2.03E-06 4.25E-04 
PLL GOCC name intracellular non-membrane-bounded organelle 402 140 0.75622 3.33E-09 6.97E-06 
PLL GOCC name non-membrane-bounded organelle 402 140 0.75622 3.33E-09 3.49E-06 
PLL GOCC name plasma membrane 189 64 0.7353 6.11E-05 4.57E-03 
PLL GOCC name cell junction 197 66 0.72748 2.68E-05 2.80E-03 
PLL GOCC name cell-substrate adherens junction 155 50 0.70046 5.99E-05 4.82E-03 
PLL GOCC name focal adhesion 155 50 0.70046 5.99E-05 4.64E-03 
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PLL GOCC name cell-substrate junction 156 50 0.69597 4.55E-05 3.81E-03 
PLL GOCC name anchoring junction 167 53 0.68914 1.65E-05 1.92E-03 
PLL GOCC name adherens junction 164 52 0.6885 1.92E-05 2.12E-03 
PLL GOCC name cell projection 145 45 0.67389 3.03E-05 3.02E-03 
PLL GOCC name nucleolus 221 67 0.65831 4.09E-08 1.43E-05 
PLL GOBP name cell adhesion 80 17 0.46143 1.16E-06 8.02E-03 
PLL KEGG name Focal adhesion 46 9 0.42484 9.46E-05 9.22E-03 
PLL GOCC name lamellipodium 36 6 0.3619 1.38E-04 8.76E-03 
FN KEGG name Cell cycle 17 0 0 1.02E-04 7.46E-03 
FN GOCC name small nuclear ribonucleoprotein complex 21 0 0 1.14E-05 1.40E-03 
 
All significantly enriched or depleted GOMP, GOBP, GOCC or KEGG categories in fibronectin with VEGF (VEGF), fibronectin (FN) or poly-l-lysine (PLL) clusters 
of the endothelial adhesome defined in figure 4-2 that were detected by Fisher’s exact t test’s. 
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Figure 4-3 Interaction Map of Fibronectin Clustered Proteins in the Endothelial Adhesome 
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Interaction network of only fibronectin adhesome proteins (cluster D-F from figure 4-2) detected in the endothelial adhesome. Mouse and human PINA 
interaction data was mapped onto the endothelial adhesome in supplementary table 2 using cytoscape. Human gene names are shown in blue except for 
those of ribosomal proteins which are shown in black. Interactions (edges) are shown in black except for Ilk (red), Pxn (purple), Fak1 (orange) and Vcp 
(green). Only proteins two interactions from fibronectin binding integrins are shown. 
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Statistical Analysis of the Integrin β3 Dependent Adhesome 
Given that β3+/- and β3-/- adhesome samples had been generated separately, due to the 
day to day consistency problem (outlined above and illustrated in figure 4-1), their 
statistical analyses were also carried out separately. Normal statistical techniques such as t-
tests could not be used here. This was because our datasets contained over 1000 proteins 
meaning that a standard t-test would indicate 50 proteins to be significantly different with 
a p value cut off of less than 0.05 by random chance. This could have generated too many 
unconnected pathways for us to investigate further that would have detracted from 
unravelling the role of β3 in the endothelial adhesome. An appropriate test would have 
been an ANOVA (Analysis of Variance) test, however this has several assumptions such as a 
normal distribution and an equal variance in protein changes342. Whilst a normal 
distribution was corrected for in our data using imputation, equal variances could not be 
assumed. For example, it could have been possible that in β3-/- cells there were significant 
changes in proteins that exclusively bind to β3 but other proteins that can also bind β1 
might not have been affected as much. 
Similar problems exist in other areas of biological research such as in the analysis of 
microarray data that produces long lists of genes for which the expression varies between 
two conditions. A new method of analysis was developed called the Significance Analysis of 
Microarrays (SAM) method. This carried out independent t tests for each gene/protein in 
the dataset, but to avoid returning every protein with a p value of less than 0.05 SAM also 
carries out many randomised permutations (250 in our analysis) to determine if the 
response in any one protein is different to the response of the whole sample (i.e. to 
account for proteins that tend to correlate301). This permutation based FDR was used to 
eliminate false positives in our data. Application of SAM to β3+/+ vs β3+/- and β3+/+ vs β3-
/- fibronectin datasets was carried out separately and is shown in supplementary tables 3 
and 4 where 269 and 137 proteins respectively were found to be significantly increased 
(right side of SAM) with Itg3 depletion or significantly decreased in the β3+/+ (left side of 
SAM).  Fewer proteins changing significantly was originally considered somewhat counter-
intuitive.  It was tempting to speculate that a more dramatic change in β3 levels in the β3-/- 
cells would result in a greater number of changes to the adhesome. However we believed 
that total deletions of β3 would result in compensation for the loss of the integrin, such as 
those seen in β3-/- cells when levels of Flk1 are elevated and drive increased 
angiogenesis215–217. The compensation by Fkl1, possibly through Nrp1 regulation by β352 
and other mechanisms, could have been preventing the need for more dramatic changes in 
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the adhesome . Moreover, studies in β3-/- cells/animals have been criticised previously as 
they were not considered physiologically relevant hence there have been efforts to repeat 
studies in β3+/- or transiently depleted situations218,223. These studies better mimicked β3 
status when it has been targeted physiologically by current or future generations of 
integrin inhibitors as it is considered unlikely that any compound, with limitations due to 
pharmacokinetics, would be able to inhibit all β3 in an animal. This could explain why we 
saw a greater number of statistically significant changes in the β3+/- adhesome than the 
β3-/- adhesome; that the β3+/- cells do not undergo compensation for the complete loss of 
β3 but instead reveal more about the role of β3 in the endothelial adhesome. We still 
continued to study the β3-/- adhesome though, as the full extent of the compensation 
mechanisms is of continued interest. Also interesting was that in the β3+/- adhesome, 175 
proteins were significantly increased whereas only 94 were decreased in response to β3 
depletion. In the β3-/- adhesome there were 88 proteins significantly increased and only 49 
decreased. Interestingly, in both cases, β3 depletion resulted in a greater number of 
proteins being incorporated into the adhesome than lost despite the apparent loss of an 
integrin and its cytoplasmic tail as a scaffold for assembly of the outside-in and inside-out 
signalling machinery343. This suggested to us that β3 may actually be playing a dominant 
negative role in the adhesome by actively preventing certain proteins from being recruited. 
To begin to fully understand the roles of β3 in the adhesome, we started by analysing 
which pathways, cell components, or processes were represented in the β3+/- and β3-/- 
adhesomes by enrichment analysis as was carried out for defining the β3+/+ endothelial 
adhesome earlier.  Tables 4-2 and 4-3 show any categories significantly enriched in the 
β3+/- and β3-/- adhesomes respectively calculated by Fisher’s exact t test. Hierarchically 
defined clusters from figure 4-2 and supplementary table 2 were also added as 
annotations, in addition to the normal KEGG, GOCC, GOBP and GOMF annotations, to the 
β3+/- and β3-/- adhesomes, which allowed us to determine if any of our endothelial 
adhesome clusters were also significantly enriched upon β3 depletion. Initially there were 
no obvious categories enriched that could easily reveal the role of β3 in the endothelial 
adhesome or the compensation mechanism in β3-/- cells. Taken together with the SAM 
statistical tests applied earlier, we speculated that the majority of individual focal 
adhesome components in the endothelial adhesome do not change significantly upon β3 
depletion. This could have been due to the ability of α5β1 to compensate for the majority 
of αvβ3’s roles or that the changes in β3 are more subtle and only involve certain proteins 
and not whole pathways, after-all the depletion of β3 is not detrimental to the ability of 
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IMMLEC to adhere or migrate (see figure 5-5). This was demonstrated by the depletion of 
cytoskeletal parts (GOCC, p = 4.73 x 10-5) from the β3+/+ adhesome and a corresponding 
enrichment in the β3+/- adhesome (p = 7.01 x 10-5) in table 4-2 which suggested that 
downstream connections to cytoskeletal components change upon β3 depletion. 
Alterations in connections from the cytoskeleton to the adhesome suggested that β3, 
whilst not making a large contribution to the composition of the adhesome, could have an 
important influence in cellular behaviour through the cytoskeleton. Additionally, there was 
no indication that ribosomes or ribosomal proteins were of interest to β3 depleted 
adhesion despite their representation in the endothelial adhesome in figure 4-3. 
Some interesting enrichments, though, were apparent in the β3+/- adhesome. Table 4-2 
showed the enrichment of several endoplasmic reticulum categories in the β3+/- 
adhesome: protein processing in endoplasmic reticulum (KEGG, p = 4.01 x 10-7), 
endoplasmic reticulum part (GOCC, p = 1.21 x 10-7) and endoplasmic reticulum (GOCC, p = 
1.39 x 10-6). These enrichments suggested the endoplasmic reticulum has become targeted 
to focal adhesions in β3+/- cells. The endoplasmic reticulum is known to extend along 
microtubules to focal adhesions where it increases their growth and promotes cell 
spreading and migration344–347. Interestingly microtubule targeting to focal adhesions is 
thought to destabilise the focal adhesions191 but this destabilisation does not occur when 
the endoplasmic reticulum also targets focal adhesions348. It was therefore decided 
important to assess specifically how microtubules were behaving in the endothelial 
adhesome given that cytoskeletal parts are depleted in β3+/- cells (table 4-2) and 
microtubules can be recruited to the adhesome with VEGF stimulation (table 4-1) – see 
figure 5-2 later . Table 4-3, the enrichment analysis of the β3-/- adhesome, showed that 
several categories of proteins with the ability to bind nucleotides were enriched, 
specifically those that could bind purines such as ATP (Adenosine Tri Phosphate). The 
enriched GOMF annotations did not provide much information about what pathways have 
been potentially enriched in the β3-/- adhesomes as many proteins have the ability to bind 
ATP. We speculated that this means that β3-/- cells, with their increased complement of 
ATP binding proteins in the adhesome and therefore near the cell surface, could be 
“triggered” by ATP signals at lower concentrations that β3+/+ cells which potentially 
explains why β3-/- cells show enhanced angiogenic responses215. Increased competition for 
ATP may also affect β3-/- cells in more specific ways as many signalling proteins important 
in angiogenesis and focal adhesion regulation use ATP such as Fak1 which can be 
influenced by both intracellular349 and extracellular350 ATP concentrations. Finally, we 
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observed that cluster F (fibronectin adhesome) was significantly depleted in both β3+/- and 
β3-/- adhesomes suggesting there was a conserved core of proteins that can only be 
recruited to the adhesome by β3 and cannot be compensated for by other 
integrins/mechanisms. The proteins must have been present in cluster F of our β3+/+ cell 
adhesome and hence any depletion of β3 resulted in somehow different adhesions. 
Regardless of whether β3 is considered pro or anti-angiogenic in any particular context, see 
review by Atkinson et al224, we now realised that targeting β3 can have a unique and 
definitive effect on focal adhesions, meaning properly directed therapies could be 
developed for potential pro or anti-angiogenic outcomes. 
We next decided to utilise our interaction database generated for the endothelial 
adhesome in figure 4-3 to investigate if β3 depletion can affect important nodes in the 
network. We took the layout defined by Cytoscape previously (from its perfuse-force 
directed layout algorithm) and incorporated significant changes in the β3+/- or β3-/- 
adhesome by changing the colour of the nodes in figure 4-4. Most of the critical nodes in 
the endothelial adhesome such as Ilk, Pxn and Fak1 were not affected by β3 depletion, 
again suggesting that β3 depletion can be compensated for in most cases by β1. However 
Vcp, a protein we earlier suggested might be a non-specific interactor, was significantly 
increased. Although it is unclear if Vcp has a defined role in angiogenesis, its relationship 
with β3 in our adhesome studies suggested it may have a currently unknown but important 
role. Interestingly, of all adjacent nodes to β3 with a significant number of edges, only 
Filamin-a was significantly increased. We believe the analysis in figure 4-4 demonstrated 
Filamin-a had the potential to be part of the β3 compensation mechanism. The network 
also reveals that Filamin-a interacts directly with β1, the most obvious candidate for β3 
compensation as another fibronectin binding integrin119. Filamin-a’s role in focal adhesions 
is to link proteins to the actin cytoskeleton, mainly integrins351 directly via their cytoplasmic 
tail352 but also to link other proteins important in cell migration and angiogenesis such as 
Vim315. Filamin-a in the context of the β3 dependent adhesome is difficult to unravel due to 
its many overlapping functions, for example it has been shown to promote focal adhesion 
stabilisation and migration in breast cancer cells via Mapk/Capn2 signalling353 but has been 
shown to be critical for Vim mediated adhesion and spreading of HEK 293 and 3T3 cells354. 
We thought that the exact contribution of Filamin-a is dependent on the cell type and 
situation, but given that Filamin-a null mice display severe angiogenesis defects355 and anti-
Filamin-a antibody treatments are anti-angiogenic356 we speculated Filamin-a is likely to be 
pro-angiogenic in endothelial cells and could explain the enhanced pathological 
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angiogenesis in β3 depleted situations. This also meant the Fln1-Vim-β1 axis was a more 
likely candidate for investigation given that Filamin-a knockdown was also shown to 
decrease β1 surface expression and activation357,358 and that Vim was also increased in the 
β3 depleted adhesome. No increase in β1 levels has been detected in the β3+/- or β3-/- 
adhesome but it is possible that β3 depletion increased Filamin-a levels which in turn 
activated more of the β1 present. Increased β1 activity would have allowed β3 inhibited 
cells to continue to adhere to and migrate on fibronectin, although at this point it was not 
clear if Filamin-a was enough to explain fully the increased angiogenesis phenotypes in 
β3+/- and β3-/- cells. 
Thbs1 (Thrombospondin-1) was an especially interesting as a protein that can interact with 
both αvβ3 and α5β1359 but was the only protein in figure 4-4 that exhibited a conflict 
between the β3+/- and β3-/- adhesomes; in β3+/- cells it was increased but in β3-/- cells it 
was decreased in the adhesome. We thought it was possible that Thbs1 may be 
upregulated in partial β3 depletion but cannot be compensated for in a total deletion 
although this was unlikely given that Thbs1 can interact with β1 which was still present in 
the β3-/- adhesome. Thbs1 itself has long been known to be a potent inhibitor of 
angiogenesis360 therefore it was even stranger that it was increased in the β3+/- adhesome; 
it was also strange that Thbs1 was decreased in the β3-/- adhesome given it could itself 
bind fibronectin361 but considering Thbs1’s anti-angiogenic functions would have 
contradicted the observed β3-/- phenotypes this was not as surprising. One of the main 
mechanisms thought to be behind the β3-/- enhanced angiogenesis phenotype was the 
increased Flk1 activation in response to VEGF217. We found our adhesome data could be 
used to expand this mechanism, specific to β3-/- angiogenesis, by rationalising Thbs1 
behaviour in the β3-/-  adhesome. Thbs1 is known to inhibit angiogenesis by binding to Flk1 
and preventing association with integrin complexes362; VEGF is still able to bind Flk1 but it 
cannot phosphorylate downstream targets such as Akt1 whilst engaged with Thbs1363. 
Therefore in β3-/- cells, lower levels of Thbs1 release Flk1 to participate in angiogenic 
signalling, enhancing angiogenesis. It is worth nothing that the kind of analysis carried out 
in figure 4-4 is not definitive due to a lack of coverage by publically available interaction 
databases. For example Nrp1 is not included in figures 4-3 or 4-4 despite it having known 
interactions with β3, Filamin-a and other proteins in the endothelial adhesome52,246. 
Additionally, to avoid overcomplicating figures we only included proteins who were two 
interactions away from α5, αv, β1 or β3 so there may have been additional unseen 
regulators. 
95 
 
We therefore decided to focus more on the SAM analysis to decide which features of the 
β3 dependent adhesome we should follow up with in vitro experimentation. Microtubule 
related proteins had appeared in our analysis several times above, where they were 
recruited to the adhesome upon VEGF stimulation (table 4-1) and potentially were involved 
in endoplasmic reticulum directed regulation of the β3+/- adhesome (table 4-2). Many 
tubulins, the main components of microtubules, were found to be significantly increased in 
the β3+/- adhesome as well (supplementary table 3) but strangely no microtubule 
categories were found to be enriched in the β3+/- adhesome (table 4-2). This was because 
the defined KEGG, GOCC, GOMF and GOBP microtubule categories contained many 
microtubule regulators that were not upregulated therefore the entire category was not 
enriched, just the tubulins themselves and potentially a few select regulators. Additionally, 
interaction analysis in figure 4-4 did show that a cluster D-F (fibronectin adhesome clusters) 
tubulin as upregulated upon β3 depletion, whereas most of the tubulins detected were in 
cluster A-C so not shown in figure 4-4. Microtubules, with their varied roles in cell division, 
focal adhesion regulation and cell migration279,291 make them valuable targets in anti-cancer 
therapies. As well as focal adhesions and cell migration being critical for angiogenesis, 
microtubules can play roles in angiogenesis through Flk1 signalling regulation286 and growth 
of cell protrusions along ECM in endothelial cells285 for example. Many microtubule 
targeting drugs are used clinically as anti-cancer agents such as paclitaxel266 or as direct 
anti-angiogenic agents (e.g. Fosbretabulin364). Indeed, most microtubule targeting drugs are 
known to have some anti-angiogenic effect in addition to their anti-cancer effects287. Given 
the prevalence of microtubules in angiogenesis literature and the potential links to β3 we 
had uncovered, we decided to visualise the SAM carried out to generate supplementary 
table 3 as a volcano plot to help better understand the changes occurring to tubulins. The 
result, in figure 4-5A, showed that all detected tubulins were significantly upregulated in 
the β3+/- adhesome. The fact that all tubulins in the endothelial adhesome were on the 
enriched (right side of SAM analysis) with β3 depletion demonstrated to us that part of the 
microtubule structure itself must be present in the adhesome of β3+/- cells but not β3+/+ 
cells. Initially we were worried that this could be indicative of an artefact in our mass 
spectrometry data resulting from the chemical modifications carried out365 such as 
crosslinking or carbamidomethylation. Alternatively, we could have been analysing our LC-
MS/MS runs incorrectly in MaxQuant or Perseus and inadvertently skewed our adhesome 
towards proteins such as tubulins in some samples. To validate our mass spectrometry 
based findings, we carried out western blots on adhesome samples as per figure 3-2 using a 
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pan-alpha tubulin antibody as this detected several tubulin proteins we had identified using 
mass spectrometry. These westerns, quantified in figure 4-5B along with an example blot, 
showed that increased tubulin presence in the β3+/- adhesome was real and not an 
artefact of mass spectrometry. Strangely though this upregulation was not apparent in 
SAM of the β3-/- adhesome data and was not reliably detect by western blot (data not 
shown). Like Thbs1, it appeared that β3+/- and β3-/- adhesomes might still be behaving 
differently in response to β3 depletion. However, given our earlier conclusions that β3+/- 
cells better represented a therapeutic targeting of β3 than β3-/- cells, we decided that 
microtubules were worth further investigation. 
Additional evidence, not relying on mass spectrometry, for the specific increase in of 
tubulin the β3+/- adhesome is shown by figure 4-5C. This figure shows that the total cell 
levels of tubulins are not increased upon β3 deletion but figure 4-5B does show an increase 
in the adhesome in β3+/-. Figures 4-5B and 4-5C together show that the increase of tubulin 
in the β3+/- adhesome is not due to whole cell upregulation of tubulins. 
Microtubules, with their complex dynamics in terms of growth, shrinkage, cargo transport 
and targeting, have many regulators. A lot of these regulators, such as RhoA366 or Cdc42367 
are also involved in actin cytoskeleton control368 as well as having their own roles in 
angiogenesis369. Cytoskeleton regulation and interaction with focal adhesions is an 
incredibly complex field with dense interaction networks to understand. This kind of 
analysis is something we specifically set out to accomplish using non-candidate analysis of 
the endothelial adhesome. We probed our SAM analysed β3+/- and β3-/- adhesomes for all 
proteins with microtubule associated KEGG, GOCC, GOMF and GOBP annotations. These 
microtubule regulators, detected in our adhesomes, were used in Cytoscape analysis to 
attempt to give us a deeper understanding of how β3 can regulate microtubules. Despite 
narrowing down the potential field of candidates, there were still too many possibilities to 
consider so we organised the network horizontally according to the clusters defined in 
figure 4-2 for the endothelial adhesome. Additionally we calculated significance for 
proteins using the adhesomes from which those proteins are clustered in, utilising fresh 
samples. This meant that, in figure 4-6, the significances of VEGF cluster proteins (A to C) 
were calculated using SAM of fibronectin with VEGF samples and the significance of poly-l-
lysine cluster (G to L) proteins were calculated using SAM of poly-l-lysine samples from 
β3+/- cells. We hoped this would give us a better chance of uncovering useful information 
about β3 regulation of microtubules by using mass analysis of samples where the 
regulators were already known to be upregulated (identified by hierarchical clustering). We 
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took this action because many well-known microtubule regulators with defined roles in 
angiogenesis285 were not present in any of our adhesome samples, likely because they are 
present at very low amounts and therefore difficult to detect. Analysis of these microtubule 
regulators will be carried out in subsequent chapters but it is worth noting that in this 
figure we have chosen to display both β3+/- and β3-/- data and if they disagree, to choose 
the one with the greatest difference from the SAM analysis. Despite the β3-/- fibronectin 
adhesome, without VEGF, not showing an increase in tubulin proteins like the β3+/- 
adhesome; when treated with VEGF, the β3-/- adhesome did show an increase of tubulin 
proteins.  This suggested to us that both VEGF and β3 were important in regulation of 
microtubules in endothelial cells. 
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Table 4-2 Enrichment Analysis of the β3+/- Endothelial Adhesome 
Adhesome Category 
column 
Category value Category 
size 
Intersection 
size 
Enrichment 
factor 
P value Benj. Hoch. 
FDR 
β3+/+ GOCC name nucleolus 147 38 1.8221 1.04E-05 7.46E-04 
β3+/+ Cluster F 295 73 1.7442 1.58E-11 1.74E-10 
β3+/+ GOCC name cytoplasm 385 35 0.64078 1.33E-05 8.60E-04 
β3+/+ GOCC name extracellular region part 388 35 0.63582 9.06E-06 7.31E-04 
β3+/+ GOCC name vesicle 384 32 0.58738 8.14E-07 1.31E-04 
β3+/+ GOCC name extracellular vesicular exosome 365 30 0.57933 1.53E-06 1.41E-04 
β3+/+ GOCC name extracellular organelle 365 30 0.57933 1.53E-06 1.65E-04 
β3+/+ GOCC name extracellular membrane-bounded 
organelle 
365 30 0.57933 1.53E-06 1.97E-04 
β3+/+ GOCC name membrane-bounded vesicle 380 31 0.57501 5.06E-07 1.09E-04 
β3+/+ GOCC name protein complex 283 18 0.44832 2.85E-07 9.21E-05 
β3+/+ GOCC name cytosol 136 7 0.36279 1.72E-04 9.28E-03 
β3+/+ Cluster I 220 11 0.35243 3.40E-07 1.87E-06 
β3+/+ GOCC name cytoskeletal part 136 6 0.31097 4.73E-05 2.78E-03 
β3+/-  KEGG name Protein processing in endoplasmic 
reticulum 
26 18 2.9918 4.01E-07 7.05E-05 
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β3+/-  GOCC name endoplasmic reticulum part 39 24 2.6593 1.12E-07 7.25E-05 
β3+/-  GOCC name endoplasmic reticulum 43 24 2.412 1.39E-06 4.50E-04 
β3+/-  Cluster I 220 78 1.5321 2.01E-07 1.11E-06 
β3+/-  GOCC name protein complex 283 90 1.3743 4.89E-06 7.90E-04 
β3+/-  GOCC name cytoplasmic part 407 115 1.221 7.01E-05 9.05E-03 
β3+/-  Cluster F 295 30 0.43947 7.51E-13 8.26E-12 
β3+/-  GOCC name nucleolus 147 14 0.41156 1.72E-06 3.70E-04 
 
All significantly enriched or depleted GOMP, GOBP, GOCC or KEGG categories in fibronectin adhered β3+/+and fibronectin adhered β3+/- of the β3+/- 
endothelial adhesome defined in supplementary table 3 that were detected by Fisher’s exact t test’s. 
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Table 4-3 Enrichment Analyysis of the β3-/- Endothelial Adhesome 
Adhesome 
Category 
column Category value 
Category 
size 
Intersection 
size 
Enrichmen
t factor P value 
Benj. Hoch. 
FDR 
β3+/+ GOCC name 
mRNA cleavage and polyadenylation 
specificity factor complex 6 5 19.533 6.40E-07 4.35E-04 
β3+/+ GOCC name mRNA cleavage factor complex 8 5 14.649 5.53E-06 1.88E-03 
β3+/+ GOCC name extracellular space 77 12 3.6528 2.97E-05 6.72E-03 
β3-/- GOCC name chaperonin-containing T-complex 8 8 9.3301 1.36E-08 9.21E-06 
β3-/- GOBP name sperm-egg recognition 10 8 7.4641 4.95E-07 5.58E-04 
β3-/- GOBP name cell-cell recognition 10 8 7.4641 4.95E-07 7.45E-04 
β3-/- GOBP name binding of sperm to zona pellucida 10 8 7.4641 4.95E-07 1.12E-03 
β3-/- GOCC name cytosolic part 20 10 4.665 8.77E-06 1.99E-03 
β3-/- GOBP name protein folding 34 16 4.3906 3.84E-08 1.73E-04 
β3-/- GOMF name adenyl nucleotide binding 168 37 2.0548 9.59E-07 9.75E-04 
β3-/- GOMF name ATP binding 167 36 2.0113 2.50E-06 8.49E-04 
β3-/- GOMF name adenyl ribonucleotide binding 167 36 2.0113 2.50E-06 1.27E-03 
β3-/- GOMF name purine nucleotide binding 204 41 1.8752 2.66E-06 6.77E-04 
β3-/- GOMF name ribonucleotide binding 203 40 1.8384 6.44E-06 9.35E-04 
β3-/- GOMF name purine ribonucleotide binding 203 40 1.8384 6.44E-06 1.09E-03 
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β3-/- GOMF name purine ribonucleoside triphosphate binding 203 40 1.8384 6.44E-06 1.31E-03 
β3-/- Cluster F 359 21 0.54577 4.63E-05 5.56E-04 
β3-/- GOCC name ribonucleoprotein complex 240 6 0.23325 8.57E-08 2.91E-05 
β3-/- GOBP name RNA processing 177 4 0.21085 3.94E-06 3.55E-03 
 
All significantly enriched or depleted GOMP, GOBP, GOCC or KEGG categories in fibronectin adhered β3+/+ cells and fibronectin adhered β3-/- cells of the 
β3-/-endothelial adhesome defined in supplementary table 4 that were detected by Fisher’s exact t test’s. 
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Figure 4-4 Interaction Map of the β3 Dependent Adhesome 
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Interaction network of fibronectin adhesome proteins (cluster D-F) detected in the endothelial adhesome taken from figure 4-3. Significant changes in 
either the β3+/- or β3-/- adhesomes was calculated using SAM analysis and coloured red (increased) and green (decreased). Note Thbs1 is represented as 
separate nodes for SAM analysis of β3+/- (H-THBS1) or β3-/- (N-THBS1) adhesomes, which was the only node that disagreed between β3+/- and β3-/- 
adhesome data.  
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Figure 4-5 Tubulins in the β3+/- Adhesome 
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A Visual representation of the significant analysis of microarrays (SAM) method as a 
volcano plot for β3β3+/+ and β3β3+/- samples (n=3). T-test difference is plotted against –
log of the P value. T-test difference is calculated from the β3β3+/- t-test value minus the 
β3β3+/+ t-test value. As log2 normalised data was used for SAM analysis, this could also be 
considered a fold change difference. The blue lines show the cut-off for significance as 
defined by the SAM. Integrin-β3 (β3) as well as all detected tubulins (Tub) have been 
highlighted as red points. B Adhesome samples from β3β3+/+ and β3β3+/- endothelial cells 
adhered to fibronectin. Samples were Western blotted for integrin-β3 (β3), α-tubulin and 
heat shock protein 70 (Hspa1a). Blot shown is representative of the 5 individual 
experiments that are quantified in the bar graph below. Bars = mean (±SEM) relative α-
tubulin levels normalised to Hspa1a levels. ***= P<0.001 in an unpaired, two-tailed t-test. C 
β3+/+, β3+/- and β3-/- endothelial cells were adhered to fibronectin for 90 minutes before 
being lysed and Western blotted for β3, α-tubulin and Gapdh (as a loading control).   
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Figure 4-6 Microtubule Regulators in the β3 Dependent Adhesome 
 
Interaction network of microtubule associate proteins, defined by GOCC, GOMF, GOBP and 
KEGG annotations detected in the endothelial adhesome. Proteins were arranged vertically 
according to the number of connections from fibronectin binding integrins and horizontally 
according to whether they are members of the fibronectin or PLL adhesome. Significant 
changes in the β3+/- fibronectin adhesome (left) was calculated using SAM analysis of 
fibronectin adhered β3+/+ and β3+/- IMMLECs whereas significant changed for the β3+/- 
PLL adhesome (right) was calculated using data from PLL adhered cells .  
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Statistical Analysis of Endothelial Adhesome with c(RGDfV) Treatment  
We had observed many interesting changed in the endothelial adhesome upon depletion 
of β3 in both β3+/- and β3-/- cells that had the potential to be exploited for desirable 
clinical outcomes if we were able to find an effective inhibitor. β3 has been of interest as an 
angiogenesis inhibitor in anti-cancer treatments previously, due to its selective 
upregulation on only angiogenic vasculature in a heterodimer with αv and the assumption 
it was a pro-angiogenic molecule205. Efforts were made to target β3 in vivo with an RGD-
mimetic that could cross the blood brain barrier called Cilengitide®, but unfortunately this 
failed clinical trials370. Several reasons have been put forward including: the dual pro and 
anti-angiogenic roles of β3371,372, highlighted particularly by pathological analysis observed 
in mice with complete deletions of β3; poor pharmacokinetics and the ability of 
Cilengitide® to actually be pro-angiogenic at low doses214; and the off-target effects on 
other integrins373. Biphasic effects, i.e. stimulation at low doses but inhibition at high doses, 
is also seen in other anti-angiogenic compounds such as sulforaphane374 
We speculated that the various mechanisms behind RGD-mimetics in general being 
disappointing in vivo could have been due to compensation in the adhesome and may have 
already been uncovered in the analysis of the β3+/- and β3-/- adhesomes. We had an 
opportunity to confirm this by generating an RGD treated adhesome using c(RGDfV), a 
Cilengitide® like compound with greater selectivity towards αvβ3375. We first tested the 
effectiveness of c(RGDfV) in our cells using adhesion assays carried out with the same 
amount of fibronectin, cell density and adhesion time as used in generating adhesome 
samples, shown in figure 4-7A. Vitronectin was used to test the effectiveness of the 
inhibitor on αvβ3 based adhesion as it is ligand specific to that integrin and so cannot be 
compensated for by α5β1376. A similar dose to that used in Cilengitide® adhesion assays377, 
20 µM, was found to be in excess because it inhibited adhesion to vitronectin as well as 50 
µM of c(RGDfV). We also showed that 20 µM c(RGDfV) was not detrimental to adhesion on 
fibronectin in case reports of the integrin specificity were incorrect because we still needed 
IMMLECs to adhere to fibronectin to generate adhesome samples. We then incubated 
β3+/+ IMMLECs with 20 µM c(RGDfV) during the 90 minute adhesion in generating 
adhesome samples as per the endothelial adhesome in supplementary table 1. Although 
small changes in adhesion to fibronectin were observed during c(RGDfV) treatment in 
figure 4-7A, this could be due to a reduction in cell spreading which was detected using 
methylene blue staining and so the adhesome (although from less spread cells) would be 
from the same number of endothelial cells. 
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Figure 4-7B, a visual representation of SAM analysis of the c(RGDfV) adhesome carried out 
as per figure 4-5, surprisingly showed only one protein was significantly affected – Ncpb1, a 
protein involved in mRNA end-capping and export378. We did not think this single protein 
provided any revelations about pharmacological inhibition of c(RGDfV) and in fact the lack 
of any other significant changes was itself more interesting. This suggested to us that 
c(RGDfV) and possibly other RGD mimetics have no effect on β3 or the adhesome when 
bound to fibronectin, potentially explaining the disappointing clinical trials. We speculated 
that binding of c(RGDfV), still triggers the outside-in signalling of β3 to recruit its 
intracellular interactors, otherwise we should have seen compensation for loss of integrin 
function just like in the β3+/- and β3-/- adhesomes. Additionally we believed the physical 
anchorage to the ECM was instead carried out by β1 when the binding sites of β3 were 
occupied as happened in figure 4-7A during adhesion to fibronectin. The c(RGDfV) 
adhesome and its DMSO control, shown in supplementary table 5, still showed a complete 
endothelial adhesome like those previously generated with 912 proteins remaining after 
stringent filtering so we believed our adhesome enrichment and mass spectrometry were 
still functioning correctly. Other studies have suggested that fibronectin and its receptors 
are not required for tumour angiogenesis at all and simply our attempts to inhibit these 
pathways simply result in a dominant negative block, meaning other tumour ECM 
substrates must be more important379. If this is the case we believe the mode of action 
behind c(RGDfV) is not able to have this dominant negative effect due to lack of changes in 
the adhesome. 
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Figure 4-7 Analysis of the c(RGDfV) Treated Adhesome 
 
A Adhesion analysis of endothelial cells adhered to saturating concentrations of fibronectin 
or vitronectin in the presence of c(RGDfV), an αvβ3-integrin specific RGD mimetic. Bars = 
mean (±SEM) adhesion relative to vehicle control (DMSO). B Visual representation of the 
significant analysis of microarrays (SAM) method as a volcano plot for DMSO versus 20µM 
c(RGDfV) treated endothelial cell samples (n=3). Endothelial cells were adhered to 
fibronectin for 90 minutes before being crosslinked, washed and proteins precipitated for 
mass spectrometry analysis. T-test difference is plotted against –log of the P value. The 
blue lines show the cut-off for significance as defined by the SAM. Integrin β3 (β3) as well 
as Ncpb1 (the only significant change) have been highlighted as red points. 
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Chapter five – Microtubule Behaviour in Integrin β3 Depleted 
Angiogenesis 
The aim of this chapter is to investigate the role and behaviour of microtubules in cells 
depleted for β3. Chapter 4 had identified several microtubule components as significantly 
increased proteins in β3 depleted adhesomes and therefore this needed validation with 
more traditional biochemistry approaches. Once validated, the effectiveness of targeting 
microtubules in β3 depleted angiogenesis can be evaluated. 
Microtubules in Endothelial Cells 
In the previous chapter, we have highlighted the interesting alterations in intracellular 
cytoskeletons, particularly microtubules, in the endothelial β3-dependent adhesome. Given 
the crossover between microtubule and actin cytoskeleton regulation368 we felt it 
important to assess the state of both of these networks in our IMMLECs. As mentioned 
previously, microtubules can have diverse roles in focal adhesion regulation, migration and 
angiogenesis but we had not yet considered the actin cytoskeleton. Table 4-2 showed that 
the cytoskeletal part category changed significantly upon β3 depletion, and the actin 
cytoskeleton was the most obvious candidate for change. Integrins are linked to the actin 
cytoskeleton by many critical focal adhesion/actin binding proteins such as Vinculin, Tln1, 
Fak1, Filamin-a and many others351,380,381. This very strong and well characterised 
connection is formed during the maturation of a focal adhesion and is responsible for 
anchoring the cell via the actin cytoskeleton/focal adhesion connection to the ECM as well 
as playing a role in matrix engagement and matrix rigidity sensing186. In cell staining 
experiments across many cell types, focal adhesions are found at the end of actin filaments 
and this was also true for our IMMLECs as seen in supplementary figure 1 using anti-Pxn 
and phalloidin staining (using two different methods of image visualisation). We therefore 
decided to simultaneously image the microtubule and actin cytoskeletons using PHEMO 
fixation which overcame the issues of fixing actin with methanol (it prefers PFA) or 
microtubules with PFA (they prefer methanol)382. We used phalloidin and anti-alpha-tubulin 
(which binds to several actin isoforms identified in our mass spectrometry) to stain actin 
and microtubules in β3+/+ and β3 depleted IMMLECs in figure 5-1A. There appeared to be 
no obvious changes in the actin cytoskeleton structure, despite the complete loss of β3 in 
the β3-/- cells. We speculated that, during the development of a focal adhesion, β1 in 
nascent focal adhesions was able to regulate the actin cytoskeleton sufficiently and that 
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the additional inclusion of β3 in β3+/+ or β3+/- mature focal adhesions, did not have a 
dramatic effect due to the continued presence of β1383. We therefore decided to focus our 
efforts on microtubules, which appeared to show subtle changes upon β3 depletion. At first 
glance, it appeared the organisation of microtubules in β3+/- and β3-/- cells was more 
chaotic than that of β3+/+ cells. From fixed cells it was difficult to draw any substantial 
conclusions on changes to microtubule organisation but we nevertheless decided it was 
worth studying microtubules further in β3 depleted cells. It also appeared that there could 
have been more microtubules in the β3+/- and β3-/- than the β3+/+ cells. Western blotting 
for alpha tubulin using whole cell protein extracts from all three genotypes, shown in figure 
4-5C, did not show any differences. Therefore we believed there was no global 
upregulation of tubulin monomers or polymerised microtubules that could have explained 
the increased tubulin proteins found in the β3 depleted adhesome. Additionally we used an 
alternative imaging technique in figure 5-1C, confocal microscopy, to only image a small z-
slice at the very bottom of a β3+/+ IMMLEC. As microtubule and actin cytoskeletons extend 
throughout the entire three-dimensional structure of the cell we felt it important to 
compare the widefield fluorescent images of figure 5-1A to the gold standard of confocal 
microscopy to ensure that the cytoskeletons above our plane of interest (focal adhesions 
being on the bottom of the cell) were not obscuring any phenotypes. The structures 
observed in figure 5-1C appeared similar to the β3+/+ IMMLEC cell in figure 5-1A therefore 
we continued to use widefield fluorescent imaging in future investigations. 
Given that figure 4-5B had shown that increased tubulin in the adhesome was not an 
artefact of mass spectrometry, and figure 4-5C had shown that there was no whole cell 
increase in tubulin, we were led to the conclusion that β3 must have been specifically 
affecting the inclusion of tubulin in the adhesome – i.e. the targeting of microtubules to 
focal adhesions. Whilst other studies have identified roles for α5β1 or focal adhesions 
generally in microtubule targeting to the cell cortex178,237,272 no work considering the role of 
β3 had yet been carried out. Also no investigation into the possible effects of VEGF on 
microtubule targeting had, to our knowledge, been carried out (n.b. mass spectrometry, 
see table 4-2, had identified a potential link between VEGF-stimulation and tubulin 
localisation within the adhesome). To investigate both the role of β3 and VEGF in 
microtubule targeting to focal adhesions we co-stained for alpha-tubulin and Tln1. By 
counting the number of microtubules that ended at a focal adhesion we were able to 
assess microtubule targeting. Figure 5-2A shows the result for both β3 depleted cells with 
and without VEGF stimulation, with representative images in figure 5-2C. Without VEGF 
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stimulation it appears that both β3+/- and β3-/- cells show increased microtubule targeting 
to focal adhesions compared to β3+/+ cells. It is important to note that for β3+/+ and β3+/- 
cells, we observed no difference in the amount or size distributions of focal adhesions 
when staining for Pxn in figure 5-2B. This fits with earlier results that showed increased 
tubulin in the adhesome upon β3 depletion. Fibronectin binding integrins such as α5β1 are 
known to target microtubules to focal adhesions possibly via Filamin-a-Iqgap1 (IQ motif 
containing GTPase activating protein 1)237 or  Tln1-Kank1178 mechanisms. These focal 
adhesion proteins are known to bind +TIPs such as Clip1278 and so would be able to anchor 
the growing ends of microtubules. However which is another fibronectin binding integrin, 
could be potentially unable to capture microtubules using similar mechanisms as α5β1. At 
this point it was unclear whether β3 was unable to participate in microtubule capture or 
played a dominant negative role in microtubule stability at focal adhesions, potentially by 
affecting key microtubule regulators that can induce catastrophe such as Kif2c (Kinesin 
family member 2C)384. Unfortunately not many of these catastrophe factors were well 
represented in the microtubule regulatory proteins detected in the endothelial adhesome 
(figure 4-6), possibly due to difficulties in detection or that they are not relevant to 
IMMLECs. Those that were detected were not β3 dependent, limiting our ability to draw 
substantive conclusions. 
The results of how VEGF affected microtubule targeting were less clear. Figure 5-2A 
suggested that more microtubules were targeted to focal adhesions in β3+/+ cells with 
VEGF stimulation than without but this was not statistically significant. This was surprising 
considering earlier enrichment analysis of the VEGF dependent adhesome of β3+/+ cells in 
table 4-1 showed an increase in microtubule proteins and so we would have expected a 
significant increase in targeting. There was, however, a significant decrease in targeting to 
focal adhesions in β3-/- cells with VEGF stimulation. Finally β3+/- cells showed no 
difference with VEGF. Whilst it was possible that β3 depletion could change the VEGF 
response, due to the upregulation of VEGFR2 observed in β3 knockouts216, the number of 
contradictions between the VEGF targeting results and the adhesome data suggested to us 
that the 10 minute VEGF stimulation may not be long enough to trigger dramatic visual 
changes in the microtubule structure. Live imaging of microtubules (see below) or 
microtubule regrowth assays (see discussion) may be more appropriate to assess the 
impact the VEGF, whereas β3 gene depletion as a permanent feature of the IMMLECs used 
was sufficient to show changes consistent with adhesome data. 
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Microtubules are dynamic structures undergoing constant growth and shrinkage, including 
dramatic separation of the protofilaments accompanied by rapid disassembly known as 
catastrophe, which can be reversed in a process known as “rescue”384. As such we decided 
we should attempt to study microtubule dynamics using live cell imaging where these 
processes could be observed. Normally microtubule dynamics are assessed using 
fluorescent protein coupled tubulin constructs to label microtubules or fluorescent protein 
coupled +TIP constructs to label the ends of microtubules. However, our primary interest 
was to study microtubule targeting to focal adhesions therefore we needed to label focal 
adhesions using another construct – GFP-Pxn. The GFP-Pxn construct used was a previously 
characterised plasmid that was known to traffic to focal adhesions and function correctly as 
native Pxn385,386, and previously used successfully in our IMMLECs218. Despite our best 
efforts, co-transfection with GFP-Pxn and a labelled tubulin or +TIP construct proved 
impossible due to very low transfection efficiencies. Instead, we decided to use a docetaxel 
based fluorescent tubulin binding compound called SiR-Tubulin. To avoid affecting 
microtubule dynamics with the binding of docetaxel, we used a low concentration of SiR-
Tubulin to label microtubules overnight with verapamil to prevent efflux using established 
protocols387. 
With the equipment available, we were unable to image both microtubules and focal 
adhesions live every three seconds, as required to measure microtubule dynamics 
accurately388. When focusing on imaging just microtubules using a single channel (SiR-
Tubulin) we were able to capture images every 3 seconds but they were not of sufficient 
quality to make meaningful measurements (data not shown). We decided to measure 
microtubule targeting instead of dynamics as this required only taking an image every 
minute. When carried out in β3+/+, β3+/- and β3-/- cells, we were still unable to generate 
enough quality images to make an assessment of microtubule targeting to individual focal 
adhesions. Instead we measured the growth/targeting of microtubules into the 
lamellipodia, a focal adhesion rich membrane extension seen in migrating cells389,390, as a 
proxy for microtubules being associated with adhesive areas of the cell. We were able to 
distinguish lamellipodia from other types of membrane extensions using the GFP-Pxn signal 
as an indicator of adhesions forming in lamellipodia. Figure 5-3B shows an example where 
we measured the area of the lamellipodia that formed over half an hour; then were able to 
count the number of microtubules that moved into the lamellipodia and normalised to the 
area measured. The results, as seen in figure 5-3A, showed that with β3 depletion there 
were significantly more microtubules targeting the lamellipodia. This was consistent with 
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adhesome data and microtubule targeting in figure 5-2A. Interestingly, unlike in figure 5-2A 
which did not show increased targeting in β3-/- cells compared to β3+/-, β3-/- cells showed 
a much higher number of microtubules targeting lamellipodia than β3+/- cells. We 
speculated this was because of the different criteria being used for measuring microtubule 
targeting to focal adhesions in the two experiments. In figure 5-2 we counted only 
microtubules whose ends overlapped with the Tln1 staining signal, whereas in figure 5-3 
we counted microtubules that terminated anywhere inside a lamellipodia and not 
necessarily in direct contact with a focal adhesion. As a result, figure 5-2 quantified 
microtubule targeting to adhesions in β3+/- above β3-/- but in figure 5-3 the opposite was 
true. β3-/- cells are exclusively reliant on α5β1 for adhesion to fibronectin and current 
thinking suggests that this integrin dimer is able to stabilise microtubules whereas our data 
so far suggests αv/β1 cannot. If this was true then we would have expected β3-/- to show 
greater microtubule targeting to focal adhesions than β3+/-. One mechanism for α5β1 
stabilisation of microtubules suggests that the stabilisation effect of the engaged integrin 
can be observed across a wider area of the cell237 possibly by using lipid rafts391 and another 
suggests that Tln1 found at engaged integrins recruits Kank1 as a scaffold for microtubule 
stabilising factors where the size of this macromolecular complex means that microtubules 
targeted end up stabilised at a significant distance from the focal adhesion, but still 
anchored to the membrane using PIP3. This remote Tln1-Kank1 scaffold means that 
fluorescent signals for Tln1 and microtubules do not overlap at all178. Both of these 
mechanisms might explain why we observed an apparent under-representation of 
microtubule targeting to focal adhesions in β3-/- cells in figure 5-2. 
Although previous adhesome results have shown no difference in integrin levels in the 
adhesome, it is important to remember that the enrichment technique and mass 
spectrometry, carried out after 90 minutes adhesion, represents a brief snapshot in time. 
Changes in β3 could have profound consequences for the behaviour of other integrins. For 
example, it has been shown that β3 can sequester Nrp1 in the plasma membrane52. 
However, with the loss of β3, Nrp1 is free to promote further angiogenesis through several 
mechanisms215,218 such as through interaction with Gipc1 (GPIC PDZ domain containing 
family member 1) which facilitates endocytosis of α5β1195. Increased trafficking of α5β1 
could therefore facilitate increased cell migration, enhancing angiogenic responses392. 
Many other mechanisms of integrin recycling could be affected by the loss of β3, but our 
study has not studied these further. Rab4, a key component in the recycling of αvβ3393 can 
also recycle α5β1394 and we speculate this could be another reason why β3 loss does not 
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detrimentally affect endothelial cells on fibronectin because the increased recycling of 
α5β1 can compensate. For a full review of integrin trafficking see Bridgewater et al194. It is 
necessary to repeat this staining in future experiments for specific integrins such as α5 
and/or β1 to see if they are indeed present at the focal adhesions being increasingly 
targeted in β3+/- and β3-/- cells. In our hands, β3 antibodies were not specific enough for 
use and we were concerned that following the more promiscuous αv would complicate 
analysis, but better antibodies are always in development and this should be revisited or 
alternatives such as labelled RGD mimetics could be explored224. The development of 
specific antibodies for both the inactive and active confirmation of α5β1 and their use has 
shown how this integrin, when active, can target microtubules to focal adhesions237 
Figure 5-2A showed how depletion of β3 in β3+/+ and β3+/- cells resulted in increased 
microtubule targeting to focal adhesions. Microtubule targeting of focal adhesions is 
known to be important throughout their lifecycle but particularly for maturation and 
disassembly291. The ability of microtubules to increase focal adhesion disassembly rates is 
dependent on Kif5b, suggesting this function is dependent on the cargo delivered by 
kinesins192. Delivery of clathrin internalisation pathway components such as clathrin and 
Dab2 (DAB2, Clathrin adaptor protein) by microtubules increases focal adhesion 
dissambly395. Prolonged targeting of microtubules to areas of important cell-ECM contacts 
has also been shown to promote integrin internalisation/recycling by the exocytosis of 
MT1-MMP which severs connections between integrins and their ligands396. 
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Figure 5-1 Microtubule and Actin Cytoskeletons in Endothelial Cells 
 
A β3+/+, β3+/- and β3-/- endothelial cells were adhered to fibronectin coated coverslips for 
90 minutes before being PHEMO fixed and immunostained for α-tubulin (green).  Nuclear 
(DAPI-blue) and Phallodin (F-actin - red) stains were also used.  Greyscale images of α-
tubulin and F-actin are shown below the three-colour overlays. Scale bar = 20 µm B β3+/+, 
β3+/- and β3-/- endothelial cells were adhered to fibronectin for 90 minutes before being 
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lysed and Western blotted for β3, α-tubulin and Gapdh (as a loading control). C Single 
β3+/+ cell adhered and stained as per panel A but imaged using a confocal microscope. 
Scale bar = 10 µm. 
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Figure 5-2 Microtubule Targeting to Focal Adhesions in Endothelial Cells 
 
A β3+/+, β3+/- and β3-/- IMMLECs were adhered to fibronectin coated coverslips for 80 
minutes then treated with VEGF for 10 minutes before being methanol fixed and 
immunostained for α-tubulin (green) and Tln1 (red). The number of microtubules that 
terminated at a focal adhesion per cell were counted for each genotype (n=15 from three 
independent experiments). Statistical significances between means were calculated using 
Student’s t-test where *, ** and *** represent p ≤ 0.05, p ≤ 0.01 and p ≤ 0.001 respectively. 
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B β3+/+ and β3+/- IMMLECs were adhered to fibronectin coated coverslips for 90 minutes 
before being methanol fixed and stained for Tln1. Images were taken of multiple cells 
across two independent experiments totalling >1,400 focal adhesions. ImageJ was used to 
measure sizes of focal adhesions and they were binned into groups of less than 2 µm, 2-10 
µm and greater than 10 µm. N.s. indicated no significant difference found using student’s t-
test. C Examples of the staining images used above with yellow circles indicating example 
microtubules that were counted. Scale bar = 5 µm.  
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Figure 5-3 Microtubule Live Imaging in Endothelial Cells 
 
A β3+/+, β3+/- and β3-/- cells were transfected with Pxn-GFP and left to recover overnight. 
The cells were then adhered to fibronectin coated coverslips and allowed to recover for 3 
hours before being treated with 100 nM SiR Tubulin and 1 μM verapamil overnight. The 
next day, fresh media containing SiR Tubulin and verampamil (same dose) was added cells 
were imaged every minute for 30 minutes (n=3). Areas of adhesive fronts were assessed by 
measuring the growth of Pxn-GFP positive areas between the 1st and 30th image. The 
number of microtubules that entered the adhesive front (GFP positive area) was quantified 
to give the number of microtubules entering lamellipodia relative to the area of adhesive 
fronts for each cell. B A Schematic demonstrating how panel A was calculated. Yellow 
0 minutes 30 minutes
GFP-Pxn
SiR-Tubulin
GFP-Pxn
SiR-Tubulin
A
B
0
2
4
6
8
10
WT NULLHET
M
ic
ro
tu
b
u
le
s
T
a
rg
e
ti
n
g
L
a
m
e
ll
ip
o
d
e
a
 p
e
r
A
re
a
o
f
A
d
h
e
s
iv
e
 F
ro
n
t
**
*
121 
 
indicates the edge of Pxn-GFP (green) positive areas at 0 minutes and blue indicated the 
edge at the end of 30 minutes. Microtubules were labelled red with SiR Tubulin, with 
example counts circled in white. The bottom panels show the area measured in yellow for 
the 0 minute image and the area measured in blue for the 30 minute image. The area of 
adhesive front is calculated by subtracting the yellow area from blue. Scale bar = 5 µm. 
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Microtubule Inhibitors in Endothelial Cells 
We have shown that microtubules are upregulated in the endothelial adhesome upon β3 
depletion by mass spectrometry, biochemically by western blotting and visually by 
fixed/live cell imaging. We decided the next stage was to see if this increased targeting of 
microtubules to focal adhesions was relevant to the behaviour of β3 depleted cells. 
Microtubules have the ability to control focal adhesion dyanmics279 and in particular 
disassembly through Dnm2, a microtubule binding protein397 and its interaction with Fak1 
in focal adhesions191. Both focal adhesion assembly and disassembly must be tightly 
controlled and synchronisedduring cellular migration to maintain the optimal focal 
adhesion size and tread-milling ability398. Therefore we felt it highly likely that targeting 
microtubule behaviour would have a downstream effect on cell migration in our cells, as 
has been seen in other cell types263,284,399, and this could have been greater in β3 depleted 
IMMLECs. Luckily there are a vast array of microtubule inhibitor compounds available for 
use in vitro and in vivo with good pharmacokinetics, many of which are used as anti-cancer 
therapies264. To test our hypothesis, we selected a wide variety of microtubule inhibitors 
with different modes of action and effectiveness: microtubule stabilisers paclitaxel288 and 
epothilone B400 which prevent depolymerisation; microtubule destabilisers colchicine401, 
fosbretabulin364 and mebendazole402 which induce depolymerisation; and a mechanistically 
unique destabiliser known as erbibulin403. Different cells can have vastly different 
responses to these inhibitors, for example endothelial cells are very sensitive to 
fosbretabulin which is being used specifically as an anti-angiogenic compound289, so we 
initially needed to test the response of our IMMLECs to each of these compounds. We used 
an overnight survival assay to determine the dose that allowed 90% of the cells to survive. 
As shown for paclitaxel and colchicine in figure 5-4A, we first used a logarithmic dose range 
before narrowing down to a more specific dose of 5 nM. We settled on the following doses 
for the remaining inhibitors: epothilone B – 1 nM, colchicine – 10 µM, fosbretabulin – 0.5 
µM, mebendazole – 0.4 µM and eribublin – 1 µM. We then visualised whether these doses 
affected microtubule organisation in IMMLECs by treating cells overnight with one 
compound from each of the three classes mentioned above followed by fixation and 
staining for α-tubulin and Pxn. Colchicine and paclitaxel were used and the results shown in 
figure 5-4B; eribulin was also tested in IMMLECs but the staining was identical to colchicine 
treated cells so is not shown. Interestingly, at the dose of colchicine used, there were no 
microtubules present in β3+/+, β3+/- or β3-/- cells after treatment. Given the specific 
targeting of microtubules to focal adhesions in β3 depleted cells we might have expected 
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to see microtubules resisting the colchicine in these cells but this was not the case. As for 
paclitaxel, strong and numerous stained microtubules were detected in all three genotypes 
reflecting the stabilising ability of the drug. We also checked that β3 cells were not more 
sensitive to microtubule destabilising drugs than β3+/+ cells, an example is shown in 
supplementary figure 2. 
Once we had decided on doses for our microtubule inhibitors we tested their effects on 
random cell migration in β3+/+, β3+/- and β3-/- cells. The results, as seen in figure 5-5A, 
showed that all microtubule targeting drugs, regardless of mechanism of action, seemed to 
significantly affect the migration of β3 depleted cells compared to β3+/+ cells. Additionally 
it was interesting that the microtubule stabilisers, paclitaxel and epothilone b, significantly 
affected all three genotypes but decreased the migration of β3+/- and β3-/- the most. The 
other drugs, microtubule destabilisers, however did not have any effect on β3+/+ cell 
migration, but still significantly slowed down β3+/- and β3-/- cells. Even with its unique 
mechanism of action, eribulin showed the same affects as the other destabilisers. Of all the 
drugs tested, only mebendazole failed to inhibit β3+/- cell migration significantly but it was 
still able to affect β3-/- migration. We speculated this was due to the weaker action of 
mebendazole against mammalian microtubules; the drug itself is currently used as an 
anthelmintic404. Figure 5-5B shows a limited example of random migration tracking used in 
the generation of figure 5-5A for β3-/- cells treated with colchicine – the most dramatic 
example. From this it was clear to see how colchicine has affected the normally highly 
migratory β3-/- cells, although it is possible at the dose used (10 µM) we have begun to 
induce apoptosis in cells and hence are seeing a reduction in cell migration due to cell 
death. However at the same dose, β3+/+ cells did not see a significant reduction in 
migration speed in figure 5-5A. Regardless of the exact mechanisms i.e. migration inhibition 
or cell death promotion we were confident that the colchicine affect was more selective for 
β3-/- cells. Interestingly, enrichment analysis of the β3 depleted adhesomes in chapter 
four, suggested that microtubule categories were upregulated in β3+/- cells but not so 
much in β3-/-. Despite this, we had observed in figure 5-5A that β3-/- cells were equally or 
sometimes more susceptible to microtubule inhibitors than β3+/-. Looking back at 
supplementary tables 3 and 4 we observed than Dnm2 was significantly increased in the 
β3-/- but not the β3+/- adhesome upon β3 depletion. If Dnm2 was, through increased 
targeting to focal adhesions by microtubules, promoting focal adhesion disassembly191,279 
then this could be assisting β3-/- migration. β3+/- do not appear to have increased Dnm2 in 
our data, but instead have more robust microtubule associations. We speculated there 
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could be subtle differences in the mechanisms of compensation for total and partial 
depletions of β3 but given the trend of increasing susceptibility to microtubule targeting 
drugs from β3+/+ to β3+/- to β3-/- ECs we believed there would also be a common 
mechanism for compensation to any level of β3 depletion. Non-normalised random 
migration data for figure 5-5A can be seen in supplementary figure 6. 
We next attempted to co-target β3 and microtubules with microtubule inhibitors and 
c(RGDfV). Figure 4-7B had demonstrated it was unlikely that c(RGDfV) had any effect on the 
adhesome. We still felt it was worthwhile to check if changes outside the adhesome, 
caused by c(RGDfV), would make IMMLEC migration susceptible to microtubule inhibition; 
especially given that most microtubule regulatory proteins, as mentioned earlier, were not 
detected in the adhesome and so could be further downstream. Additionally, c(RGDfV) 
does have some influence on adhesion to vitronectin (figure 4-7A) so we thought it could 
also affect migration. However, when testing random migration in figure 5-6A with 
c(RGDfV), there was no significant effect on cell movement in combination with any 
microtubule inhibitor on fibronectin. To confirm this finding we took colchicine, as the 
inhibitor closest to significance with c(RGDfV) co-treatment, and obtained fresh supplies of 
both drugs in case there were unforeseen stability issues in storing these compounds. In 
figure 5-6B, new experiments were carried out using the fresh colchicine and c(RGDfV) 
where the lack of affect was shown to be consistent with figure 5-6A. Finally, we suspected 
that part of the apparent lack of c(RGDfV) effets could have been due to the length of 
inhibition. Earlier work in our lab had shown that tumour growth and angiogenesis was 
reduced using short term deletion of β3 using an inducible cre with acute tamoxifen doses. 
However, long term inhibition using constitutive cre or inducible cre with chronic tamoxifen 
administration had no effect on angiogenesis223. We therefore tested whether an 
alternative method of inhibition, using a siRNA against β3, would sensitise IMMLEC 
migrations to microtubule inhibition where c(RGDfV) could not. Figure 5-6C shows that, 
despite β3 siRNA knockdown, there was no synergistic effect with additional colchicine 
treatment. This led us to the interesting conclusion that no mode of short term 
depletion/inhibition of β3 was able to induce microtubule based changes and therefore the 
increased microtubule targeting of the adhesome could be the mechanism behind long 
term adaptation to long term β3 loss observed by Steri et al223.  
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Figure 5-4 Use of Microtubule Inhibitors in Endothelial Cells 
 
A β3+/+ endothelial cells were adhered to fibronectin before being treated with a range of 
paclitaxel or colchicine doses overnight. Residual cells after treatment was assessed using 
methylene blue staining followed by de-staining and absorption measurements. Red line 
indicates 90% cell survival n = 8. B β3+/+, β3+/- and β3-/- endothelial cells were adhered to 
fibronectin coated coverslips for 60 minutes before treated with colchicine (10 µM), 
paclitaxel (5 nM) or DMSO then fixed and immunostained for α-tubulin (green) and Pxn 
(red). Scale bar = 20 µm.  
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Figure 5-5 Random Migration in β3 Depleted Endothelial Cells with Microtubule 
Inhibitors 
 
A β3+/+, β3+/- and β3-/- endothelial cells were adhered to fibronectin overnight. Migration 
speed of individual cells was measured over 15 hours using the MTrackJ plugin for ImageJ 
whilst under the influence of the indicated microtubule agent. Migration speeds are shown 
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as a percentage of the speed of the corresponding genotype under DMSO (vehicle) 
treatment (n=46). B Example of tracking data generated for β3-/- cells treated with DMSO 
or colchicine (10 µM) with graphs showing paths taken from a unified starting point. Scale 
bar = 100 µm. 
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Figure 5-6 Random Migration in Microtubule Inhibitor Treated Endothelial Cells with 
Alternative Modes of β3 Inhibition 
 
A β3+/+ endothelial cells were adhered to fibronectin overnight. Migration speed of 
individual cells was measured over 15 hours using the MTrackJ plugin for ImageJ whilst 
under the influence of the indicated microtubule agent and either DMSO or c(RGDfV) (20 
µM). Migration speeds are shown as a percentage of the speed under DMSO (vehicle) 
treatment alone (n=49). B β3+/+ endothelial cells adhered and quantified as in panel A. 
Treated with DMSO, c(RGDfV) (20 µM), Colchicine (10 µM) or a combination (n=59) C β3+/+ 
endothelial cells were treated with control pool (CP) or β3 siRNA and allowed to recover 
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overnight. The next day they were adhered to fibronectin overnight and migration speed 
was measured as per panel A. Treated with colchicine (10 µM) or DMSO (n=45).  
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Microtubule Inhibitors in vivo 
We were confident in our studies that showed microtubule inhibition lead to a reduction of 
migration in long term β3 depleted cells. Our wide choice of drugs with their distinct 
mechanisms, targets, off-targets and pharmacokinetics made it very unlikely that off-target 
effects on another protein were causing the phenotype.  Additionally, the experiments of 
figures 5-5 and 5-6 had confirmed to us that changes in the adhesome translate to changes 
in migration behaviour, which was strengthened by the negative case of c(RGDfV) where no 
changes in the adhesome translated to no changes in migration behaviour. We decided the 
next step was to test if microtubule inhibition affected β3 depleted angiogenesis in a more 
complete system using in vivo tumour growth assays. This also gave us the opportunity to 
confirm that the phenotypes observed so far were not an artefact of in vitro 
experimentation or a quirk unique to IMMLECs.  
Tie1 cre294 driven deletion of β3 specifically in endothelial cells had been observed 
successfully in our mice218,223. This cre is also constitutively active so would closely mimic 
the genetically deleted IMMLECs used so far without having to use β3+/- or β3-/- mice that 
would have global β3 depletion, complicating analysis due to the potential involvement of 
other cell types expressing β3 in tumour growth. We crossed β3 floxed mice295 with Tie1 
cre mice to produce Tie1 cre negative β3 floxed/floxed and Tie1 cre positive β3 
floxed/floxed mice which were littermates to reduce genetic differences across or 
experimental animals. CMT19T, a lung carcinoma cell line, was chosen because it develops 
well vascularised tumours218,223, grow predictably in our experience, and can be used to 
produce allograft tumours without immune suppression in our animals405. We also chose to 
use eribulin as the microtubule targeting drug. Figure 5-4 had shown that eribulin, like all 
destabilisers, had no effect on β3+/+ cells. Part of the issue with anti-angiogenic treatments 
to date is the toxicity or bleeding side effects observed406. As a result, significant efforts are 
being made in treatment of cancer to target therapies more accurately to just 
tumours224,407 and not systemically exposing the whole body to these toxic agents. Even 
though β3 is only expressed on angiogenic vasculature, this still includes events such as 
wound healing; therefore we wanted to choose a microtubule targeting drug that would be 
compatible with targeted β3 depletion in the future. Using a destabiliser allowed us to do 
this as it would not affect β3+/+ vasculature unlike stabilisers which could stop any 
angiogenesis from occurring (see above), regardless of β3 co-depletion, and cause side 
effects. Eribulin is also well tolerated in mice and actively being developed for use in human 
breast cancer408. 
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We grew subcutaneous CMT19T tumours for a week before intravenous administration of 
eribulin once a week for two weeks then harvesting the tumours a week later, see 
schematic in figure 5-7A. There have been reports that β3 depletion can make vasculature 
leaky409, potentially allowing more chemotherapeutic agents to reach the tumour; tumours 
themselves also have leaky vasculature410 that could become even more so under β3 
depletion. Therefore we also used a non-microtubule targeting drug, doxorubicin405, as a 
control for this possibility. Doxorubicin, a DNA damaging agent, is known to have significant 
issues with toxicity, particularly cardiomyopathy411. We decided to use a sub-optimal dose 
of eribulin to strengthen our results if we did see significant reductions in tumour growth 
but for doxorubicin we needed to use an optimal dose i.e. a dose that would definitely 
affect tumour growth in order for us to be able to make a conclusion on possible vessel 
leakiness. As a result the doxorubicin treated mice experienced significant toxicity hence 
the decision was taken to use doxorubicin over a shorter time frame as shown in figure 5-
7A. 
Firstly, the results in figure 5-7B showed there was no difference in tumour growth 
between control Tie1 cre positive and negative mice meaning that, in agreement with 
literature assessing why β3 treatments failed clinically, there was no effect from β3 
depletion. Additionally there was no difference observed in tumour growth between Tie1 
cre negative mice treated with vehicle control or eribulin, demonstrating that our dose 
chosen was indeed sub-optimal. There was however a significant reduction in tumour 
growth when Tie1 cre positive mice were treated with eribulin. This synergy is in 
agreement with in vitro random migration data in figure 5-5A for eribulin’s effects on β3+/- 
and β3-/- cell migration. Doxorubicin did not show similar synergy, demonstrating the 
reduction observed with eribulin was most likely due to action on vasculature rather than a 
consequence of exceptional leakage of drugs into the tumour stroma in Tie1 cre positive 
animals killing tumour cells directly. Vessel density, shown in figure 5-7C with example 
staining in figure 5-7D, directly correlated with the tumour volumes measured in figure 5-
7B. We therefore came to the conclusions that targeting microtubules in endothelial cells 
with destabilising drugs in long term β3 depleted animals was potentially a viable anti-
angiogenic/anti-cancer strategy in vivo and not an artefact of in vitro experimentation. 
Additionally the synergy observed using a sub-optimal dose of eribulin had the potential to 
lower side effects observed with any chemotherapeutic agent. 
Next, we wanted to test whether acute deletions of β3 would reduce tumour growth and 
angiogenesis in vivo. We speculated it could have also been an artefact/quirk of in vitro 
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experimentation on IMMLECs that c(RGDfV) or β3 siRNA treatment in figure 5-6 did not 
have any additional reduction in migration speed when microtubule inhibitors were used. 
Tamoxifen induced deletions of β3 using β3 flox/flox Pdgfb-iCreERT2  mice (Pdgfb cre) have 
also been used to great effect in proving acute deletions of β3 can reduce tumour 
growth223. We therefore used the same model and induction schedule as described for the 
Tie1 cre model. In figure 5-8 we compared tumour growth in Pdgfb cre positive β3 
floxed/floxed and Pdfgb cre negative β3 floxed/floxed littermates, both treated with 
eribulin as above. This time we observed no difference in tumour growth, consistent with 
figure 5-6 where short term depletions of β3 had no synergy with microtubule inhibitors. 
Again this suggested that increased microtubule targeting to focal adhesions is not a 
symptom of β3 loss but is a long term compensation for its complete removal from the 
cells. Both Tie1 and Pdgfb cre driven deletions of β3 have been shown to be specific and 
effective in our mice223. 
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Figure 5-7 Constitutive Integrin β3 Depletion in Tumour Vasculature 
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B β3 flox/flox Tie1 cre positive (pos) and negative (neg) animals were injected 
subcutaneously with 1x106 CMT19T lung carcinoma cells and then treated with eribulin, 
doxorubicin or vehicle control according to the indicated schematic (A). Bar graph shows 
mean tumour volumes at the end of the experiment.  Micrographs (below) show 
representative tumours from 2 independent experiments (n≥5). Scale bars = 5 mm. C After 
excision, tumours from β3 flox/flox Tie1 cre positive (pos) and negative (neg) animals were 
processed and endomucin staining was assessed over entire tumour sections to measure 
vascular density. Bars = mean vessel number per mm2 (n≥5). Micrographs (D) show 
representative images of sections stained for alpha smooth muscle actin (αSMA=green), 
Endomucin (red) DAPI (blue). Scale bars = 100µm.  
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Figure 5-8 Inducible Integrin β3 Depletion in Tumour Vasculature 
 
A β3 flox/flox Pdgfb-iCreERT2 positive (pos) and negative (neg) animals were treated with 
tamoxifen as per Steri et al223 for acute β3 depletion, injected subcutaneously with 1x106 
CMT19T lung carcinoma cells and then treated with eribulin as seen in the schematic (B). 
Bar graph shows mean tumour volumes at the end of the experiment.  Micrographs 
(below) show representative tumours (n≥5). Scale bars = 5 mm.   
A
B
ns
Pdgfb-iCre ERT2
β3 floxed/
floxed
136 
 
Chapter six – Mechanisms of Integrin β3 Regulation of 
Microtubule Stability 
After confirming the potential of inhibiting microtubules to halt endothelial cell migration 
and tumour growth in β3 depleted angiogenesis, this chapter aims to explain the 
mechanisms behind these observations. This was achieved by using microtubule stability 
assays and further mining the endothelial adhesome plus other datasets for the additional 
proteins in the pathways involved before validating their participation. 
Microtubule Stability in Integrin β3 Depleted Cells 
We had so far demonstrated in chapter five that migration in β3 depleted endothelial cells 
is more susceptible to microtubule inhibitors than in β3+/+. This was also replicated in vivo, 
where microtubule inhibitors reduced the growth of tumours in β3 depleted mice. We 
needed to establish how β3, using the tools established earlier such as the endothelial and 
β3 dependent adhesomes, influenced microtubule behaviour. Microtubules have many 
roles themselves in regulating focal adhesion behaviour especially during directional 
migration such as by trafficking focal adhesion components to the cell cortex or by 
participating in signalling279, and because of this they can often be stabilised near or at focal 
adhesions via +TIPs272,412. Given that focal adhesions are known to capture and promote 
stability of microtubules280,413 it was interesting that the presence of an integrin, β3, was 
apparently preventing the targeting of microtubules to focal adhesions in figures 5-2 and 5-
3. It seemed that β3 was playing an opposing role in microtubule regulation to β1 which 
can capture and stabilise microtubules237. This could have explained why β3+/- and β3-/- 
endothelial cells have more microtubules in the adhesome/at focal adhesions and that this 
could act as a compensation for the loss of β3, making them more reliant on microtubules 
and therefore vulnerable to microtubule targeting agents. 
We already knew that β3 was not promoting targeting of microtubules to focal adhesions 
but to completely test if β3 was opposing β1 in other modes of microtubule regulation, we 
needed to assess the stability of microtubules in our endothelial cells as well. Microtubule 
stability can be assessed by their post-translational modifications such as acetylation414, 
however in our hands the antibodies for acetylated mouse tubulin were unreliable 
preventing us from obtaining reliable staining or western blots. As an alternative we 
investigated microtubule stability in response to cold treatment. Low temperatures are 
known to induce disassembly of microtubules in a short time258,260. Some cell types, 
including endothelial cells, also have microtubules that are permanently resistant to cold 
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treatment known as cold stable microtubules due to the action of protective capping 
proteins such as Map6259. We designed experiments where cells were adhered to 
fibronectin for 90 minutes, to be consistent with adhesome samples and figure 5-2, but 
exposed to cold treatment in the last 15 minutes before fixation. In preliminary 
experiments we discovered the vast majority of microtubules were indeed depolymerised 
during the cold exposure but, as shown in figure 6-1A, the resulting cloud of liberated 
tubulin monomers preventing us from being able to quantify cold stable microtubules 
when staining for α-tubulin. To overcome this we used a gentle lysis buffer (PEM) to wash 
out soluble tubulin, leaving behind insoluble tubulin, before fixation as per Ochoa et al259. 
The washout step allowed us to only stain cold stable microtubules, making quantification 
much easier as can be seen for β3+/+, β3+/- and β3-/- cells in figure 6-1B. 
Figure 6-1C compares the average number of cold stable microtubules between β3+/+, 
β3+/- and β3-/- IMMLECs. The difference observed between β3+/+ cells and Itb3 depleted 
ones was astounding, and in most cases β3+/+ cells had no stable microtubules remaining. 
This result suggested that in endothelial cells expressing β3 there are very low levels of 
microtubule stabilisation or conversely cells without β3 undergo more stabilisation. The 
very simple but time-consuming technique of counting microtubules was, we believe, 
sufficient to accurately reflect the phenotype of increased microtubule stability upon β3 
depletion but was not flawless. For example this technique did not discriminate between 
long microtubules travelling from the centrosome to the cell cortex or short ones just 
beginning to be nucleated. Additionally microtubules were occasionally broken in the 
middle making counting difficult, likely due to mechanical destruction during 
washing/washouts/fixation rather than spontaneous breakdown because microtubules 
tend to disassemble from the plus end415. To confirm that the dramatic difference in 
microtubule stability was not an artefact of staining during this experiment, we also tested 
microtubule stability biochemically using western blotting. In figure 6-2 we used the same 
procedure as before except capturing and western blotting the washout material for α-
tubulin to quantify soluble tubulin. After washout we were then able to lyse the cells 
separately to assess the amount of insoluble tubulin. The amount of cold soluble tubulin 
washed out of the endothelial cells, in figure 6-2A, was greatest in the β3+/+ and the least 
in the β3-/-. Conversely in figure 6-2B, the amount of cold insoluble tubulin remaining 
behind after the washout was greatest in the β3-/- and the least in the β3+/+.  Not only did 
this experiment confirm the findings in figure 6-1 that decreasing levels of β3 led to 
increased microtubule it was also able to validate our cold stability and washout technique 
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for cell staining. The graphs presented in figure 6-2 are near mirror images of each other 
meaning that the entire cellular pool of tubulin was represented in our cold soluble or cold 
insoluble samples; no tubulin was lost during washing stages and hence the staining 
approach was also a good indicator of the number of cold stable microtubules. We 
speculated that the difference between figures 6-1 and 6-2 concerning stability in β3+/- vs 
β3-/- was part of a trend discussed in earlier chapters and possibly down to the 
length/breakages of microtubules that could be accounted for in figure 6-2 but not 6-1. 
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Figure 6-1 Cold Stable Microtubule Staining in β3 Depleted Endothelial Cells 
 
 
A β3+/+ IMMLECs adhered to fibronectin coated coverslips for 75 minutes at 37°C before 
being moved to ice for 15 minutes and then fixed with methanol. Immunostaining was 
carried out for α-tubulin (green) scale bar = 20 µm. B β3+/+, β3+/- and β3-/- IMMLECs 
treated as in A except soluble tubulin washed out using PEM buffer before fixation. 
Immunostaining was carried out for α-tubulin (green) and Tln1 (red). DAPI (blue) was used 
as a nuclear stain scale bar = 20 µm. C Quantification of microtubules per cell treated as in 
B. Bars represent mean ± SEM n = 519.  
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Figure 6-2 Cold Soluble Microtubules in β3 Depleted Endothelial Cells 
 
A β3+/+, β3+/- and β3-/- IMMLECs were adhered to fibronectin for 75 minutes before 
being moved to ice for 15 minutes. Soluble tubulin was washed out using PEM buffer, 
collected and western blotted for α-tubulin and Gapdh as a loading control. Bars represent 
mean soluble tubulin ± SEM n = 5 with a representative blot shown below. B Cells used in 
generating panel A were then lysed after PEM washout and western blotted for α-tubulin 
and Gapdh as a loading control. Bars represent mean insoluble tubulin ± SEM n = 5 with a 
representative blot shown below. 
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β3 Dependent Microtubule Stability Regulators in Endothelial Cells 
We next turned our attention to elucidating the mechanism behind changes in microtubule 
stability in β3 depleted endothelial cells. We had the possibility of searching for a protein 
that was recruited to the adhesome upon β3 depletion to promote stability or one that was 
displaced from the adhesome to destabilise microtubules. We knew that β1 is known to 
stabilise microtubules at focal adhesions237, however none is the proteins involved in that 
mechanism such as β1, α5, Tln1, and Kank1178 or similar proposed mechanisms involving 
Iqgap1278 were detected or upregulated upon β3 depletion in the endothelial adhesome 
(see supplementary tables 3 and 4). Therefore we attributed the changes in microtubule 
stability to a dominant negative role played by β3, supported by the fact that β1 was still 
present in β3+/+ cell adhesomes at equal levels to that of β3+/- and β3-/- cells; narrowing 
down candidate regulators to those that were lost from the adhesome upon β3 depletion. 
We also knew that from figures 5-2 and 5-3 that β3 containing cells show less targeting of 
microtubules, which was also not VEGF dependent, leading us to the conclusion to search 
for microtubule regulating proteins in the fibronectin adhesome. Figure 4-6, which was 
built from our adhesome data, identified a number of candidate proteins that could have 
been behind the increased microtubule stability of β3 depleted cells using our adhesome 
data. Only two proteins were labelled green (decreased abundance in the adhesome upon 
β3 depletion) and in the central column (the fibronectin adhesome): Rcc2 and Pdcd6ip 
(Programmed cell death 6 interacting protein). Of the two, Rcc2 appeared a much more 
promising candidate as a microtubule regulator that could explain our phenotypes 
according to literature. 
Rcc2 is known to interact with microtubules and be important in spindle assembly during 
early mitosis243,416. Recently, Rcc2 has been found to possess GEF ability and can use this to 
control Rac1 activity244 through its interaction with Coro1c (Coronin, actin binding protein 
1c) which can assist with directional migration417,418. Figure 4-6 suggested that Rcc2 is only 
recruited to the adhesome with β3 presence making Rcc2 a likely candidate in our cells for 
β3 driven microtubule regulation. We initially tested this candidate using siRNA to produce 
a knockdown of Rcc2 protein levels. We were reliably able to knockdown Rcc2 in β3+/+ 
IMMLEC cells, with an example blot shown in figure 6-3A. After Rcc2 knockdown we 
subjected our cells, along with control pool siRNA treated control cells, to the same cold 
stability assay used in figure 6-1. Staining and counting of microtubules revealed a 
significant increase in the number of cold stable microtubules upon Rcc2 knockdown, 
shown in figure 6-3B with example images in figure 6-3C. Even with incomplete 
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knockdown, the increase in microtubule stability with lower levels of Rcc2 lead us to the 
conclusion that Rcc2 is at least partially responsible for the effects of β3 on microtubules. 
Also, we had shown that our adhesome data could be used to successfully identify targets 
relevant to endothelial cell behaviour and perhaps with future uses in anti-angiogenic 
therapies. 
Although the interactions of Rcc2 with microtubules are quite well known, and we had 
shown this was somehow inhibitory to stability in endothelial cells, we did not yet know 
how Rcc2 interacts with β3. Figure 4-6, as the culmination of different sources of adhesome 
data, showed Rcc2 and β3 to be in the same adhesome cluster; which gave a higher 
probability these proteins were involved in the same complex than if Rcc2 was found in a 
different cluster. Williamson et al418 had previously carried out GFP-Rcc2 fusion protein 
pulldowns and compared this with GFP-only control pulldowns using mass spectrometry in 
HEK-293T cells but had only published part of the dataset. We believed the full dataset 
could provide us with more information about Rcc2 interactions and potentially reveal the 
link to β3. Through a collaborative agreement, we obtained the full list of proteins which 
we found in higher abundance in GFP-Rcc2 pulldowns compared to GFP control pulldowns 
which is shown in supplementary table 6. We correlated this data with our adhesome data, 
specifically to identify proteins in the same cluster as β3 and Rcc2 but also decreased in the 
adhesome with β3 depletion like Rcc2. We found Anxa2 correlated in this manner between 
the Rcc2 pulldown and in both the β3+/- (supplementary table 3 row 185) and β3-/- 
(supplementary table 4 row 111) adhesomes. Anxa2 is a calcium dependent phospholipid 
binding protein found in many cellular compartments including on the cell surface and 
involved in many different roles, cell types and diseases including a strong association with 
cancer when misregulated419; Anxa2 also has specific roles in angiogenesis during tumour 
growth420. Additionally Anxa2 has been shown to interact with β1421 and αm422and can 
therefore influence focal adhesion behaviour such as recycling423. 
We set out to prove the relevance of Anxa2 in β3 dependent microtubule stability using 
knockdown experiments as before with Rcc2. Knockdowns of Anxa2 using siRNA proved to 
be more difficult and were not overly successful as shown in figure 6-4A however across 
multiple experiments the reduction of Anxa2 protein level, shown in figure 6-4B was 
significant. Despite the modest knockdown, figure 6-4C shows that there was still a 
significant increase in cold stable microtubules compared to control pool siRNA treated 
cells. Example images shown in figure 6-4D illustrate how dramatic the increase was and 
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hence we believed Anxa2 to be very important in the mechanism of β3 dependent 
microtubule stability considering the strong phenotype on top of a modest knockdown. 
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Figure 6-3 Rcc2 Regulates Microtubule Stability in Endothelial Cells 
 
 
A β3+/+ IMMLECs were transfected with control pool (CP) or Rcc2 smart pool siRNA and 
allowed to recover for 48 hours. Cells were lysed and western blotted for Rcc2 or Gapdh as 
a loading control. Blot is representative of all Rcc2 knockdowns used in this figure. B Cells 
transfected as per panel A were adhered to fibronectin coated coverslips for 75 minutes at 
37°C before being moved to ice for 15 minutes. Soluble tubulin was washed out using PEM 
buffer before fixing with -20°C methanol. Immunostaining for α-tubulin was carried out to 
allow counting of cold stable microtubules per cell. Bars = mean number of cold stable 
microtubules shown as a percentage relative to CP treated cells ± SEM n = 224. C 
Representative immunostaining of cells used from panel B. α-tubulin (green), Tln1 (red) and 
DAPI (blue) as a nuclear stain. Scale bar = 20 µm.    
Rcc2
Gapdh
50
30
Mw
(kDa)
siRNA
CP Rcc2
CP Rcc2siRNA:
C
o
ld
 s
ta
b
le
 M
ic
ro
tu
b
u
o
le
s
(P
e
rc
e
tn
a
g
e
 o
f 
C
o
n
tr
o
l)
0
150
50
100
200
250
*
A B
C
CP Rcc2siRNA:
D
A
P
I
α
-T
u
b
u
lin
T
ln
1
145 
 
Figure 6-4 Anxa2 Regulates Microtubule Stability in Endothelial Cells 
 
 
A β3+/+ IMMLECs were transfected with control pool (CP) or Anxa2 smart pool siRNA and 
allowed to recover for 48 hours before being lysed and western blotted for Anxa2 or 
Hspa1a as a loading control. Three different knockdowns are shown to illustrate the small 
but consistent knockdown. B Quantification of knockdown efficiency of Anxa2 shown in 
panel A as a percentage of control pool signal. Bars = mean ± SEM. C Cells transfected as 
per panel A were adhered to fibronectin coated coverslips for 75 minutes at 37°C before 
being moved to ice for 15 minutes. Soluble tubulin was then washed out using PEM buffer 
before fixing with -20°C methanol. Immunostaining was carried out for α-tubulin to allow 
counting of cold stable microtubules. Bars = mean number of cold stable microtubules per 
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cell as a percentage of control pool ± SEM n = 100. D Representative images of cells used in 
panel C. Immunostained for α-tubulin (green), Tln1 (red) and nuclear stained using DAPI 
(blue). Scale bar = 20 µm. 
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Rac1 Drives Microtubule Stability in β3 Depleted Endothelial Cells 
The next stage in our investigation was to explain how β3 directed changes in Rcc2 and 
Anxa2 affected microtubule stability. We had shown earlier that Rcc2 and Anxa2 
knockdowns had increased microtubule stability in β3+/+ cells and that Rcc2 and Anxa2 are 
lost from the adhesome upon β3 depletion. Therefore it was reasonable to believe that 
Rcc2 and Anxa2 function were related to or responsible for the increased microtubule 
stability in β3 depleted cells seen in figures 6-1 and 6-2. Previous work from our 
collaborators and others had shown that Rcc2 is able to bind Rac1 directly and in doing so 
can control its access to GEFs which would alter its activity416–418. Rac1 is of considerable 
interest in anti-angiogenesis and anti-cancer treatments due to its many roles in cell 
migration275, either through direct effects on actin dynamics or on downstream signals also 
affecting cell survival, growth or pro-angiogenic signalling utilising important pathways 
such as Erk1/Erk2424. Interestingly Rac1 has also been associated with β3 in endothelial 
cells. D’Amico et al425 showed that, in tumour angiogenesis, Rac1 depletion has no effect on 
angiogenic responses in β3+/+ mice or cells.  However, upon β3 depletion, Rac1 co-
depletion did affect angiogenesis. It appeared to us that Rac1 driven processes were not 
sensitive to depletion unless β3 was also depleted or that Rac1 somehow became more 
important for endothelial cells in β3 depleted situations. The mechanisms behind this β3 
dependence were never fully derived but we believed we may have found them in the form 
of microtubule stability. Rac1 is currently known to have several mechanisms through 
which it can influence microtubule stability426–428 including capture through Iqgap1 and 
Clip1274. 
Given we had successfully shown tumour growth and endothelial migration was sensitive 
to microtubule inhibitors during β3 depletion in figure 5-5 and that this correlated with 
microtubule stability in figures 6-1 and 6-2, we decided to test if Rac1 activity was behind 
these affects using further microtubule cold stability assays as before. We chose to use a 
Rac1 inhibitor known as NSC23766 which can reduce Rac1 activity by inhibiting specific 
Rac1 GEFs without inhibiting the binding of Rac1 to downstream effectors or the activity of 
closely related Rho-GTPases such as Cdc42 or RhoA429. Figure 6-5A shows that NSC23766  
only affects microtubule stability in β3+/- or β3-/- cells but not β3+/+ cells, which can also 
be seen in the representative pictures of figure 6-5B. This key finding indicated to us that 
the increased microtubule stability in β3 depleted cells is dependent on Rac1 activity. 
We were tempted to speculate that the simplest explanation of Rac1 involvement would 
have been true; that Rac1 recruitment to the endothelial adhesome was dependent on β3. 
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However this was not the case in supplementary table 3 or 4-5. Rcc2’s role in regulating 
GEF exposure of Rac1 therefore seemed more a more likely explanation instead of Rac1’s 
localisation being the driving factor of phenotypes observed so far. Additionally we 
believed Anxa2 was able to bind Rcc2, as shown in supplementary table 6, and assist in 
Rcc2 localisation to the adhesome by interaction with β3. If true, then both Rcc2 and Anxa2 
would have a role to play in making Rac1 activity important for microtubule stability. Anxa2 
has also been shown to interact itself with Rac1 and control its localisation to the 
membrane430. We tested this theory using Rcc2 and Anxa2 siRNA knockdowns as before in 
figures 6-3 and 6-4 in microtubule cold stability assays along with the Rac1 inhibitor 
NSC23766. Figure 6-6A, along with representative pictures in figure 6-6B, show that the 
increased microtubule stability observed with Rcc2 and Anxa2 depletion earlier is 
dependent on Rac1 activity. I.e. without Rac1 activity, Rcc2 and Anxa2 depletion had no 
effect. 
We believed, from the combination of experiments carried out in this investigation, that 
Rcc2 and Anxa2 loss from the adhesome was causing an increase in Rac1 activity which 
lead to an increase in microtubule stability in β3 depleted cells. In β3+/+ cells Rac1 activity 
was held in check by its association with Rcc2/Anxa2/β3 in the adhesome, preventing 
microtubule capture at or around focal adhesions by not allowing Rac1 directed 
microtubule stability to occur. To investigate this mechanism further we decided to assess 
the amount of active Rac1 in β3+/+, β3+/- and β3-/- cells using a Pak1-PBD pulldown assay 
which worked on the principle that Pak1-PBD coated magnetic beads would only bind to 
GTP-Rac1. This assay proved to somewhat unreliable, likely due to rapid hydrolysis of GTP 
to GDP preventing the successful pulldown of GTP-bound (active) Rac1, therefore we did 
not apply a full statistical analysis to the results however figure 6-7A does show increased 
active Rac1 in β3+/- cells compared to β3+/+ cells. We were not able to reliably detect an 
increase in active Rac1 in β3-/- cells however. Given the conclusions of how important Rac1 
activity was shown to be important in figures 6-5 and 6-6 to explain β3 driven changes in 
microtubule stability, and that Rac1 is actually a cluster I protein in the endothelial 
adhesome (figure 4-2 and supplementary table 2) meaning it was found more in the non-
focal adhesion areas of the adhesome but still present in focal adhesions, we came to the 
conclusion that both Rac1 activity and localisation of active Rac1 were important. 
Adhesome enrichment and mass spectrometry experiments were not able to distinguish 
from inactive or active Rac1 to support this conclusion, however we were able to probe for 
several proteins that complex with active Rac1 in IMMLEC cells using the Pak1-PBD 
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pulldowns. In figures 6-7A ad 6-7B, β3 was detected in association with active Rac1 only in 
β3+/+ but not β3+/- cells, and obviously none in β3-/- cells. Additionally greater 
associations were detected between Rcc2 and active Rac1 in β3 depleted cells, and a 
similar result for Anxa2 strengthening our conclusion. Finally, much greater α5 associations 
were detected in β3 depleted cells suggesting that without β3 there was more active Rac1 
associated with α5. Active Rac1 associations with α5 offer a different interpretation of 
α5β1 directed microtubule stabilisation than is often found in the literature such as via Tln1 
and Kank1178 which will be discussed in the next chapter. 
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Figure 6-5 Rac1 Inhibition Decreases Microtubule Stability in β3 Depleted Endothelial 
Cells 
 
 
A β3+/+, β3+/- and β3-/- IMMLECs were adhered to fibronectin coated coverslips for 60 
minutes at 37°C before being treated with DMSO (control) or 50 µM NSC23766 and 
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incubated at 37°C for a further 15 minutes. Coverslips were moved to ice for 15 minutes. 
Soluble tubulin was then washout out using PEM buffer before fixing with -20°C methanol. 
Immunostaining was carried out for α-tubulin to allow for counting of cold stable 
microtubules. Bars = mean number of microtubules per cell shown as a percentage relative 
to the DMSO control ± SEM n = 218. B Representative images of cells treated as in panel A, 
immunostained for α-tubulin (green), Tln1 (red) with DAPI (blue) as a nuclear stain. Scale 
bar = 20 µm. 
  
152 
 
Figure 6-6 Rcc2 and Anxa2 Dependent Microtubule Stability is driven by Rac1 in 
Endothelial Cells 
  
A β3+/+ IMMLECs were transfected with control pool (CP), Anxa2 or Rcc2 smart pool siRNA 
and allowed to recover for 48 hours then were adhered to fibronectin coated coverslips for 
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75 minutes at 37°C before being moved to ice for 15 minutes. Soluble tubulin was then 
washed out using PEM buffer before fixing with -20°C methanol. Immunostaining was 
carried out for α-tubulin to allow counting of cold stable microtubules. Bars = mean 
number of cold stable microtubules per cell as a percentage of DMSO treated control pool 
cells ± SEM n = 100. B Representative images of cells from panel A, immunostained for α-
tubulin (green), Tln1 (red) with DAPI (blue) as a nuclear stain. Scale bar = 20 µm.  
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Figure 6-7 Active Rac1 Associates with Different Microtubule Regulators in Itb3 
Depleted Endothelial Cells 
 
A β3+/+, β3+/- and β3-/- IMMLECs were adhered to fibronectin coated plates for 90 
minutes before being lysed in MLB. GTP-Rac1 and bound proteins were extracted from 
cleared MLB using Pak1-PBD magnetic beads at 4°C for an hour as per manufacturer’s 
instructions before being western blotted for α5, β3, Rcc2, Anxa2 and Rac1. Blot (top) is 
representative of at least 3 independent experiments.  Quantification of experiments is 
shown in bottom panel. Bars = mean level of association of the indicated protein with GTP-
Rac1, shown relative to β3+/+ associations ± SEM. B. Independently of panel A, β3+/+, 
β3+/- and β3-/- endothelial cells were adhered to fibronectin for 90 minutes before being 
lysed and Western blotted for β3, Hspa1a (Hsc70; as a loading control) and Rac1. Blot is 
representative of 3 independent experiments with quantification of experiments shown in 
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bottom panel. Bars = mean relative amount of Rac1 ± SEM. Panel B experiments were 
performed with assistance from Abdullah Alghamdi, University of East Anglia. 
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Chapter seven – Discussion 
Modes of Integrin β3 Inhibition 
In order to define the role β3 plays in the endothelial cell adhesome we had to find ways of 
inhibiting it. We used various methods throughout this investigation in an attempt to 
strengthen our conclusions by overcoming the possibility that one method could have an 
inherent flaw. As a by-product we discovered that the method of β3 disruption greatly 
affects the outcome. It had previously been observed that β3-/- mice show increased 
angiogenic responses215 and that this was due to a combination of increased VEGFR2 
signalling and an increase in β1 focal adhesion formation through decreases in Vasp 
(Vasodilator stimulated phosphoprotein) and RIAM216,386. These mechanisms are primarily 
driven by phosphorylation and hence would not necessarily be evident in our quantitative 
mass spectrometry datasets and indeed no total protein levels of VEGFR2, Vasp or RIAM 
were upregulated in any of our adhesome datasets in chapter 4. These β3-/- studies had 
peviously been criticised in that a global and complete knockout of β3 was not 
physiologically relevant and would not represent a cancer treatment setting where an 
inhibitor would not be perfectly efficient. β3+/- mice had also showed enhanced 
angiogenesis with the study by Ellison et al and others expanding the mechanism of β3 
angiogenesis suppression to include the VEGF co-receptor Nrp152,218. Supplementary figure 
3 shows that there is a linear relationship between β3 gene deletion and migration speed 
i.e. β3-/- IMMLECs migrate faster than β3+/- which migrate faster than β3+/+ on 
fibronectin, which suggested to us that there may be similarities in the adaption to partial 
and total losses of β3. However adhesome results in chapter 4 casted doubt on this 
suggestion, where significant changes in supplementary tables 3 and 4 were not similar. 
Enrichment analysis of the adhesome results in tables 4-2 and 4-3 confirmed this 
dissimilarity between β3+/- and β3-/- β3 gene deletion as no similarities were shown with 
the exception of cluster F, a focal adhesion cluster defined in figure 4-2, suggesting that a 
minority of core focal adhesion proteins were affected in the same way, possibly ones that 
bind directly to β3 only, but that this led to no meaningful downstream consequences. We 
speculated the lack of similarities in the β3+/- and β3-/- adhesomes could have been due to 
the samples being prepared in difference experiments, however the β3+/+ controls used in 
both the generation of the β3+/- and β3-/- samples did show a reasonable correlation in 
figure 4-1C. An alternative explanation was that there are different compensation 
mechanisms for total and partial loss of β3 and that it is merely coincidence that this results 
in a linear relationship between migration speed and extent of gene deletion in 
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supplementary figure 3. The true answer is likely somewhere in between and would 
require further investigation.  
Significant increases in microtubule recruitment to the adhesome in β3+/- cells was the 
most striking finding from our adhesome analysis. Yet, every readout of microtubule 
function tested in this investigation suggested that β3-/- cells were just as susceptible to 
microtubule inhibition as β3+/- cells and, as mentioned in chapter 4, the β3-/- adhesome 
with VEGF stimulation does include some significant enrichment of microtubule categories. 
Figure 5-2, showing the effects of β3 deletion and VEGF in targeting microtubules to focal 
adhesions and in this case there was a significant decrease of microtubule targeting to focal 
adhesions in β3-/- cells with VEGF compared to without, but β3+/- cells appeared 
unaffected by VEGF. The differences in the way VEGF affects adaptation to β3 is possibly 
due to the increased VEGFR2 expression reported in β3-/- mice and liberation of Nrp1 to 
participate in VEGF signalling52,215. We considered the investigation into why both β3-/- and 
β3+/- cells were more sensitive to microtubule inhibition a more pressing subject, but we 
have not fully explored the adhesome datasets for β3+/- and β3-/- cells with VEGF 
stimulation which could be investigated further. 
We also wanted to investigate how inhibitors like RGD mimetics affected the endothelial 
adhesome and if these were similar to that of genetic deletions in the β3+/- and β3-/- 
IMMLECs; we also hoped this would explain the disappointing clinical data behind drugs 
such as Cilengitide®212. Figure 4-7B and supplementary table 5 showed that c(RGDfV) had 
no effect on the composition of the adhesome, despite figure 4-7A showing the dose of 
c(RGDfV) used was able to inhibit αvβ3 dependent vitronectin binding. Concerned a 
problem with the mass spectrometry dataset had obscured any potential findings, we 
tested the c(RGDfV) inhibitor on random migration in combination with microtubule 
inhibitors, shown in figure 5-6A, as this had a dramatic effect on IMMLECs with a genetic 
deletion of β3 but no synergy between the inhibitors was observed. This led us to the 
conclusion that c(RGDfV), and possibly other RGD mimetics, had no effect on the 
endothelial adhesome and hence would likely have little impact on tumour growth. We 
believe this tells us that in endothelial cells, β3 ligation is enough to trigger recruitment of 
β3 dependent members of the adhesome. RGD mimetics are designed to fit into the 
fibronectin binding site of αvβ3, in an attempt to prevent matrix engagement and pro-
angiogenic signalling. However it appears that RGD mimetics like Cilengitide® are actually 
able to activate β3 in a similar way to matrix engagement377 which could be part of the 
reason that Cilengitide® has been found to be pro-angiogenic in low doses214. Ligation to a 
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small molecule like c(RGDfV) would not provide the same stiffness response as that of a 
complex matrix, but this may be beyond the range of normal β3 function in endothelial 
cells. Schiller et al186 had already shown that β1 containing integrins are responsible for 
stiffness sensing in fibroblasts via Myh2. They showed that if a fibroblast was able to sense 
a matrix stiff enough using β1, then mature focal adhesions would develop containing β3. If 
we assume this is also true in endothelial cells, then it would make sense that soluble RGD 
mimetic ligation is sufficient to activate β3 and recruit its mediators to the adhesome 
because the stiffness sensing is carried out by β1 instead. As a result there would be no 
difference in downstream signalling from c(RGDfV) binding as fibronectin ligation, which is 
supported by our adhesome data showing no differences between c(RGDfV) and DMSO 
control treated IMMLECs, as stiffness sensing is not within the “repertoire” of β3. This is 
consistent with our adhesion assays showing c(RGDfV) reduces adhesion to vitronectin in 
figure 4-7A: whilst c(RGDfV) may induce similar signalling to matrix ligation, it does not 
form a physical connection to anchor the cell. As a future investigation, it would be 
interesting to evaluate whether α5β1 blocking peptides or antibodies431,432 also have no 
effect on the endothelial adhesome with and without constitutive activation of Myh2, to 
induce the matrix stiffness response. 
Finally, in an attempt to explain the conflicting pro and anti-angiogenic roles of β3, Steri et 
al223 had observed that acute genetic depletion of β3 inhibited tumour growth and 
angiogenesis whereas long term depletion promoted it. We thought this could also offer 
some insight into the differences between our c(RGDfV) treated IMMLECs and β3+/-/β3-/- 
as our pharmacological inhibition was always a short term treatment during the 90 minute 
adhesions of the cell. We had shown that β3+/- and β3-/- IMMLECs were sensitive to 
microtubule inhibition during random migration in figure 5-5 and that tumour growth and 
angiogenesis in Tie1 cre β3 floxed/floxed mice was decreased when β3 was deleted along 
with eribulin treatment in figure 5-7. Tie1 driven cre is a constitutively active cre in 
endothelial cells, therefore we used an inducible cre in figure 5-8 to test whether eribulin 
treatment would synergise with acute β3 loss. It turned out that it did not, confirming the 
findings that the method and length of β3 depletion is important in determining the 
angiogenic responses that arise from compensation for its loss.  A useful further 
investigation would be to disentangle the length and method of inhibition further to allow 
us to develop better therapeutic strategies.  For example, Steri et al used tamoxifen to 
induce β3 depletion over a long time and this phenocopied the constitutive Tie1 cre 
deletion. A similar investigation using c(RGDfV) or other RGD mimetics should be carried 
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out to see if long term pharmacological inhibition of β3 has a similar effect, which could 
also explain why the c(RGDfV) adhesome showed no differences compared to control in 
the short experiments we carried out. A summary of how different modes of β3 inhibition 
affects angiogenesis can be seen in figure 7-1.  
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Figure 7-1 Effects of Different Modes of β3 Inhibition During Angiogenesis 
 
A schematic overview showing how different modes of β3 Inhibition can affect 
angiogenesis, which is represented by the numbers of sprouts coming from the rings. A 
Different mouse studies show that: β3 knockouts can result in increased angiogenesis215, 
acute deletion of β3 driven by Pdgfb cre prevents angiogenesis but chronic does not223 and 
this study demonstrates how angiogenesis with constitutive Tie1-cre deletion of β3 is 
vulnerable to microtubule targeting agents (MTAs). B Processes important in angiogenesis 
such as cell migration can be inhibited or brought down to β3+/+ levels in β3+/- and β3-/- 
cells with MTA treatment. C Preliminary results in this study suggests that short term β3 
inhibition with siRNA or c(RGDfV) does not synergize with MTA treatment but based on 
results shown in panel A and B, we believe it should be important to investigate long term 
siRNA or c(RGFfV).  
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Microtubule Regulation by Integrin β3 
Much of the evidence provided in this thesis points to β3 having a dominant negative role 
on the recruitment of microtubules to the endothelial adhesome. Without β3 present there 
is an increase in microtubule components at the adhesion, which was particularly evident 
in the β3+/- adhesome. Additionally there was a significant increase in both microtubule 
targeting to focal adhesions and lamellipodia in β3+/- and β3-/- endothelial cells shown in 
figures 5-2 and 5-3 respectively. Prevention of microtubule recruitment to focal adhesions 
by β3 appears to be the opposite to the role of β1, which is thought to recruit microtubules 
to focal adhesions237. Increased microtubule targeting, due to the lack of β3, seems to aid 
the migration of the β3+/- and β3-/- cells shown in supplementary figure 3, probably by 
increasing focal adhesion turnover189,291. This greater use of microtubules makes β3+/- and 
β3-/- cells susceptible to microtubule inhibitors as shown in figure 5-5. Interestingly 
though, we found that microtubules in the β3+/- and β3-/- cells were more stable 
compared to those in β3+/+ cells, despite this increased susceptibility to inhibitors. Cold 
stability assays showed, by both staining and biochemical methods in figures 6-1 and 6-2, 
that more β3+/- and β3-/- microtubules resisted cold induced depolymerisation. Ochoa et 
al259 have suggested that Map6 is responsible for protecting microtubules during low 
temperatures and was observed that pulmonary endothelial cells have a permanent cold 
stable microtubule population as a result. We did not observe Map6, or many microtubule 
+TIPs at all, in any adhesome datasets, likely due to the difficulty of detecting them and 
their low abundance.  We also did not observe a permanent cold stable microtubule 
population in our IMMLECs, as was seen in the study identifying Map6. The vast majority of 
β3+/+ IMMLECs in the cold stability assays were observed with no microtubules at all 
indicating that our cells may not have Map6.   However, it was not clear that from if the 
work by Ochoa et al on cold stability in endothelial cells whether cells were adhered to any 
matrix prior to cold stability testing. In our assays cells were adhered to fibronectin so it is 
possible that over 90 minutes, matrix engagement prevented microtubule stabilisation in 
an αvβ3 dependent manner not possible if cells were simply adhered to uncoated glass 
coverslips. 
It was tempting to speculate that the increased stability and targeting of microtubules to 
focal adhesions was due to an increase in β1 in order to compensate for the loss of β3 as 
has been observed previously386. However, no adhesome datasets showed a significant 
increase in α5 or β1. Additionally, proteins involved in the two known mechanisms behind 
microtubule capture by β1 via Tln1-Kank1 or via Iqgap1178,278 were not significantly 
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increased in any adhesome datasets. Therefore, the other possible explanation is that β3 
presence inhibits microtubule recruitment to focal adhesions via a novel mechanism. We 
mined our adhesome dataset for proteins that appeared to be recruited to the adhesome 
by β3 according to SAM analysis and were known to have a role in microtubule regulation. 
The result of this analysis, as seen in figure 4-6, was that we identified Rcc2 as a possible 
mediator of the β3 effects on microtubules. Rcc2 has been shown to interact with 
microtubules during mitosis but has recently been found to have other roles in cell 
migration244,433. Knockdown of Rcc2 in β3+/+ endothelial cells increased the number of cold 
stable microtubules which suggested Rcc2 was negatively regulating microtubule stability. 
Although Rcc2 had been detected in adhesome enrichments previously244, the mechanism 
behind its apparent β3 dependent recruitment was unknown. Mass spectrometry analysis 
of Rcc2 pulldowns had previously been carried out but only partially published418. Through 
collaborative arrangements we obtained the full dataset and carried out a comparison with 
our mass spectrometry datasets to identify Rcc2 interactors that were also dependent on 
β3 for adhesome inclusion. Our conclusion was that Anxa2 was the most likely candidate, 
given it had been previously shown to interact with some integrins421,422 and has known 
roles in angiogenesis420. Like Rcc2, Anxa2 knockdown increased the number of cold stable 
microtubules in figure 6-4. It was suggested to us by reviewers that we should also 
knockdown Rcc2 and Anxa2 in combination to double confirm that they were part of the 
same system as both knockdowns were incomplete, the results in supplementary figure 4 
showed that the double knockdown significantly increased microtubule stability more than 
single knockdowns. 
We believed we had begun to develop an understanding of a protein complex which gave 
β3 the ability to negatively regulate microtubule stability: β3 recruits Anxa2 to the 
adhesome which is bound to Rcc2. We reasoned that the other unknown members of the 
β3/Anxa2/Rcc2 complex must be the driving force behind the microtubule recruitment and 
stability phenotypes observed so far. Rcc2 was originally thought to act as a Rac1 GEF but 
now is thought to bind it and control its access to GEFs through changing Rac1 localisation 
and inclusion into certain complexes417,418. We knew Rac1 itself had multiple roles in cell 
migration and itself has been shown to recruit microtubules through Iqgap1 and Clip170 
when activated274, hence the localisation and GTP status of Rac1 was of great interest to us 
in potentially explaining how β3 regulated microtubules. Studying Rac1 is always hard due 
to the difficulty of distinguishing the active GTP bound and inactive GDP forms, with the 
GTP being unstable and easily hydrolysable, compared to proteins that are regulated by 
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phosphorylation which often have phospho-specific antibody tools. Instead we initially 
turned to studying Rac1 indirectly through use of the inhibitor NSC23766 where, in figure 
6-5.  We found NSC23766 supressed the increase microtubule stability observed in β3+/- 
and β3-/- cells. Additionally, in case the roles of Rac1 in regulating microtubules were 
unrelated to the β3/Anxa2/Rcc2 system we had identified, we also observed that 
NSC23766 prevented the increased stability of microtubules when Rcc2 or Anxa2 were 
reduced.  
Normally active Rac1 is able to recruit microtubules through Iqgap1274, therefore we 
considered it unlikely that the recruitment of Rac1 by Rcc2 and Anxa2 to β3 containing 
focal adhesions was activating. However, Humphries et al244 noted that when Rcc2 was 
found in focal adhesions, its role was primarily to inhibit cell migration, which would fit 
with our finding that the β3/Anxa2/Rcc2 complex is inhibiting Rac1 and therefore 
microtubule stability and cell migration on fibronectin; we believed we could have found 
the mechanism behind Rcc2’s influence. For this to occur the localisation of Rac1 to focal 
adhesions by β3/Anxa2/Rcc2 must be to prevent Rac1 from interacting with GEFs. In figure 
6-7 we measured protein associations with active Rac1 using Pak1-PBD coated bead 
pulldowns, which preferentially interacts with GTP-bound Rac1434. We found that GTP-Rac1 
only interacts with β3 in β3+/+ cells and not in β3+/- or β3-/- cells.  We suspect there was 
likely some low level interaction in the β3+/- cells as well, but at a level too low to detect by 
western blotting. We also found an increased association with Anxa2 and Rcc2 in β3 
depleted cells suggesting that Anxa2/Rcc2/Rac1 still form a complex even in the absence of 
β3. Additionally the observation of increased α5 association with active Rac1 in β3+/- and 
β3-/- cells suggested that the documented interaction of α5 with Rac1 is still the primary 
method of microtubule recruitment to focal adhesions that do not contain β3. We 
concluded that the most likely explanation for our observations is that the Anxa2/Rcc2 
complex localises Rac1 to focal adhesions. If the adhesion contains β3 then Rac1 is not 
activated but if the adhesion contains α5 then Rac1 is activated by GEFs. Williamson et al418 
have identified several Rcc2 interacting proteins that are Rac1 GEFs which could be 
responsible for this activity and we believe one or more of these are missing from β3 
containing focal adhesions, or alternatively a new Rac1 GAP (GTPase activating protein) is 
present in the β3 adhesome. Unfortunately the coverage of Rac1 GEFs/GAPs is low in our 
adhesome studies but a key future experiment would be to repeat active Rac1 pulldowns in 
β3+/+, β3+/- and β3-/- endothelial cells use quantitative mass spectrometry instead of 
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candidate western blotting to further elucidate our mechanism. A schematic outlining the 
basics of this mechanism can be seen in figure 7-1. 
Although we have highlighted, in this work, some novel ways that β3 can affect 
microtubule behaviour, it is important to consider that β3 could also affect microtubule 
behaviour indirectly through known pathways such as with α5. α5 and its common 
heterodimer β1 are known to capture microtubules through a number of adapters such as 
Iqgap1237,291. Therefore, any changes in α5 behaviour or trafficking from β3 inhibition could 
have profound consequences. For example it has been shown that inhibiting αvβ3 short-
loop recycling can dramatically increase the rate of α5β1 recycling through Rab11435. A 
recent study by Mana et al436 highlighted how Rab11 along with Ppfia1 (Protein Tyrosine 
Phosphatase, Receptor Type, F Polypeptide (PTPRF), Interacting Protein (Liprin), Alpha 1) 
directs and localises α5β1 recycling as well as promoting microtubule targeting to Ppfia1 
positive areas. To further our study into the role of β3 in regulating microtubule behaviour, 
it would be important to measure α5 recycling, potentially by surface biotinylation195. We 
should also determine if inhibition of α5 recycling is responsible for any of the phenotypes 
observed in IMMLECs from β3 depletion by inhibiting known recycling pathways though 
Rab knockdowns, pharmacological inhibitors such as primaquine or depletion of α5437,438. 
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Figure 7-2 Possible Mechanisms Behind β3 Regulation of Microtubules 
 
A model representing how β3 could control microtubule behaviour in fibronectin adhered 
endothelial cells. A line drawn through the cell shows allows the comparison of two 
scenarios: one where there are normal levels of β3 (bottom) and another where there is β3 
depletion (top). β3 recruits a complex of Rac1-GTP, Rcc2 and Anxa2 which can reduce the 
stability of microtubules at focal adhesions. When β3 is absent, α5 instead can recruit the 
same complex which leads to stabilisation of microtubules.    
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Microtubules as Targets for Integrin β3 Treatment Escape 
Regardless of the exact mechanism behind β3 control of microtubule targeting and 
stability, we have shown that using microtubule targeting agents is a potentially powerful 
anti-cancer tool in combination with β3 inhibition. Steri et al223 observed  that short term 
depletion of β3 decreased tumour growth and angiogenesis whereas long term depletion 
increased it. Although done with genetic tools, this kind of investigation could be 
considered a surrogate for β3 treatment escape. Tumours grown in mice tend to develop a 
lot quicker than in humans and partly this is by design as a mouse’s lifespan is much shorter 
than a human’s. Therefore it is impossible to model a slow development of a tumour over 
several years as sometimes happens in humans439. This is a problem in many studies into 
tumour angiogenesis where drugs like Cilengitide® could be successful in a fast growing 
mouse tumour but fail in a slow growing human tumour due to a long term treatment 
escape. We found that microtubule inhibition did not synergise with c(RGDfV) treatment, 
siRNA or Pdgfb cre inducible β3 depletion as it did with global knockouts or Tie1 cre 
constitutive depletions, offering further explanations for the failure of RGD mimetics but 
hope that β3 is still a valid target. Therefore we concluded that a possible mechanism 
behind long term anti-β3 treatment escape is the increased targeting and stability of 
microtubules to focal adhesions, aiding in cell migration. 
It was interesting to us that despite increased microtubule stability in response to cold 
treatment, β3+/- and β3-/- endothelial cells were more sensitive to microtubule inhibitors. 
We thought that because the microtubule phenotypes were likely a compensation 
mechanism for loss of β3, then it made sense that β3+/- and β3-/- cells were dependent on 
microtubule function. We have not in this investigation considered what the effects of 
extra microtubule interaction with focal adhesions are in β3 depleted cells but it appears to 
be pro-angiogenic due to the increased migration speed observed in supplementary figure 
3 and the increased tumour growth observed in β3 depleted mice223,440. Additionally, it is 
worth considering that the doses of microtubule destabilising drugs were high enough to 
depolymerise all microtubules in figure 5-4B, and we assumed stabilising drugs doses were 
enough to polymerise all microtubules, with no differences between β3+/+, β3+/- and β3-/- 
cells observed, which we believed was due to our doses being much higher than the 
increased cold stability effect could cope with. Interestingly, with the same doses of 
inhibitors and presumably completely rigid or no microtubules, β3+/+ endothelial cell 
migration was unaffected in figure 5-5 unlike β3+/- and β3-/- cells for microtubule 
destabilisers. This indicated that microtubules were not essential for β3+/+ cell migration 
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but are for β3 depleted cells, backing up the theory that the microtubule phenotype is a 
compensation for loss of β3. We presumed that overly stabilised microtubules, such as 
from the action of paclitaxel and epothilone B, in figure 5-5 were still able to affect β3+/+ 
migration because the rigid microtubules physically resisted the rear edge of cells 
contracting263. However it was still promising that β3+/- and β3-/- cells migrated slower 
than β3+/+ possibly due to the fact β3 containing focal adhesions do not attract as many 
focal adhesions to the lamellipodia of the cell in the first place as shown in figure 5-3, 
reducing hindrance in the event of microtubule stabilisation treatment. 
Microtubule inhibitors are already being used as anti-angiogenic treatments and, even at 
sub toxic doses, stabilisers such as docetaxel have been observed to inhibit endothelial cell 
migration and tube formation in a mechanism also thought to involve Rac1441,442. These 
results have been exciting clinically because it means that lower doses can be used to 
achieve the desired therapeutic outcome with fewer side effects289. Our results have shown 
that efficacy of microtubule stabilisers can be increased even further in combination with 
β3 inhibition, which could be used to widen the therapeutic window further with even 
lower doses or more aggressively inhibit tumour vascularisation. We have also shown that 
microtubule destabilising drugs could become even more useful clinically if sufficient β3 
depletion can be achieved. Drugs such as eribulin had a powerful effect on β3+/- and β3-/- 
endothelial cell migration but left β3+/+ cells completely unaffected suggesting that side 
effects could be lower in patients. Indeed, when we tested a low dose of eribulin in mice in 
figure 5-7 it reduced tumour growth at sub toxic doses in combination with β3 deletion 
with no side effects but doses of a non-microtubule targeting drug, doxorubicin, were met 
with significant side effects. 
For these strategies to work in human tumours, there is an urgent need for effective 
integrin inhibitors. We have shown that RGD mimetics like c(RGDfV) induce no changes to 
the adhesome in figure 4-7 despite still being able to physically block cell adhesion likely 
because they still trigger outside-in integrin signalling. RGD mimetics may still be useful in 
targeting other fibronectin binding integrins such as α5 as this could interfere with their 
stress sensing abilities as hypothesised earlier186. Function blocking antibodies for certain 
integrins do exist such as Volociximab for α5β1 which have been shown to suppress 
angiogenesis and tumour growth443. So far only an effective function blocking antibody is 
available for use against human αvβ3 known as LM609444, which would not function in our 
mice. However it would function in human endothelial cells such as HUVECs (Human 
umbilical vein endothelial cells) and so it would be fairly straight forward to test if it 
168 
 
synergised with microtubule inhibition during random migration or cold stability assays in 
future studies. Additionally, allosteric inhibitors of β3 are being developed such as 
ProAgio445 which could have the potential to inhibit β3 without triggering outside-in 
signalling i.e. prevent the recruitment of the β3 adhesome. Alternatively, there are a large 
number of proteins in the β3 dependent adhesome for which we have not characterised 
their contribution to angiogenesis. Some of them will be unique mediators of β3 functions 
and could include Rac1 effectors. Targeting these proteins instead with inhibitors could be 
easier using pre-existing compounds that do not have the same issues as RGD mimetics. 
Any of these strategies would allow us to continue to use β3 as a therapeutic target due to 
its excellent restriction to only angiogenic vasculature371 to reduce side effects in vivo. 
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Further Work – Other Adhesome Targets 
Aside from further developing our β3/Anxa2/Rcc2/Rac1 mechanism of microtubule stability 
in endothelial cells, there is still a vast array of data within our adhesome datasets that 
likely does not affect microtubule stability but could still contribute to the long term escape 
from β3 inhibition. For example there are enrichments of several endoplasmic reticulum 
categories in table 4-2 and enrichment of protein folding categories in table 4-3 suggesting 
that endoplasmic reticulum stress is increasing without β3 which has been linked to 
angiogenesis446. Many endoplasmic proteins have been found at focal adhesions and the 
association of the organelle with adhesions can promote focal adhesion turnover and 
growth348. At first glance this appears to be a similar phenotype to microtubules in β3 
depleted cells, where the integrin is preventing the association of the otherwise pro-
migratory organelle and so would be worth investigating in the future. 
Alternatively, there are many individual proteins that may have unique roles in the 
adhesome that are recruited to the adhesome upon β3 loss and could be equally useful 
combination therapy targets like microtubules. We have begun to characterise a few of 
these with the most notable targeting so far being Hsp90, where different isoforms are 
significantly increased in the β3+/- adhesome as shown in supplementary table 3 lines 37, 
66 and 107. Additionally, some but not all of the isoforms detected were significantly 
increased in the β3-/- adhesome as shown in supplementary table 4 line 86. Heat shock 
proteins like Hsp90 often act as chaperones to ensure correct folding of proteins under 
normal and stress conditions but Hsp90 is unusual as its activity is ATP dependent447. The 
ATP binding site of Hsp90 therefore is unique and drugs such as tanespimycin show 
incredible specificity and, when used clinically, few side effects448,449. Hsp90 is of 
considerable interest in cancer therapies due to its increased expression in some cancer 
cells448. Interestingly Hsp90, and its ATP metabolising functionality, are thought to be 
involved in the cross talk between VEGFR2 and Fak1 in an β3 dependent mechanism447 
although why Hsp90 is increased in β3 depleted adhesomes is unclear.  However, it is 
worth noting that VEGFR2 is also not present in the adhesome , suggesting there may be 
alterations to the VEGFR2/Hsp90 interactions by moving Hsp90 to the adhesome without 
β3. 
To begin to understand Hsp90’s role in the β3 depleted adhesome, we tested the effects of 
its inhibitor in β3+/+, β3+/- and β3-/- IMMLECs in random migration assays similar to figure 
5-5. The results, as shown in supplementary figure 5, indicated that tanespimycin 
significantly inhibited the migration of β3+/- and β3-/- endothelial cells much like 
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microtubule inhibitors did. β3+/+ cells were not affected which suggests that, Hsp90 is not 
required for endothelial cell migration when β3 is present. Hsp90 therefore may represent 
another aspect of compensation for β3 loss in endothelial cells and is therefore a good 
target for further investigation, especially given the availability of effective pharmacological 
inhibitors. The full extent and diversity of hidden targets in the β3 adhesome like Hsp90 has 
yet to be realised, so this investigation into β3 is only just beginning. 
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Appendix 
Supplementary Figures 
Supplementary Figure 1 Comparison of Microscopy Techniques 
 
β3+/+ endothelial cells were adhered to fibronectin coated coverslips for 90 minutes then 
treated with VEGF for 10 minutes before being PHEMO fixed and immunostained for Pxn 
A
B
Actin Pxn DAPI
Actin Pxn
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(green). DAPI (blue) and Phalloidin-actin (Red) staining were also used. Images taken using 
a A widefield microscope (scale bar = 20 µm) or a B confocal microscope (scale bar = 10 
µm)  
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Supplementary Figure 2 Resistance to Mebendazole treatment by β3 Depleted 
Endothelial Cells 
  
β3+/+ endothelial cells were adhered to fibronectin before being treated with a range of 
Mebendazle doses overnight. Cell survival was assessed using methylene blue staining of 
cells followed by de-staining and absorption measurements n = 16. 
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Supplementary Figure 3 Random Migration of β3 Depleted Endothelial Cells 
 
β3+/+, β3+/- and β3-/- endothelial cells were adhered to fibronectin overnight. Migration 
speed of individual cells was measured over 15 hours using the MTrackJ plugin for ImageJ 
(n=69). 
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Supplementary Figure 4 Dual Knockdown of Rcc2 and Anxa2 Cumulatively Increases 
Microtubule Stability 
 
 
A β3+/+ IMMLECs were transfected with control pool (CP) or Rcc2 smart pool siRNA and 
allowed to recover for 48 hours then were adhered to fibronectin coated coverslips for 75 
minutes at 37°C before being moved to ice for 15 minutes. Soluble tubulin was washed out 
using PEM buffer before fixing with -20°C methanol. Immunostaining for α-tubulin was 
carried out to allow counting of cold stable microtubules per cell. Bars = mean number of 
cold stable microtubules shown as a percentage relative to CP treated cells ± SEM n = 224. 
B Representative immunostaining of cells used from panel A. α-tubulin (green), Tln1 (red) 
and DAPI (blue) as a nuclear stain. Scale bar = 20 µm.    
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Supplementary Figure 5 Hsp90 Inhibition in β3 Depleted Endothelial Cell Migration 
 
β3+/+, β3+/- and β3-/- endothelial cells were adhered to fibronectin overnight. Migration 
speed of individual cells was measured over 15 hours using the MTrackJ plugin for ImageJ 
whilst under the influence of the tanespimycin (0.08 µM). Migration speeds are shown as a 
percentage of the speed of the corresponding genotype under DMSO (vehicle) treatment 
(n=58).  
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Supplementary Figure 6 Non-normalised Random Migration of Endothelial Cells with 
Microtubule Inhibitors 
 
β3+/+, β3+/- and β3-/- endothelial cells were adhered to fibronectin overnight. Migration 
speed of individual cells was measured over 15 hours using the MTrackJ plugin for ImageJ 
whilst under the influence of the indicated microtubule agent (MTA) or DMSO (vehicle) 
treatment (n=46).  
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Supplementary Tables 
Table 1 Raw MaxQuant Output of the Endothelial Adhesome 
 
Unaltered MaxQuant output from analysis of the endothelial adhesome. Fibronectin adhered (FN), fibronectin adhered with VEGF (VEGF) and poly-l-lysine 
adhered (PLL) triplicate adhesome samples were used in MaxQuant analysis. Ordered alphabetically by gene name. 
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Table 2 LFQ of the Endothelial Adhesome 
 
 
Normalised and filtered MaxQuant output from analysis of the endothelial adhesome generated in table 1. Listed in the same order defined by 
unsupervised hierarchical clustering in figure 4-2. Angiogenesis associated proteins, highlighted at the start of the table, were defined using the GOBP 
annotations: GO:0001525, GO:0002040, GO:0002042, GO:0016525, GO:0045765 and GO:0045766 
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Table 3 β3+/- Endothelial Cell Adhesome 
 
Normalised and filtered MaxQuant output from analysis of the β3+/- endothelial adhesome. Fibronectin adhered β3+/+ cell and fibronectin adhered β3+/- 
cell triplicate adhesome samples were used in MaxQuant analysis. Ordered by significance defined by SAM analysis.  
  
  
181 
 
Table 4 β3-/- Endothelial Cell Adhesome 
 
Normalised and filtered MaxQuant output from analysis of the β3-/- endothelial adhesome. Fibronectin adhered β3+/+ cell and fibronectin adhered β3-/- 
cell triplicate adhesome samples were used in MaxQuant analysis. Ordered by significance defined by SAM analysis.  
  
182 
 
Table 5 c(RGDfV) Treated Endothelial Cell Adhesome 
 
Normalised and filtered MaxQuant output from analysis of the c(RGDfV) treated endothelial adhesome. Fibronectin adhered β3+/+ cells treated with 
c(RGDfV) (RGD) and fibronectin adhered β3+/+ cells treated with DMSO (DMSO) triplicate adhesome samples were used in MaxQuant analysis. Ordered by t 
test difference defined by SAM analysis with Ncbp1 (Nuclear cap binding protein subunit 1) as the only significant change on top.
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Table 6 Mass Spectrometry of Rcc2 Pulldown 
SILAC mass spectrometry of GFP-Rcc2 vs GFP control pulldown represented as heavy/light ratio. Full details of experiment can be found in Willamson et 
al418
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Abbreviations 
α5 – Integrin α5 (mouse) 
α6 – Integrin α6 (mouse) 
αv – Integrin αv (mouse) 
αm – Integrin αm (mouse) 
Acta2 – Actin alpha 2 smooth muscle (mouse)  
ADAM10 - A disintegrin and metalloproteinase domain 10 
ADAM17 - A disintegrin and metalloproteinase domain 17 
Akt1 – AKT serine/threonine kinase 1 (mouse) 
ANOVA – Analysis of Variance 
Anxa2 – Annexin A2 (mouse) 
Arf6 – ADAP-ribosylation factor 6 (mouse) 
ATP – Adenosine tri-phosphate 
β1 – Integrin β1 (mouse) 
β3 – Integrin β3 (mouse) 
β3+/+ – Integrin β3 Wild-type (for the β3 gene) 
β3+/- – Integrin β3 Heterozygous (for the β3 gene) 
β3-/- – Integrin β3 Null Homozygous (for the β3 gene) 
β5 – Integrin β5 (mouse) 
β6 – Integrin β6 (mouse) 
Bcar1 – Breast Cancer Anti-Estrogen Resistance Protein 1 (mouse) 
BSA – Bovine serum albumin 
CAF – Cancer associated fibroblasts 
CAM – Cell adhesion molecule 
Capn2 – Calpain 2(mouse) 
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Cdc42 – Cell division cycle 42 (mouse) 
Clip1 – CAP-Gly domain containing linker protein 1 (mouse) (aka CLIP-170) 
Coro1c – Coronin, actin binding protein 1c (mouse) 
Crebbp – Creb binding protein (mouse) 
c(RGDfV) - Cyclo(-Arg-Gly-Asp-D-Phe-Val) trifluoroacetate (aka Bachem H-2574) 
Crk – CRK proto-oncogene, adaptor protein (mouse) 
Dab2 – DAB2, Clathrin adaptor protein (mouse) 
DAG – Diacylglycerol 
Dll4 - Delta like canonical notch ligand 4 (mouse) 
DMSO – Dimethyl sulfoxide 
Dnm2 – Dynamin-2 (mouse) 
Dock1 – Dedicator of cytokinesis 1 (mouse) 
DPDPB - 1,4-Bis[3-(2-pyridyldithio)propionamido]butane 
DSP - Dithiobis(succinimidyl propionate) 
DTT – Dithiothreitol 
Dyn2 – Dynamin 2 
EB2 - Microtubule Associated Protein RP/EB Family Member 2 (mouse) 
ECM – Extracellular matrix 
Egfr – Epidermal growth factor receptor (mouse) 
Emcn – Endomucin (mouse) 
Ep300 – E1a binding protein p300 (mouse) 
Epo – Erythropoietin (mouse) 
Erbb2 – Erb-B2 receptor tyrosine kinase 2 (mouse) 
Erk1 – Extracellular regulated kinase 1 aka Mitogen-activated protein kinase 3 (mouse) 
Erk2 – Extracellular regulated kinase 2 aka Mitogen-activated protein kinase 1 (mouse) 
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Fak1 – Focal adhesion kinase 1 aka Ptk2 (mouse) 
FDR – False discovery rate 
FN – Fibronectin 
GAP – GTPase activating protein 
Gapdh - Glyceraldehyde-3-phosphate dehydrogenase (mouse) 
GDP – Guanine di-phosphate 
GEF – Guanine exchange factor 
Gipc1 – GPIC PDZ domain containing family member 1 (mouse) 
GOBP – Gene ontology: biological process 
GOCC – Gene ontology: cellular compartment 
GOMF – Gene ontology: molecular function 
Gpcr – G protein coupled receptor 
Grb7 – Growth factor receptor bound protein 7 (mouse) 
GTP – Guanine tri-phosphate 
Hif1a – Hypoxia inducible factor 1 alpha subunit (mouse) 
Hif1b – Hypoxia inducible factor 1 beta subunit (mouse) 
Hsp90 – Heat shock protein 90 (mouse) 
Hspa1a – Heat shock protein family A (Hsc70) member 1A (mouse) 
HUVECs – Human umbilical vein endothelial cells 
IAA – Iodoacetamide 
ICAM1 – Intracellular adhesion molecule 1 
ICAM2 – Intracellular adhesion molecule 2 
Il6 – Inteleukin 6 (mouse) 
Ilk – Integrin linked kinase (mouse) 
IMMLEC – Immortalised mouse lung endothelial cell 
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IP3 - Inositol trisphosphate 
Iqgap1 – IQ motif containing GTPase activating protein 1 (mouse) 
Itpr3 - Inositol 1,4,5-trisphosphate receptor type 3 (mouse) 
Kank1 – KN Motif and Ankyrin Repeat Domains 1 (mouse) 
KEGG – Kyoto encyclopaedia of genes and genomes 
Kif2c – Kinesin family member 2C (mouse) 
Kif5b – Kinesin family member 5B (mouse) 
LC-MS/MS – Liquid chromatography tandem mass spectrometry 
LFQ – Label free quantification 
LTQ – Linear trap quadrupole (mass spectrometer) 
Macf1 – Microtubule actin crosslinking factor 1 (mouse) 
Map6 – Microtubule associated protein 6 (mouse) 
Map4k4 - Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (mouse) 
MAP – Microtubule associated protein 
Met – MET proto-oncogene, receptor tyrosine kinase (mouse) 
MLB – Magnesium lysis buffer 
MMP9 – Matrix metalloproteinase 9 
MMP14 – Matrix metalloproteinase 14 
Mtor - Mechanistic Target Of Rapamycin (mouse) 
Myc - MYC proto-oncogene, BHLH transcription factor (mouse) 
Myh2 – Myosin heavy chain 2 (mouse) 
Ncbp1 – Nuclear cap binding protein subunit 1 (mouse) 
Nfatc1 - Nuclear factor of activated T-cells 1 (mouse) 
Nos2 – Nitric oxide synthase 2 (mouse) 
Nrp1 – Neuropilin-1 (mouse) 
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PAGE – Polyacrylamide gel electrophoresis 
Pak1 – P21 (Rac1) activated kinase 1 (mouse) 
PBD – P21 (Rac1) binding domain 
PBS – Phosphate buffered saline 
Pdcd6ip – Programmed cell death 6 interacting protein (mouse) 
Pdgfb – Platelet derived growth factor subunit b (mouse) 
PEM – PIPES, EGTA, MgCl2 buffer 
PFA – Paraformaldehyde 
Pgf – Placental growth factor (mouse) 
PHD2 – Prolyl hydroxylase domain containing protein 2 
PHEMO – PIPES, HEPES, EGTA, MgCl2 and DMSO containing buffer 
PI3K-alpha - Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 
(mouse) 
PINA – Protein interaction network analysis platform 
PIP2 - Phosphatidylinositol 4,5-bisphosphate 
PIP3 - Phosphatidylinositol 3,4,5-trisphosphate 
Pkcb – Protein kinase c beta (mouse) 
PLL – Poly-l-lysine 
Ppfia1 - Protein Tyrosine Phosphatase, Receptor Type, F Polypeptide (PTPRF), Interacting 
Protein (Liprin), Alpha 1 (mouse) 
Pxn – Paxillin (mouse) 
Rab4 – Ras-related protein Rab-4 (mouse) 
Rab6 – Ras-related protein Rab-6 (mouse) 
Rab11 - Ras-related protein Rab-11 (mouse) 
Rac1 - Ras-related C3 botulinum toxin substrate 1 (mouse) 
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Raf1 - Raf-1 proto-oncogene, serine/threonine kinase (mouse) 
Rcc2 – Regulator of Chromatin Condensation 2 (mouse) (aka TD-60) 
RGD – Arginine, glycine, asparagine tri-peptide 
RhoA – Ras homologue family member A (mouse) 
RIAM – Rap1-GTP Adapter Interacting Molecule (APBB1IP) 
RIPA – Radioimmunopreciptation assay buffer 
RO – Reverse osmosis 
Rock1 - Rho associated coiled-coil containing protein kinase 1 (mouse) 
SAM – Significance analysis of microarrays 
Sdc1 – Syndecan-1 
SDS - Sodium dodecyl sulphate 
Sem3a – Semaphorin 3a (mouse) 
SH2 – Src homology domain 2 
Slc2a1 – Solute carrier family 2, facilitated glucose transporter member 1 (mouse) 
Src - SRC proto-oncogene, non-receptor tyrosine kinase (mouse) 
Tie1 – Tyrosine-protein kinase receptor 1 (mouse) 
Thbs1 – Thrombospondin-1 (mouse) 
TIPS – Microtubule plus end tracking proteins 
Tln1 – Talin 1 (mouse) 
Tsc2 – Tuberous sclerosis 2 (mouse) 
Vasp – Vasodilator stimulated phosphoprotein (mouse) 
VCAM1 – Vascular cell adhesion protein 1 
Vcp – Vasolin containing protein (mouse) 
VEGF – Vascular endothelial growth factor 
VEGFR2 – Vascular endothelial growth factor receptor 2 
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VE-cadherin – Vascular endothelial cadherin (mouse) (aka Cdh5) 
Vhl – Von Hippel-Lindau tumour suppressor (mouse) 
Vim – Vimentin (mouse) 
Zyx – Zyxin (mouse) 
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